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Abstract 
Although widespread availability of antiretroviral therapy (ART) has markedly enhanced survival in 
HIV-1 infected individuals, its long-term use and cessation has been linked to an increase in non-AIDS 
morbidity and mortality. The pathogenesis of these complications is thought to reflect excessive 
immune activation and inflammation. The SMART trial showed that in chronic HIV-1 infection, 
inflammatory and coagulation biomarkers were predictive of all cause mortality, and that stopping 
ART lead to a rise in these biomarkers. The impact of interrupting ART started in primary HIV-1 
infection (PHI) on these biomarkers is unknown. This thesis examines the effect of different stages of 
HIV-1 infection on markers of inflammation, coagulation and immune activation, and focuses on the 
effects of short-course ART in participants enrolled in the SPARTAC trial; a blinded RCT investigating 
the role of short-course ART versus no therapy in PHI.  
Baseline parameters associated with biomarkers of inflammation, coagulation, immune activation, 
endothelial activation and microbial translocation, and the effect of starting and stopping ART on IL-
6 and D-dimer levels, were examined in SPARTAC participants. Viral dynamics on treatment 
discontinuation were compared in PHI (SPARTAC) to chronic infection (SMART).  
The majority of biomarkers were raised in HIV-1 infected individuals compared to healthy controls 
and highly correlated with HIV RNA levels. Viral and host factors, including age, HLA type and viral 
tropism, determined levels of T-cell activation. IL-6 and D-dimer fell significantly on commencing ART 
but rebounded to baseline levels within 4 weeks of stopping.  Viral rebound after stopping ART 
initiated in PHI was lower than that observed in chronic infection.  
This work highlights factors associated with immune activation and inflammation in PHI, which could 
potentially be used to identify individuals at high risk of disease progression. Immune activation and 
inflammation are influenced by direct effects of the virus, ART and other variables. The clinical 
impact of these findings warrants further investigation. 
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Chapter 1: Introduction  
In 2009, the United Nations estimated 33.4 million people worldwide to be living with Human 
Immunodeficiency Virus type-1 (HIV-1) infection, of whom 2.7 million were newly infected (UNAIDS 
2009).  The use of combination antiretroviral therapy (ART) has led to a dramatic increase in life 
expectancy and quality of life amongst HIV-1 infected individuals (Hogg 2008; Palella, et al. 1998), 
however, overall mortality rates for ART treated individuals are still higher than in the general 
population (Cockerham, et al. 2010; Lewden, et al. 2007). Where AIDS-related mortality has 
continued to decline, non AIDS-related morbidity and mortality has increased, resulting in 
heightened attention to conditions that have not traditionally been considered to be HIV-1 related, 
including cardiovascular disease (CVD), cancers, and liver disorders (Lau, et al. 2007).  
This thesis examines factors associated with immune activation and inflammatory responses in HIV-1 
infection, and discusses the role of inflammation and immune activation in driving both HIV-1 
related and non-AIDS disease processes in HIV-1 infected individuals. In particular this thesis will 
focus on inflammation and immune activation in Primary HIV-1 infection (PHI) and the effect of 
short-course ART in this setting.   
1.1: HIV-1 biology 
Structure and genome 
The HIV-1 virus is a retrovirus belonging to the genus Lentivirus.  Lentivirus infections are typically 
characterised by a long latent period, a chronic course of disease and persistent viral replication. 
HIV-1 and HIV-2 are closely related to the Simian Immunodeficiency virus (SIV), although HIV-2 more 
closely resembles the strain of SIV seen in Sooty Mangabeys (SIVsmm), whereas HIV-1 resembles the 
more pathogenic strain of SIV seen in chimpanzees (SIVcpz).  
The structure of the HIV-1 virus is shown in Figure 1.1. HIV-1 has a diameter of 100nm and is 
composed of two copies of single-stranded RNA enclosed by a conical capsid composed of viral 
protein p24. The single-stranded RNA is part of a protein-nucleic acid complex and is tightly bound 
to a nucleocapsid protein, p7, and enzymes necessary for viral replication including reverse 
transcriptase (RT),  protease (PR), and integrase. The capsid is surrounded by a matrix composed of 
the viral protein p17 ensuring the integrity of the virion particle. The virus is surrounded by a 
lipoprotein viral envelope that is composed of two phospholipid layers derived from human cell 
membrane during the process of viral budding from the cell. The viral envelope incorporates 
proteins from the host cell and 72 glycoprotein complexes, consisting of trimers of an external 
12 
 
glycoprotein gp120 loosely bound to a stem consisting of three gp41 molecules which span the 
membrane and anchor the structure into the viral envelope. This glycoprotein complex, known as 
Env, enables the virus to attach to and fuse with target cells to initiate viral replication (Hoffmann 
and Rockstroh 2009).  
The RNA genome consists of nine genes encoding 16 viral proteins. Three genes are integral for viral 
replication: gag (group antigen), which codes for the nucleocapsid, env (envelope) coding for 
membrane glycoproteins, and pol (polymerase) coding for viral enzymes RT, PR and integrase.  In 
addition there are two regulatory genes, rev and tat, and four accessory genes: vif, vpu, vpr, and nef 
(Hoffmann and Rockstroh 2009).    
 
Figure 1.1. Structure of HIV-1  
 
  
Schematic representation of an HIV-1 virion showing the nucleocapsid, containing core proteins and viral enzymes, 
surrounded by the lipoprotein envelope. Reproduced from HIV-1 2009, Medizin Fokus Verlag, Hamburg (Hoffmann 
and Rockstroh 2009) 
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Replication cycle 
The CD4 receptor is expressed on the cell surface of T-lymphocytes, on T-cell precursors within the 
bone marrow and thymus, and on monocytes and macrophages, eosinophils, dendritic cells and 
microglial cells of the central nervous system (CNS). Binding of the viral surface protein gp120 to the 
CD4 receptor induces a structural change in the envelope complex also allowing interaction with a 
host cell chemokine coreceptor, either cysteine-cysteine receptor 5 (CCR5) or cysteine-X-cysteine 
receptor 4 (CXCR4), necessary for viral entry into the cell (Hoffmann and Rockstroh 2009).  In early 
infection the majority of viral strains, termed R5 or M-tropic strains, use the CCR5 (R5) receptor, 
primarily expressed on activated T-cells, macrophages, dendritic cells and microglia.  In the later 
stages of disease about 50% of individuals undergo a shift in viral tropism to CXCR4 (X4 or T-tropic) 
or mixed R5/X4 (dual tropic) strains of virus (Karlsson, et al. 2005). The CXCR4 receptor is expressed 
mainly on naïve T-cells. The binding of gp120 induces a conformational change in the envelope 
protein allowing gp41 to insert into the target cell membrane, resulting in fusion of the viral and cell 
membranes and allowing viral entry into the cell (Chan and Kim 1998). After target cell entry, the 
RNA genome is reverse-transcribed into unintegrated proviral DNA by the use of viral RT.  The 
provirus is subsequently transported into the nucleus and integrated into the host cell genome by 
viral integrase. Following integration, production of viral proteins takes place in the cytoplasm 
followed by assembly of new virions at the cell surface. HIV-1 proteases cleave polyproteins into 
individual functional HIV-1 proteins and enzymes, allowing generation of infectious viral particles 
and budding through the host cell membrane.   Maturation either occurs in the forming bud or in the 
immature virion after budding. 
Viral diversification 
The process of reverse transcription lacks a proof-reading mechanism and results in a high rate of 
nucleotide sequence changes. On average, 1-10 errors occur per genome and per round of 
replication (Hoffmann and Rockstroh 2009), and this, coupled with the ability to undergo 
recombination, leads to a high mutation rate. Escape mutants allow the virus to evade the host 
immune response, contributing to the long-term failure of the virus to be contained by the immune 
system. This results in a highly variable population of viruses (quasi-species) containing few identical 
sequences. Where there is selective pressure due to specific ART agents in the absence of complete 
viral suppression, this high mutation rate enables development of resistance to ART.  
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Natural history 
The natural history of untreated HIV-1 infection consists of a primary phase of infection lasting up to 
six months and characterised by extremely high HIV-1 plasma viral load (VL) and a profound 
decrease in CD4 cell count, followed by a clinically latent phase usually lasting between 3-10 years. 
During the chronic phase of disease patients may have few clinical symptoms, despite persistent 
viral replication in blood and lymphoid tissue leading to progressive decline in CD4 cell count.   
Progressive immunosuppression leads to susceptibility to opportunistic infection or HIV-1 related 
malignancy, resulting in a diagnosis of AIDS. AIDS is defined as having one or more of a list of many 
AIDS defining illnesses, or in the American classification system, a CD4 cell count less than 200 
cells/µl (CDC 1993). It has been estimated that CD4 cells are lost at an average rate of 67 cells/µl per 
year (Lodi, et al. 2010). The natural history of HIV-1 is demonstrated in Figure 1.2.  
The CD4 cell count is the most significant predictor of disease progression and survival. The overall 
risk of AIDS increases dramatically once the CD4 cell count drops below 200 cells/µl, however those 
with a CD4 cell count <350 cells/µl are still at increased risk compared to those with CD4 350-500 
cells/µl. The predicted risk of developing an AIDS defining illness within a 6 month period has been 
estimated to be 1.3%, 2.3%, 4.1%, 8.5% and 23.1% in individuals with a CD4 cell count of 450, 350, 
250, 150 and 50 cells/µl respectively, based on a 35 year old individual with VL of 100,000 cp/ml 
(Phillips and Pezzotti 2004). The level of VL is also an important predictor of disease progression 
(Mellors, et al. 1997; Mellors, et al. 1996; Phillips and Pezzotti 2004). 
Figure 1.2. Natural history of untreated HIV-1 Infection 
 
 
  
Schematic representation of the natural course of untreated HIV-1 infection.  After an initial peak during 
primary infection, VL stabilizes at a set-point, before rising again in advanced disease. After an initial 
decline, CD4 cell count gradually declines over a period of years  
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Factors associated with HIV-1 disease progression 
Substantial variation in HIV-1 progression occurs between individuals. Older subjects experience 
faster rates of CD4 cell decline and there is a significant correlation between age, higher VL and 
lower CD4 cell count (Phillips and Pezzotti 2004; Touloumi, et al. 1998). Approximately 3-5% of HIV-1 
infected individuals are termed long-term non progressors (LTNP), usually defined as individuals who 
do not experience CD4 cell decline for at least 7 years after infection (Okulicz, et al. 2009).  “Elite 
Controllers”, who naturally control viral replication to HIV RNA <50 copies/ml in the absence of ART, 
represent 0.1-2% of HIV-1 infected individuals in Western cohorts (Grabar, et al. 2009; Okulicz, et al. 
2009; Sajadi, et al. 2009). A high proportion, but not all, elite controllers are LTNP (Grabar, et al. 
2009; Sajadi, et al. 2009).  
Several host and viral factors predict HIV-1 disease progression. The genetic human leukocyte 
antigen (HLA) background of an individual influences the quality and the efficiency of the immune 
response against HIV-1 infection (Altfeld, et al. 2003).  Individuals with homozygous HLA types have 
faster HIV-1 progression than those heterozygous for HLA, possibly due to reduced host genetic 
diversity allowing an increased propensity for HIV-1 viral escape from cytotoxic lymphocyte (CTL) 
responses (Carrington and O'Brien 2003). Several individual HLA alleles have been associated with 
either faster or slower progression to AIDS (O'Brien, et al. 2001). HLA B*57 and B*27 are over-
represented amongst cohorts of LTNP and elite controllers (Migueles, et al. 2000; Sajadi, et al. 2009), 
whereas HLA B*35 has been associated with fast progression (Klein, et al. 1994). Altfeld et al. 
demonstrated that individuals expressing HLA B*57 present significantly less frequently with 
symptomatic seroconversion illness, mount more numerous  HIV-1 specific T-cell responses 
restricted by the protective HLA alleles and exhibit better control of viral replication following  acute 
infection (Altfeld, et al. 2003; Altfeld, et al. 2006). Selection of escape variants with a significant 
fitness cost leads to lower VL in individuals with these HLA types (Martinez-Picado, et al. 2006; 
Miura, et al. 2009). Goepfert et al. (2008) showed that CTL from patients with B*57 force the virus to 
develop mutations in gag that enable it to escape from the CTL response, resulting in reduced 
replicative competence and lower VL. If the virus is transmitted to another individual with a different 
HLA type it will mutate back to the original genotype and regain its full replicative capacity 
(Goepfert, et al. 2008). Enhanced CTL cytolytic ability may also contribute to enhanced 
immunological control in individuals with protective HLA alleles (Migueles, et al. 2008).  
 An inherited deletion in the host CCR5 gene (delta 32 mutation) confers a significant protective 
effect against acquisition of HIV-1 infection and a survival advantage in those who acquire the virus 
(Michael, et al. 1997; Smith, et al. 1997). The majority of individuals with homozygous deletion in 
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CCR5 are resistant to HIV-1 infection (Liu, et al. 1996a), although transmissions with CXCR4 using 
viral variants have been reported (O'Brien, et al. 1997). Heterozygous individuals are frequently 
encountered amongst LTNP cohorts and have slower progression to AIDS (Dean, et al. 1996). 
Viral factors also influence outcome. Individuals with CXCR4 or dual R5/X4 strains show more rapid 
clinical and immunological deterioration compared to individuals with CCR5 tropic virus (Connor, et 
al. 1997; Koot, et al. 1993; Schuitemaker, et al. 1992; Tersmette, et al. 1989). Deletions in the Nef 
gene (Deacon, et al. 1995; Kirchhoff, et al. 1995) and other viral polymorphisms (Alexander, et al. 
2000), have been described amongst cohorts of LTNP and are associated with reduced disease 
progression.  
1.2: Primary HIV-1 infection (PHI) 
Immunological and virological events during PHI 
Primary HIV-1 infection refers to the initial phase up to 6 months following HIV-1 acquisition and is 
characterised by a transient period of very high level viral replication with consequent destruction of 
memory CD4 T-cells.  Most HIV-1 infections worldwide occur following sexual exposure, and over 
75% of mucosally transmitted infections are initiated by a single virus (Keele and Derdeyn 2009). 
Infectious founder viruses preferentially infect CCR5+CD4 T-cells, and established infection following 
sexual transmission probably arises from a single focus of infected mucosal cells. Following 
transmission of the virus, there is a period of 10 days before HIV RNA becomes detectable in the 
plasma, known as the eclipse phase, where active HIV-1 replication occurs at the site of transmission 
(McMichael, et al. 2010).  This is followed by rapid dissemination to local lymphoid tissues, and 
subsequent trafficking of virus throughout entire body. This "ramp-up" period is characterised by 
massive uncontrolled viral replication in the blood and lymphoid tissues, particularly the gut-
associated lymphoid tissue (GALT), resulting in irreversible immunological damage, high levels of free 
HIV-1 virions circulating in the plasma, and dissemination to  sanctuary reservoirs. The preferential 
site for HIV-1 replication occurs in the gut lamina propria and submucosa due to the predominant 
population of activated CCR5+CD4 memory cells providing prime targets for the virus, and over one-
half of effector CD4 T-cell reserves in the GALT are irreversibly lost during acute infection 
(Mattapallil, et al. 2005). CD4 activation facilitates integration of HIV DNA into the host genome and  
lymphatic tissue provides an optimal environment for HIV-1 replication due to close cell contact 
between CD4 T-cells, antigen presenting cells (APC) and infectious virions in the follicular dendritic 
cell network, optimised by the local cytokine rich environment (Hoffmann and Rockstroh 2009). 
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Plasma viraemia increases to reach a peak of several million copies of HIV RNA/ml 21-28 days after 
initial HIV-1 infection and is accompanied by a substantial decrease in CD4 T-cell numbers, which 
may return later to near-normal levels in the blood but not in the GALT. The very high levels of HIV-1 
viraemia are normally short lived due to the appearance of initial cellular HIV-1 specific T-cell 
responses which exert an immune pressure on the virus, leading to the selection of multiple escape 
variants and the generation of a diverse viral population (McMichael, et al. 2010; Shacklett and 
Anton 2010). The VL thereafter decreases over 12-20 weeks allowing the development of a viral set-
point that is maintained by a balance between viral turnover and host immune responses 
(McMichael, et al. 2010). The viral set point, generally described as a quasi-steady state of viral 
replication occurring after the period of acute infection has resolved, varies between individuals and 
is prognostic of future disease course (de Wolf, et al. 1997; Lyles, et al. 2000; Mellors, et al. 1995). 
Immune responses to PHI 
Even prior to the development of detectable viraemia in PHI, increased levels of acute-phase 
proteins are detectable in the serum (McMichael, et al. 2010).  Further acute-phase protein 
production is triggered by an intense cytokine storm which accompanies the rise in plasma viraemia. 
Elevations in plasma levels of multiple cytokines and chemokines occur, including rapid and transient 
elevations in interferon-alpha, a rapid and more sustained increases in tumour necrosis factor alpha 
(TNF-α) and Chemokine (C-C motif) ligand 2 (CCL2), more slowly-initiated elevations in additional 
pro-inflammatory factors including interleukin 6 (IL-6) and interferon-gamma (IFN-γ), and a late-
peaking increase in the immunoregulatory cytokine IL-10 (Stacey, et al. 2009). This intense cytokine 
response to acute infection is much greater in magnitude to that observed in other viral infections, 
such as acute hepatitis B or C infections (Stacey, et al. 2009), indicating that the systemic cytokine 
response observed following acute infection is not a prerequisite for viral clearance, but may instead 
promote ongoing immune activation, viral replication and CD4 cell loss. A recent study showed that 
concentrations of various cytokines (IL-7, IL-12p40, IL-12p70, IFN-γ and IL-15) during acute infection 
better predicted viral set-point (defined as average of 3 VL measurements on 3 consecutive visits 
after a median of 47 weeks post-infection) than initial VL or CD4 cell count, and that plasma cytokine 
concentrations (IL-7,  IL-1a, and eotaxin) during acute infection were associated with more rapid CD4 
cell loss (Roberts, et al. 2010). The cellular sources of acute phase cytokines and chemokines have 
not been fully identified but include CCR5+CD4 T-cells, activated dendritic cells, monocytes, 
macrophages and natural killer cells, with HIV-1 specific T-cells also playing a later role (McMichael, 
et al. 2010) 
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The first T-cell responses to HIV-1 occur as viraemia approaches its peak, and peak 1-2 weeks later as 
the level of viraemia declines. The appearance of HIV-1 specific CD8 T-cells, and the peak in CD8 T-
cell responses, is thought to be a key factor driving the development of viral immune escape variants 
and the decline in HIV RNA. The strong association between the rate of disease progression and  
different HLA class I alleles indicates that the interaction between the T-cell receptor of the CD8 T-
cells and the HLA of the APC is a key element in the overall control of HIV-1 replication (Streeck and 
Nixon 2010). In PHI, the initial CD8 T-cell responses are directed against a narrow range of epitopes, 
whilst in chronic infection, an increase in the breadth and magnitude of the CTL response occurs, but 
is not accompanied by any increase in control of viral replication (Streeck and Nixon 2010).  This 
suggests that the first CD8 T-cell responses are unique in their ability to efficiently suppress viral 
replication. Streeck et al. (2009) showed that the ability to mount a strong CD8 T-cell response 
during PHI is significantly associated with lower viral set-point, and that preservation of the initial 
CD8 T-cell immunodominance patterns from acute into the chronic phase of infection were 
significantly associated with slower CD4 T-cell decline (Streeck, et al. 2009).  
Proliferation and activation of CTL responses are dependent on antigen specific CD4 T-cell help 
(Streeck and Nixon 2010).  Vigorous CD4 T-cell responses in acute HIV-1 infection have been 
associated with subsequent control of viral replication (Rosenberg, et al. 1997). The contribution of 
CD4 T-helper responses against HIV-1 has been highlighted by studies demonstrating that viral 
escape occurs from CD4 T-cell targeted epitopes during PHI (Jones, et al. 2009; Rychert, et al. 2007).  
However, the exact contribution of CD4 T-cell responses to HIV-1 control is difficult to measure and 
the antiviral action is likely to be indirect through other effector cells.  
Neutralising antibodies against autologous virus appear after the VL peak in PHI, approximately 12 
weeks or longer after initial infection and, therefore, do not majorly contribute to the initial control 
of viral replication.  Non-neutralising antibodies appear prior to this, but do not exert selective 
pressure or reduce VL (Frost, et al. 2008; Tomaras and Haynes 2009).  
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Establishment of a latent reservoir 
During acute infection, the virus disseminates throughout the body and becomes trapped in the 
follicular dendritic cell network within lymphatic tissue, where macrophages and activated T-cells 
are the main targets of infection. During this time HIV-1 establishes a stable permanent viral 
reservoir of latently infected cells. The virus enters into quiescent T-cells where reverse transcription 
results in the accumulation of proviral HIV DNA. However, as cellular activation is necessary for 
integration of the proviral HIV DNA into the host cell genome, the virus persists in resting cells, 
resulting in a latent reservoir of virus. ART is unable to affect non-replicating proviruses, and latently 
infected memory CD4 T-cells are thought to be the major reservoir that contribute to rebound 
viraemia after cessation of ART (Siliciano and Siliciano 2006). 
Clinical Features of PHI 
After an incubation period which ranges from a few days to a few weeks, PHI presents as a transient 
symptomatic illness which may be manifest by a wide range of ‘flu like symptoms including fever, 
fatigue, sore throat, maculopapular rash, myalgia, mouth ulcers, headache and lymphadenopathy. 
Symptoms are present in 40-90% of individuals, and typically last approximately 2 weeks, although 
durations of up to 10 weeks have been reported (Kassutto and Rosenberg 2004). Less common 
manifestations include development of opportunistic infection, and neurological presentations 
including aseptic meningitis, cranial nerve palsies and radiculopathy (Kassutto and Rosenberg 2004). 
The severity and duration of the acute illness predicts the rate of progression to AIDS (Lavreys, et al. 
2006; Vanhems, et al. 1998). The diagnosis of HIV-1 infection may be easily overlooked due to the 
non-specific nature of symptoms, and in one UK study, approximately 50% of PHI diagnoses were 
missed on first presentation to a healthcare provider (Sudarshi, et al. 2008). A high degree of 
awareness and clinical suspicion is therefore required.   
Diagnosis of PHI 
Even in resource rich settings, uptake of HIV-1 testing remains disappointingly poor, with 27% of the 
HIV-positive population in the UK remaining unaware of their HIV-1 status in 2009 (HPA 2009). The 
symptomatic phase of PHI coincides with the development of HIV-1 specific immune responses, but 
occurs prior to development of HIV-1 specific antibodies. 1st and 2nd generation HIV-1 tests detect 
anti-p24 IgG antibodies, with positive result only after HIV-1 seroconversion. Third generation tests 
detect IgM and will give an earlier positive result(Hecht, et al. 2002). UK guidelines recommend that 
the first-line assay for detection of HIV-1 infection should be a 4th generation test, which 
simultaneously tests for HIV-1 antibody in combination with p24 antigen, reducing the time from 
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initial infection to testing positive to 1 month, 1–2 weeks earlier than current standard third-
generation antibody tests (BHIVA, et al. 2008).  
Current available 3rd generation point-of-care tests (POCT), using fingerprick or mouth swab 
sampling, measure detectable antibody only, and have reduced specificity and sensitivity compared 
to 4th generation laboratory tests (Patel 2010; Winter, et al. 2006). Preliminary data on fourth-
generation antigen/antibody POCT show high specificity and increased sensitivity for early diagnosis 
of HIV-1 infection compared to 3rd generation POCT,  however these assays are not standard care 
and further validation is required in clinical settings (Beelaert and Fransen 2010). 
 The most sensitive test for detecting PHI is by detection of plasma HIV RNA, and nucleic acid 
amplification tests (NAAT) with a sensitivity of 50 copies/ml typically detect HIV-1 infection 
approximately 7 days before a p24 antigen test, and 12 days before a sensitive HIV-1 antibody test 
(Fiebig, et al. 2003). Current UK HIV-1 testing guidelines do not recommend HIV RNA quantitative 
assays for routine screening because of the possibility of false-positive results, but advocate their 
use where PHI is clinically suspected (BHIVA, et al. 2008). However the use of HIV RNA testing of 
pooled antibody-negative samples, followed by individual NAAT of positive specimens, maybe a 
cost-effective and effective way of diagnosing acute infection in targeted high-risk populations 
(Patel, et al. 2010).  
Cross-sectional incidence assays capable of accurately differentiating primary from chronic infection 
are essential to estimate HIV-1 incidence at a public health level and to evaluate efficacy of 
prevention strategies, and have also be used to identify eligible subjects for targeted prevention 
strategies or enrolment into clinical trials evaluating early treatment strategies. The serologic testing 
algorithm for recent HIV-1 seroconversion (STARHS) assay, or detuned assay, combines a high-
sensitivity and a low-sensitivity enzyme immune assay at the same time, differentiating early from 
chronic infection. These assays have a high false incident rate in those with established HIV-1, which 
is reduced when combined with clinical data (Fisher, et al. 2007). A further method for identifying 
recently acquired HIV-1 infection is the use of avidity testing, measuring strength of antibody–
antigen binding which rises with established infection, although results are affected by advanced 
disease and should  be interpreted in the context of other clinical parameters (Chawla, et al. 2007). 
Novel cross-sectional incidence assays are in development. 
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Onward transmission in PHI  
The high level plasma VL during PHI is reflected in the genital tract secretions and confers a marked 
enhanced risk of onward transmission to sexual partners (Morrison, et al. 2010; Pilcher, et al. 2007).  
Specific characteristics of recently transmitted viral variants appear to make them particularly 
efficient at onward transmission (Keele and Derdeyn 2009). CCR5-coreceptor utilizing variants are 
preferentially transmitted, corresponding with the initial cell types first infected in the genital 
mucosa (Margolis and Shattock 2006). Transmission of CXCR4 utilizing HIV-1 variants has been 
described, although this is uncommon (Brumme, et al. 2005). The enhanced transmissibility of 
recently acquired variants has been highlighted by recent data from primate models showing that in 
SIV infected Rhesus macaques, a significantly lower number of infectious virions are required to 
infect a new host when the source virus was isolated from an animal in the ramp-up phase of acute 
infection, compared with virus isolated from macaques who had reached viral set-point (Ma, et al. 
2009). Data from observational studies in humans suggest that there is a similar enhanced risk of 
onward transmission from individuals with PHI. Population based studies indicate that the highest 
rate of HIV-1 transmission per coital act is during PHI, even after adjustment for VL (Wawer, et al. 
2005), and mathematical models estimate that in high mixing populations, individuals with PHI 
disproportionately contribute to driving the HIV-1 epidemic (Miller, et al. 2010). Phylogenetic 
analyses demonstrate a clustering of infections during PHI (Pao, et al. 2005) and early infections 
account for about 50% of new sexual transmission in some populations (Brenner, et al. 2007). Thus 
identification and targeting of individuals with PHI to limit HIV-1 transmission could potentially 
confer a significant benefit at a population level. 
Role of treatment in PHI and use of short-course ART  
Early events following acute HIV-1 infection are likely to influence later disease course and outcome. 
It has been proposed that the ‘die is cast’ for long-term clinical outcome at the time of acute 
infection, and PHI therefore represents a unique window of opportunity where intervention may 
confer longstanding benefits (Centlivre, et al. 2007). Early treatment with ART during PHI may 
preserve HIV-1 specific T-cell responses, reduce the number of infected cells and limit the size of the 
viral reservoir, conferring enhanced control of viral replication when therapy is stopped.  The aim of 
early ART in PHI is therefore to delay disease progression and subsequently defer the need for long-
term ART.  An additional goal of treatment may be to reduce onward viral transmission of the virus.  
The strategic use of short-course ART during PHI with the goal of limiting long-term disease 
progression has been supported by initial randomised controlled trials (RCT) (Kinloch-De Loes, et al. 
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1995) and observational studies which have provided encouraging support for the role of early ART 
initiated in PHI for long-term clinical benefit (Fidler, et al. 2008). An early RCT, investigating 
zidovudine monotherapy for 6 months in individuals with PHI, showed beneficial rises in CD4 cell 
count amongst treated individuals, but no difference in VL between study groups.  However, this 
regimen was not fully suppressive and data cannot, therefore, be extrapolated to studies of 
combination ART (Kinloch-De Loes, et al. 1995).  Another study of 89 patients treated with 12 weeks 
of highly active ART (HAART) commenced an average of 1.5 months after seroconversion, compared 
with a matched untreated population of seroconverters from the CASCADE cohort, showed a 
significant decrease in the rate of CD4 cell decline in those receiving therapy (Fidler, et al. 2007).  
 Whether short-term treatment given at the time of early HIV-1 infection has an impact on the long-
term viral set-point is unclear. Despite initial control of plasma viraemia reported in some studies 
(Hecht, et al. 2006; Rosenberg, et al. 2000; Steingrover, et al. 2008), durable long-term viral control 
following treatment in PHI was not observed in others (Desquilbet, et al. 2004; Fidler, et al. 2002; 
Hecht, et al. 2006; Kaufmann, et al. 2004; Koegl, et al. 2009; Streeck, et al. 2006), and few 
randomised studies have assessed the effect of short-term ART on viral set-point in PHI. The A5217 
study, a RCT which aimed to investigate the effect of short-course ART in PHI on viral set-point, was 
discontinued early due to a high rate of CD4 cell decline across all treatment arms, so that the 
primary end-point of viral set-point could not be assessed due to initiation of long-term ART (Hogan 
C 2010). Lampe at al. compared data from the QUEST randomised study, where ART was given for an 
average of 2.6 years, with historical data from the CASCADE cohort of seroconverters. No difference 
in median VL was seen six months after stopping ART when compared with CASCADE 3 years 
following seroconversion, however 17.7% of QUEST patients had VL<1000 copies/ml compared with 
10% CASCADE patients at a similar time point, suggesting some effect on lowering VL (Lampe, et al. 
2007). 
Studies of patients receiving short-course ART at PHI have demonstrated preservation of robust HIV-
1 specific CD4 T-helper responses that are not detected during the chronic stage of HIV-1 infection,  
(Fidler, et al. 2002; Rosenberg, et al. 1997), however it is unknown whether these immunological 
observations confer a clinical benefit. To date there are no published studies which definitively 
address the role of ART in PHI on long-term clinical outcomes. This concept is currently under test in 
the Short Pulse AntiRetroviral Therapy at HIV-1 seroConversion (SPARTAC) study; an international 
RCT investigating the effect of short-term ART ( 12 or 48 weeks) versus no therapy commenced in 
PHI on long-term disease progression with a primary outcome measure of time to CD4 cell count 
<350 cells/mm³ or the initiation of clinically-indicated therapy (SPARTAC 2006).  
23 
 
In the absence of any demonstrated individual benefit, and pending the results of SPARTAC, ART in 
PHI should be given as part of a clinical trial or for clinical indications such as severe symptomatic 
illness, immune reconstitution in those with large CD4 cell count losses during the acute illness, 
development of opportunistic infection or development symptomatic CNS disease.  It is hoped that 
the SPARTAC trial will definitively address the role of strategic use of short-course ART in PHI once it 
reports in mid 2011.  
1.3: HIV-1 Immunopathogenesis 
Mechanisms of immune dysfunction in HIV-1 infection 
The mechanisms by which HIV-1 infection leads to the depletion of CD4 cells and subsequent 
immunodeficiency are not completely understood but include a) the direct infection of CD4 cells by 
the HIV-1 virus and their subsequent destruction through cytopathic and apoptopic mechanisms, b) 
generalised immune hyper-activation and c) immune dysfunction and exhaustion.  
Direct viral Infection 
HIV-1 preferentially infects activated CD4 cells, and as HIV-1 specific CD4 T-cells are among the first 
cells to be activated during HIV-1 infection, cells directed against the virus are at greatest risk of 
infection. Thus a continuous supply of target cells for the virus is maintained (Douek, et al. 2002; 
Grossman, et al. 2006). During acute infection, over one-half of all memory CD4 T-cells are destroyed 
by direct viral infection, and in particular, selective infection of  CCR5 positive CD4 memory T-
lymphocytes in the gut lamina propria and submucosa leads to massive depletion of CD4 T-cell 
reserves (Li, et al. 2005; Mattapallil, et al. 2005).  Viral replication in lamina propria CD4 cells leads to 
direct CD4 cell death through cell lysis and through Fas-Fas-ligand mediated apoptotic pathways 
resulting in their preferential ablation (Li, et al. 2005).  
During the chronic phase of disease, CD4 T-cell depletion continues to occur predominantly in the 
gut, however, at this time HIV-1 infects an apparently small proportion of CD4 T-cells directly, 
estimated at 1 in 100 to 1 in 1000, and thus indirect mechanisms account for the majority of T-cell 
losses (Brenchley, et al. 2004; Douek, et al. 2009). 
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HIV-associated immune activation 
Chronic immune activation is a hallmark of HIV-1 infection and may be manifested by polyclonal B 
cell activation (Lane, et al. 1983), increased T-cell turnover (Hazenberg, et al. 2000), high levels of T-
cell activation (Hazenberg, et al. 2003b), and raised levels of circulating cytokines and other pro-
inflammatory mediators (Aziz, et al. 1999b; Molina, et al. 1989; Valdez and Lederman 1997).  
The T-cell receptor on CD4 and CD8 T-cells cannot recognise antigen unless it is presented in 
association with a major histocompatibility complex (MHC) molecule, and recognises peptides 
bound to HLA molecules on APC. The stimulation of CD8 T-cell lymphocytes and formation of antigen 
specific CTL depend on presentation of an antigenic peptide together with class I MHC antigens, 
whereas CD4 T-cell activation depends on antigen presentation together with a class II MHC 
molecules.  There is a strong selective pressure for pathogens that have mutated in such a way that 
they escape presentation by a MHC molecule. The effector functions of T-cells are determined by 
the array of effector molecules they produce. The CD4 effector T-cells mainly act through the 
production of cytokines and other proteins. They have a wide repertoire of effector activities, and 
after recognition of a pathogen presented by MHC class II, can differentiate into effector subsets 
with different immunological functions. The main subsets are Th1, Th2 and Th17 which activate their 
target cells and several regulatory T-cell subsets (T regs) that have inhibitory activity, limit immune 
activation and suppress T-cell responses. Once an effector T-cell has completed its differentiation it 
finds target cells displaying the MHC-peptide complex that it recognises. The CD8 CTL recognise and 
eliminate virus infected cells by releasing cytotoxic granules which trigger apoptosis. CTL also act by 
releasing cytokines such as IFN-γ and TNF-α.  
Upregulation of CD38, a multifunctional transmembrane glycoprotein, occurs during early stages of 
T-cell activation (Giorgi and Detels 1989). Its expression correlates with other markers of cellular 
activation and is associated with increased cytokine production, increased CD4 cell proliferation and 
cell to cell adhesion (Savarino, et al. 2000). HLA-DR, a MHC class II antigen, is also upregulated on 
activated T-cells. Expression of HLA-DR increases on T-cells at HIV-1 seroconversion, and remains 
high but stable throughout disease progression (Giorgi and Detels 1989).  
Although the presence of immune activation usually reflects a mounting immune response to a 
pathogen, it was noted early on that increased levels of T-cell activation were associated with poor 
prognosis in HIV-1 infected patients (Giorgi, et al. 1993).  Numerous studies have now shown that 
the level of CD4 and CD8 T-cell activation in chronic HIV-1 infection is associated with HIV-1 disease 
progression (Giorgi, et al. 1993; Hazenberg, et al. 2003b; Liu, et al. 1997) and in some studies T-cell 
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activation has been shown to have stronger prognostic significance than CD4 cell count or VL (Giorgi, 
et al. 1999; Giorgi, et al. 2002; Liu, et al. 1997). The level of T-cell activation may be measured by 
assessing either the percentage of cells expressing activation markers of interest, or by the density 
per cell.  Liu at el (1997) examined the prognostic value of several immunological markers in chronic 
HIV-1, including CD8 cell expression of CD38 and HLA-DR antigens, CD4 cell count and serum 
markers of immune activation, including neopterin, β2-microglobulin and soluble tumour necrosis 
factor receptor-α type II (sTNFR2). Of these, elevated expression of CD38 on CD8 cells was the best 
predictive marker for subsequent AIDS diagnosis and death. Giorgi et al. (1999) showed that in 
advanced disease (CD4 cell count of <50 cells/µl), CD38 expression on both CD4 and CD8 T-cells  was 
strongly predictive of progression to death, but that VL was not (Giorgi, et al. 1999). A further study 
showed that CD38 expression on CD8 T-cells to be an exceptionally strong predictive marker for 
disease progression after both short duration (median 2.8 years) and long duration (median 8.7 
years) of HIV-1 infection, and that in later infection it was a stronger predictor of time to AIDS than 
either CD4 cell count or VL (Giorgi, et al. 2002). In a case control study comparing fast and slow 
progressors, increased CD38 expression on both CD4 and CD8 T-cells, and elevated proportion of 
CD8+ T-cells with dual expression of CD38 and HLA-DR, were all associated with rapid HIV-1 
progression (Cao, et al. 2009). This study further showed a relative expansion of T regs identified as 
FoxP3+CD25+CD4+ T-cells  during HIV-1 infection, which positively correlated with CD4+ T-cell 
activation among HIV-1 infected fast progressors and which were associated with disease 
progression. In contrast to the assumed role of T regs as the suppressors of activation, the authors 
concluded that these cells may have a negative impact on the immune control of HIV-1 infection 
(Cao, et al. 2009). The presence of FoxP3 expression in the CD4 T-cell population as a marker of 
severity of HIV-1 infection has been confirmed in other studies (Suchard, et al. 2010).   
The pathogenic significance of immune activation has been highlighted in several animal models. In 
non-human primates, SIV infection of both the Sooty Mangabey and the Rhesus macaque results in 
high levels of SIV replication. However, in macaques high levels of immune activation occur resulting 
in progressive immunodeficiency, whereas Sooty Mangabeys display no increases in immune 
activation and rarely exhibit clinical disease, despite evident viral replication (Meythaler, et al. 2009; 
Silvestri, et al. 2003; Sumpter, et al. 2007).  A similar observation comes from human studies of HIV-
2 infection. HIV-2 is associated with lower levels of immune activation, and individuals with HIV-2 
typically experience a more benign disease course compared to those with HIV-1 infection (Sousa, et 
al. 2002). The Nef protein from non-pathogenic SIV strains and from HIV-2 has a T-cell activation 
suppressing function which appears to have been lost in HIV-1 infection evolution (Schindler, et al. 
2006). 
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Levels of T-cell activation correlate with plasma HIV RNA and following introduction of ART, a decline 
in plasma HIV RNA is accompanied by a reduction, but not normalization, in immune activation 
(Deeks, et al. 2004).  However, several studies indicate that immune activation also occurs 
independently of direct antigenic stimulation resulting from HIV-1 viraemia. In transgenic mice, 
chronic immune activation persistently triggered through CD27-CD70 interactions, leads to the 
exhaustion of the naive T-cell pool, loss of immune responses, and susceptibility to opportunistic 
infections, indicating that this phenomenon triggers immunodeficiency in the absence of a viral 
infection (Tesselaar, et al. 2003).  Elite controllers have higher levels of T-cell activation than those 
suppressed on ART, or than HIV-negative controls, and high levels of immune activation correlate 
with a lower CD4 cell count, suggesting that immune activation remains a pathogenic phenomenon 
and contributes to CD4 cell loss in the absence of detectable viraemia (Hunt, et al. 2008).  In ART 
treated patients with sustained viral suppression, persistent T-cell activation is associated with lower 
CD4 T-cell gains (Hunt, et al. 2003). In keeping with this, individuals who have long-term 
asymptomatic HIV-1 infection despite high VLs, have significantly lower levels of activated T-cells 
than those with progressive disease (Choudhary, et al. 2007).   
Immune activation in PHI  
Few studies have focussed on levels of T-cell activation in PHI, a time when immunological events 
may have a marked impact on disease outcome. Hazenburg et al. (2003) assessed levels of T-cell 
activation, as measured by CD38% expression, HLA-DR%  expression and dual expression of both 
markers, 12 months after seroconversion in a cohort of 97 individuals followed up for a median of 4 
years. CD4 CD38% and dual CD8 CD38 HLA-DR% were predictive of progression to AIDS, however on 
adjusting for VL, only CD8 CD38 HLA-DR dual expression remained significant. When treated as time-
dependant covariates, CD38 expression on CD8 and CD4 T-cells were predictive for disease 
progression, although on multivariate analysis only CD4 CD38% expression remained significant 
(Hazenberg, et al. 2003b). Another study by Deeks et al. (2004) assessed CD4 and CD8 CD38 
expression in 68 untreated individuals within 12 months of seroconversion, and found that CD8 
CD38 was independently associated with the rate of CD4 cell decline (Deeks, et al. 2004).  It is clear 
from these studies that not all activation markers have equally predictive value, possibly reflecting 
their different roles in amplifying and maintaining immune responses.   
Hazenburg at el. (2003) showed that levels of T-cell activation, even prior to seroconversion, predict 
HIV-1 disease progression.  In a cohort of 56 individuals who were HIV-negative at the time of 
analysis but who seroconverted during a period of follow-up, higher proportions of CD70+CD4 T-cells 
before seroconversion were associated with a shorter AIDS free survival, and CD4 cell count <500 
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cells/µl prior to seroconversion was also associated with a significantly shorter median time to AIDS 
compared to those with CD4 cell count >500 cells/µl.  The CD70 antigen is expressed on activated T-
cells and controls for the magnitude and duration of T-cell responses. This study highlights that 
factors relating to the host immune system, even prior to HIV-1 acquisition, determine subsequent 
outcome upon infection with HIV-1.  
Mechanisms driving HIV-1-mediated immune activation  
The exact mechanism driving HIV-1 related immune activation is not fully understood. The first 
immune responses against HIV-1 generated in PHI are aimed at controlling the virus. The adaptive 
immune response to HIV-1 infection is a key driver of immune activation and persists into the 
chronic phase of HIV-1 infection. Chronic antigenic stimulation from HIV-1 viraemia, both directly 
and indirectly, leads to immune activation, but does not solely account for the full extent of immune 
activation seen. Antigenic stimulation from other infections may also contribute to immune 
activation, as demonstrated by studies showing accelerated SIV induced disease progression in 
macaques subjected to repeated immune stimulation via repeated injection of SIV independent 
antigens (Villinger, et al. 2001), and  observations of reduced CD4 cell counts in association with 
raised levels of serum pro-inflammatory cytokines during intercurrent infections in humans (Anzala, 
et al. 2000).  In addition, viruses such as cytolomegalovirus (CMV) and Epstein-Barr virus (EBV) 
induce antigenic stimulation, particularly due to reactivation during the latter stages of HIV-1 
infection.  
A recent study showed that CD4 cell depletion results in CD4 cell proliferation, probably through the 
increased production of IL-7, a cytokine linked to cell cycle progression, secreted as a homeostatic 
response (Catalfamo, et al. 2008). It has been hypothesised that the massive depletion of mucosal 
CD4 cell reserves occurring during PHI creates a permanent imbalance, and that immune activation 
occurs as a homeostatic mechanism in order for the immune system to replace its losses (Cadogan 
and Dalgleish 2008).  
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Role of the gastro-intestinal (GI) tract  
The role of the GI tract in the aetiology of HIV-associated immune activation has been highlighted in 
recent studies. The high level HIV-1 replication in GALT, occurring mainly during PHI, but continuing 
into the chronic phase of disease, is associated with permanent damage to both the structural and 
immunological environment of the GI tract (Centlivre, et al. 2007).  Massive CD4 cell losses, in 
particular to the Th17 cells involved in generating a rapid response to microbial pathogens at 
mucosal sites, have a direct effect on the intestinal epithelial barrier as well as local innate and 
adaptive immune function (Dandekar, et al. 2010). In addition to CD4 cell losses, other abnormalities 
have been observed within the GI tract in both HIV-1 and SIV infections. Gene expression profiles 
from GI biopsies in HIV-1 infected individuals indicate downregulation of genes associated with cell 
cycle regulation, lipid metabolism and epithelial cell barrier functions (Brenchley and Douek 2008).  
HIV-1 infection is associated with a clinical enteropathy that can occur from acute phase through to 
advanced stages of disease and is associated with villous atrophy, crypt hyperplasia and villous 
blunting (Brenchley and Douek 2008). Brenchley et al. (2006) hypothesized that these factors result 
in an increase in gut permeability, permitting translocation of gut-colonising bacteria and their 
metabolites across the gut epithelium and into the systemic circulation.  This microbial translocation 
results in activation of the innate immune system, with microbial products acting as toll-like receptor 
ligands, stimulating macrophages and dendritic cells to produce pro-inflammatory cytokines such as 
TNF-α and IL-6, and activating lymphocytes and further monocytes to induce systemic immune 
activation. This theory is supported by evidence of higher levels of circulating lipopolysaccharide 
(LPS), or endotoxin, in patients with chronic HIV-1 infection which correlate with the degree of both 
innate and adaptive immune activation (Brenchley, et al. 2006; Jiang, et al. 2009).  Furthermore, in 
animal models, microbial translocation does not occur during non-pathogenic SIV infection of Sooty 
Mangabeys, whereas LPS levels are significantly increased in SIV-infected macaques (Brenchley, et 
al. 2006).  
That LPS mainly is derived from gut sources is indicated by animal studies observing rises in LPS 
levels when measured before and after  acute infection with SIV and dramatic reductions in LPS 
levels in SIV infected monkeys upon receipt of  gut sterilizing antibiotics (Brenchley, et al. 2006).  
These data are supported by non-HIV-related disease models such as inflammatory bowel disease 
and graft versus host disease where gut-derived bacterial translocation is a well established factor in 
the pathogenic process (Caradonna, et al. 2000; Cooke, et al. 2002).   
Brenchley et al. (2006) demonstrated the potential role of microbial translocation in causing immune 
activation in a series of experiments examining LPS in HIV-1 infection. In a cross-sectional study 
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looking at independent cohorts of HIV-1 infected individuals, LPS was raised in individuals with 
chronic HIV-1 infection, both in those with a CD4 T-cell count >200 cells/µl (n=59) and in those with a 
CD4 T-cell count <200 cells/µl (n=39), compared to HIV-negative individuals. When LPS was 
examined in relation to manifestations of immune stimulation not directly related to LPS mediated 
activation, a direct correlation between LPS and frequency of CD38+HLA-DR+ CD8 T-cells, and 
between LPS and IFN-α, was seen. There was no correlation between LPS level and CD4 cell count or 
VL.  LTNP had higher LPS than HIV-negative individuals and showed a trend towards lower levels 
than progressors. In longitudinally followed up patients who received 48 weeks ART and achieved 
undetectable VLs, there was a significant decrease in LPS, but levels were still raised compared to 
HIV-negative patients. LPS was inversely correlated with rise in CD4 cell count on ART (Brenchley, et 
al. 2006). Another study found that LPS was raised in HIV-1 infected patients compared to HIV-
negative controls, but levels normalised after 2 years of effective ART (Troseid, et al. 2010).  These 
findings are supported by another study which amplified a well-conserved 16S ribosomal DNA 
(rDNA) subunit common to most bacteria. Bacterial rDNA was higher in HIV-positive patients than 
HIV-negative controls and in untreated patients with chronic HIV infection compared with 
individuals on ART.  Higher levels of bacterial DNA were associated with higher levels of T-cell 
activation (dual CD38 HLA-DR expression) and lower levels of immune restoration on commencing 
ART (Jiang, et al. 2009). A cross-sectional study in Sweden showed that levels of LPS were directly 
correlated with the severity of both HIV-1 and HIV-2 infection, and that LPS levels correlated with VL 
and inversely with CD4 cell count (Nowroozalizadeh, et al. 2010). Microbial translocation has also 
been associated with HIV-1 related neurological disease, as indicated by raised levels of LPS and LPS 
induced monocyte activation (sCD14) in individuals with HIV-associated dementia compared to 
other HIV-infected individuals with a CD4 cell count of <300 cell/µl, independent of CD4 cell count 
and HIV RNA levels (Ancuta, et al. 2008).   
Although there are much data supporting the hypothesis that microbial translocation is a key 
mediator of immune activation, other groups have been unable to show a correlation between T-cell 
activation and LPS levels (Cassol, et al. 2010; Papasavvas, et al. 2009; Wallet, et al. 2010), and the 
relationship between microbial translocation, immune activation, and disease outcomes is unclear. A 
recent study in Ugandan patients found that LPS has little effect on rate of HIV-1 progression in the 
African population (Redd, et al. 2009), but showed that levels of C-reactive protein (CRP) were 
predictive of HIV-1 disease outcome, concluding that immune activation is associated with HIV-1 
disease progression in the absence of microbial translocation (Redd, et al. 2010). Another study 
demonstrated increased levels of both circulating LPS and T-cell activation in HIV-1–infected South 
Africans with advanced disease (CD4<200 cells/µl) compared with uninfected African controls, but 
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did not observe any direct correlations between the frequency of CD38+HLADR+ CD8 T-cells or IFN-γ 
and plasma LPS levels. LPS levels correlated with sCD14 and TNF-α, and remained elevated in 
patients receiving effective ART, suggesting that microbial translocation is a driver of inflammation. 
The authors conclude that the processes contributing to the increase in immune activation in an 
African setting are multifactorial (Cassol, et al. 2010). Few longitudinal studies have assessed the 
prognostic importance of microbial translocation in HIV-1 infection in Western cohorts and thus its 
clinical significance is not completely understood. 
T-cell dysfunction and exhaustion 
The preferential infection of virus specific CD4 T-cells leads to impairment of HIV-1 specific CD4 cell 
function, occurring very early in acute infection (Lichterfeld, et al. 2004; Rosenberg, et al. 1997), 
followed by a reduced ability of CD4 T-cells to respond to other antigens (Lange, et al. 2003). 
Impairment of CD4 T-cell responses also affects HIV-1 specific CD8 T-cells responses (Lichterfeld, et 
al. 2004) resulting in functional deficits ranging from loss of cytolytic activity to complete exhaustion 
of T-cells.  
T-cell exhaustion may be defined as an inability of a CTL to produce cytokines or proliferate in 
response to environmental stimulus, resulting in functional CTL impairment and loss of viral control 
(Day, et al. 2006).  Multiple studies have reported an association between expression of inhibitory 
molecules, such as Programmed Death-1 (PD-1) and T cell exhaustion in chronic viral infection 
(Barber, et al. 2006; Day, et al. 2006; Trautmann, et al. 2006). Barber et al. showed that high levels of 
PD-1 were expressed on CTL in chronic mouse Lymphocytic Choriomeningitis virus (LCMV) infection, 
and that antibody blockade of the PD-1 signaling pathway resulted in a rapid increase of effector CTL 
function and enhanced viral clearance, indicating that virally-mediated CTL exhaustion may be 
reversible and raising possibilities for novel therapies (Barber, et al. 2006). 
Several studies have highlighted the role of PD-1 in negatively regulating the CTL response to HIV-1. 
Apoptosis of HIV-1 specific CTL is promoted by PD-1, and its expression on HIV-1 specific CTL 
correlates with other features of functional CTL exhaustion, such as impaired cytokine production 
and reduced capacity for CTL proliferation (Day, et al. 2006; Trautmann, et al. 2006). Expression of 
PD-1 on both HIV-1 specific CD8 and CD4 cells has been shown to correlate with predictors of 
disease progression, such as VL and inversely with CD4 T-cell count (D'Souza, et al. 2007; Day, et al. 
2006). Blockade of PD-1 increases PD-1+ T-cell function, and in animal studies leads to reduction in 
plasma SIV VL (Day, et al. 2006; Petrovas, et al. 2007; Trautmann, et al. 2006).    
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Sauce et al. (2007) looked at PD-1 in relation to the expression of CD38 and HLA-DR in both healthy 
controls and chronically infected HIV-1 infected individuals and observed that activated CD8 T-cells 
express higher levels of PD-1, compared to resting cells. Within the PD-1 positive cell population, a 
consistent up-regulation of PD-1 was observed on the cell surface of CD8 T-cells with higher CD38 or 
HLA-DR expression. Expression of PD-1 was also related to differentiation stage, expressed by 
subsets of antigen-experienced CD8 T-cells and strongest on early/intermediate differentiated CD8 
cells.  In addition, the study observed that in individuals undergoing interruption of ART, a 
concomitant up-regulation of CD38 and PD-1 on antigen-experienced CD8 T-cells occurred alongside 
viral rebound.  No direct association between the PD-1 expression and functional capacity of HIV-1 
specific CD8 T-cells was seen in this study. The authors concluded that on the one hand, high PD-1 
expression on HIV-1 specific CD8 T-cells may reflect cellular exhaustion and result in uncontrolled 
high VL, on the other hand, PD-1 is up-regulated further due to T-cell activation in the presence of 
high VL. Petrovas et al. showed that cells expressing high levels of PD-1 undergo high levels of 
spontaneous apoptosis and that manipulation of PD-1 leads to changes in the ability of the cells to 
survive and expand (Petrovas, et al. 2006; Petrovas, et al. 2007). Upregulation of PD-1 on activated 
CD8 T-cells in HIV-1 infected individuals may, therefore, be part of the homeostatic mechanism 
controlling T-cell proliferation and activation.  
Consequences of immune activation and exhaustion 
As cellular activation facilitates viral integration, T-cell activation promotes further HIV-1 replication, 
partly through increasing intracellular-nuclear-factor-kappa, which enhances transcription of 
integrated virus (Kawakami, et al. 1988).  Increased levels of HIV RNA promote further immune 
activation thus establishing a self perpetuating vicious circle. In addition, the release of pro-
inflammatory cytokines leads to ongoing T-cell activation.  
Cellular activation induces T-cell proliferation and differentiation, and persistent viral replication and 
repeated antigenic stimulation results in exhaustion of replicative capacities and functional T-cell 
impairment.  The dynamics of activation, expansion and apoptosis differ between CD4 and CD8 T-
cells, and whereas CD8 T-cells expand rapidly on activation, establishing a pool of resting memory 
cells, the capacity of CD4 cells to expand and survive is lower, so that many activated CD4 cells 
undergo apoptosis, resulting in a decline in total CD4 T-cell numbers (Appay and Sauce 2008). 
Chronic immune activation results in fibrosis of the lymphatic tissue, thymic dysfunction, and a 
general decline in T-cell renewal capacities, meaning that the naive T-cell pool cannot be replenished 
and is unable to replace exhausted CD8 T-cell clones or depleted CD4 T-cells. Consequently, a shift 
towards differentiated antigen experienced cell populations occurs, resulting in an overall 
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immunosenescence similar to that seen with age. Senescent antigen experienced memory T-cells 
display a CD28-/CD57+ phenotype which is associated with reduced proliferative capacity and 
shortened telomere length, a marker of biological aging (Appay, et al. 2007).  
As uncontrolled viral replication leads to depletion of the remainder of the CD4 cell pool, the 
immune system’s ability to control pathogens is lost resulting in the clinical manifestations of 
immunodeficiency characteristic of HIV-1 infection (Appay and Sauce 2008). In addition, ongoing 
viral replication and immune activation result in a chronic pro-inflammatory state, leading to 
activation of pro-coagulatory pathways, endothelial activation, and accelerating non AIDS-related 
disease processes such as CVD. A model of HIV-1 disease pathogenesis is shown in Figure 1.3. 
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Figure 1.3. Model of HIV-1 pathogenesis  
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1.4: Inflammatory responses in chronic infection and implications for clinical disease 
Inflammatory responses in chronic HIV-1 infection 
Viral replication and immune activation in chronic HIV-1 infection induce a pro-inflammatory state 
associated with raised levels of inflammatory biomarkers, such as IL-6 and CRP, thrombotic markers, 
such as D-dimer and fibrinogen, and markers of endothelial activation such as Inter-Cellular 
Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) (Neuhaus, et al. 
2010; Tien, et al. 2010; Wolf, et al. 2002). Inflammatory and coagulation pathways are closely linked, 
and whilst inflammation leads to activation of coagulation, coagulation also considerably influences 
inflammatory activity (Levi, et al. 2004). Inflammation leads to induction of tissue factor pathways, 
resulting in generation of thrombin and subsequent conversion of fibrinogen to fibrin. Tissue factor, 
thrombin, and other activated coagulation proteases bind to specific cell receptors called protease 
activated receptors to induce signalling pathways that mediate further inflammatory responses (Levi, 
et al. 2004). Endothelial cell activation results in the formation and shedding of pro-coagulant 
microparticles and leukocyte adhesion molecules, triggering inflammatory responses, adhesion and 
transmigration of leucocytes, platelet aggregation and activation of coagulation pathways (Shantsila, 
et al. 2010).  
In HIV-uninfected individuals, levels of IL-6, hs-CRP (high-sensitivity CRP) and ICAM-1 predict the risk 
of future cardiac events (Ridker, et al. 1998; Ridker, et al. 2002; Ridker, et al. 2000b). Raised D-dimer 
and fibrinogen are also associated with increased cardiovascular risk in apparently healthy 
individuals, indicating that activation of the endogenous fibrinolytic system occurs many years in 
advance of subsequent cardiovascular complications (Mora, et al. 2006; Ridker, et al. 1994).   
Early studies showed that pro-inflammatory cytokines such as IL-6 were associated with markers of 
HIV-1 disease progression, such as low CD4 cell count (Aziz, et al. 1998; Lafeuillade, et al. 1991). A 
cross-sectional analysis of 513 patients with chronic HIV-1 infection enrolled in the US Multicenter 
AIDS Cohort Study (MACS) in the pre-HAART era, found that levels of hs-CRP, an acute-phase protein 
generated in response to proinflammatory cytokines, such as IL-6, correlated with VL and inversely 
with CD4 cell count. In a longitudinal analysis of 81 individuals from the same study cohort, hs-CRP 
levels increased over time and raised levels were significantly associated with HIV-1 progression to 
AIDS, independent of CD4 cell count and HIV RNA levels  (Lau, et al. 2006). A recent analysis from the 
Fat Redistribution and Metabolic Change in HIV-1 Infection (FRAM) study showed that both 
fibrinogen and hs-CRP levels in HIV-1 infected patients independently predicted mortality over a five 
year follow-up period. When stratified by CD4 cell count, this was true even for individuals with high 
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CD4 cell count of >500 cells/µl, although the magnitude of risk was smaller (Tien, et al. 2010). A 
study in individuals commencing ART showed that higher pre-treatment concentrations of IL- 6, as 
well as soluble TNF receptor-1 (sTNFR-1), soluble CD27, and soluble CD40 ligand (sCD40L), were 
associated with a new AIDS-defining illness or death, occurring while on ART. Soluble TNFR-1, sCD27 
and sCD40L belong to the TNF superfamily of receptors that regulate lymphocyte proliferation, 
differentiation and survival, indicating that a heightened state of immune activation and 
inflammation prior to commencing ART is associated with adverse outcome while on treatment 
(Kalayjian, et al. 2010).  
Treatment interruption and Inflammation: The SMART study 
The first major indications that subclinical inflammation in chronic HIV-1 infection was associated 
with significant morbidity and mortality were made apparent through the results from a large-scale 
RCT, Strategies for Management of Anti-Retroviral Therapy (SMART), which investigated the use of 
strategic treatment interruption in individuals with chronic HIV-1 infection and CD4 cell counts > 350 
cells/µl.  The study was conducted to determine the effects of discontinuing successful ART in 
individuals with controlled infection, as a strategy to limit the complications of ART.  
Although widespread availability of ART has lead to a dramatic decrease in HIV-associated morbidity 
and mortality, ART regimens are associated with significant drug-associated toxicities, development 
of resistance and high costs. Early studies showed a link between ART therapy and metabolic 
complications, such as dyslipidaemia and  insulin resistance (Grunfeld, et al. 2008), and cumulative 
ART exposure was shown to be associated with increased cardiovascular risk in a large prospective 
cohort study, the Data Collection on Adverse Events of Anti-HIV-1 Drugs (DAD) study (Friis-Moller, et 
al. 2003). Treatment strategies conferring sustained immunological function in the absence of these 
complications are, therefore, highly desirable and several studies investigated strategies minimising 
ART exposure with this goal in mind (Ananworanich, et al. 2006; El-Sadr, et al. 2006).  
The SMART study, which included 5000 participants, compared a CD4-guided strategy of planned 
treatment interruptions versus continuous ART. Participants with CD4 >350 cells/µl were 
randomised to either a Drug Conservation (DC) arm or a Viral Suppression (VS) arm. In the DC arm, 
ART was deferred until CD4 cell count fell to <250 cells/µl and was discontinued when it returned to 
>350 cells/µl measured on two consecutive occasions at least two months apart. In the VS arm, ART 
was continued irrespective of CD4 cell count.  
In contrast to expectation, interruption of ART was associated with an increased frequency of all 
cause mortality (Hazard ratio (HR) 1.8 95% CI, 1.2 to 2.9; p=0.007), and following interim analyses, an 
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independent data and safety monitoring board recommended premature termination of the study in 
January 2006. Most of the deaths that occurred were attributable to non-AIDS events, including an 
increased risk of cardiovascular events (HR 1.57 95% CI 1-2.46, p=0.05) (El-Sadr, et al. 2006).  
The investigators hypothesised that the increased risk of treatment interruption in chronic infection 
may be due to HIV-1 induced activation of inflammatory and coagulation pathways. They therefore 
examined six plasma biomarkers (IL-6, D-dimer, Amyloid A, Amyloid P, hs-CRP and prothrombin 
fragment 1+2) in a random sample of 499 participants divided between the two study arms. Prior to 
randomisation, 74% of participants in this random sample were on ART and among these, 71% had a 
HIV RNA ≤400 copies/ml. Median age at baseline was 44 (IQR 38 to 51) years and 71% were male. 
The median baseline CD4 cell count was 540 (IQR 432 to 730) cells/µl. Baseline D-dimer was 
significantly higher in those not on ART (p<0.001) and in those with detectable viraemia on ART 
(p=0.02), but IL-6 did not vary significantly according to use of ART and HIV RNA at baseline. Higher 
D-dimer levels were also associated with higher age (p=0.002), black ethnicity (p=0.01), female 
gender (p<0.001), lower CD4 cell count (p=0.002), and greater body mass index (BMI) (p<0.001). 
Higher IL-6 at baseline was associated with age (p<0.001) and BMI (p<0.001)(Kuller, et al. 2008).  
Treatment interruption was associated with significantly increased levels of the systemic 
inflammatory markers IL-6 and D-dimer coincident with recrudescent HIV-1 viraemia. One month 
after randomisation, there was a 16% increase in D-dimer and a 30% increase in IL-6 in those 
discontinuing ART. In the subgroup of participants with HIV RNA <400 copies/ml at study entry there 
was a median increase in D-dimer of 0.07μg/ml (a 27% increase) in those stopping ART, compared 
with a reduction of 0.02μg/ml in the continuous treatment arm (p<0.0001 for difference). Similarly, 
for IL-6 the median increased by 0.98pg/ml (a 43% increase) in those stopping ART and increased by 
0.08pg/ml in the continuous treatment arm (p<0.0001).  There was a significant association between 
the magnitude of HIV RNA rebound on discontinuing ART and the rise in both IL-6 (p=0.003) and D-
dimer (p=0.005).  In a case control analysis comparing those who died with those who survived, both 
baseline levels of IL-6 ad D-dimer, and latest level prior to death, were strongly predictive of all-
cause mortality (p<0.0001 for all). There was a weaker association between hs-CRP and mortality. 
Kuller et al. concluded that the adverse events seen in the SMART study were likely to be related to 
inflammatory and coagulatory processes induced by HIV-1 replication upon discontinuing therapy 
(Kuller, et al. 2008).  
Further analyses of SMART data have shown that IL-6 and hs-CRP levels independently predict the 
development of opportunistic infection (Rodger, et al. 2009), and that sCD14, a marker of 
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macrophage activation secondary to LPS stimulation, is also predictive of all cause mortality 
(Sandler, et al. 2010). 
In a cross-sectional analysis involving SMART participants, biomarkers of inflammation, coagulation 
and renal function in 781 SMART study participants were compared to individuals enrolled in the 
Multi-Ethnic Study of Atherosclerosis (MESA), and Coronary Artery Development in Young Adults 
(CARDIA) studies. MESA and CARDIA are two large cohort studies of healthy individuals assessing 
long-term cardiac risk in individuals aged 45-76 years, and 33-44 years, respectively. Levels of hs-
CRP, IL-6, D-dimer and cystatin C (a marker of renal function) were all significantly higher in SMART 
study participants than in healthy control populations.  This remained true when SMART participants 
receiving ART with HIV RNA levels <400 copies/ml were compared to the healthy control population. 
Biomarker levels in ART treated individuals were approximately 40–60% higher than matched 
controls from the general population (Neuhaus, et al. 2010).  In a recently published SMART study 
analysis of a subgroup of participants who were naïve to ART or off ART for 6 months or longer at 
study entry, starting ART was associated with a 32% reduction in D-dimer levels at 6 months 
compared to those who did not initiate ART (p<0.001); but no significant differences were seen for 
hs-CRP or IL-6 levels compared to healthy controls. It should be noted that only 62% of ART treated 
individuals achieved HIV RNA levels <400 copies/ml in this analysis, and amongst those with VL 
suppression to below this level, significant reductions in IL-6 and hs-CRP were seen compared to 
baseline biomarker levels (Baker, et al. 2010). However, these recent analyses indicate that ART may 
not completely normalise levels of inflammation and risk associated with inflammation may remain 
even after ART is commenced. 
Other treatment interruption studies assessing inflammatory responses 
The SMART findings are supported by further studies indicating a rise in markers of inflammation 
and immune activation upon treatment interruption in chronic HIV-1 infection, which may persist 
even after reintroduction of ART (Calmy, et al. 2009; Papasavvas, et al. 2008; Tebas, et al. 2008). 
Papasavvas, et al. (2008) assessed changes in endothelial activation and T-cell markers of immune 
activation in individuals undergoing treatment interruption, and demonstrated that stopping ART 
was associated with rises in markers of endothelial activation (VCAM-1 and ICAM-1) and T-cell 
activation (CD8 CD38 expression). Rises in VCAM-1 correlated with both CD38 expression and HIV 
RNA, supporting a direct pathogenic relationship between viral replication, immune activation and 
endothelial stress. Tebas et al. (2008) also showed that there was an increase in T-cell activation 
(CD8 CD38 HLA-DR expression) on stopping ART, as well as rises in sTNFR2, and decreases in HDL 
cholesterol,  and hypothesised that these factors may contribute to the adverse cardiovascular risk 
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seen in the SMART study. In the Swiss-Thai-Australia Treatment Interruption Trial (STACCATO), 
Calmy et al.(2009) measured a selection of biomarkers before ART was initiated, after ART had 
suppressed HIV RNA to < 50 copies/ml and 12 weeks after randomization to continued ART (n=48) or 
interrupted ART (n=97). Initiation of ART resulted in significant declines in s-VCAM-1, P-selectin (a 
marker of platelet activation), and D-dimer, whereas cytokines with anti-inflammatory properties, 
such as IL-10, increased. Twelve weeks after stopping therapy, increases in plasma RNA were 
associated with rises in VCAM-1 and CCL2. There was no association between treatment interruption 
and IL-6, however a low sensitivity assay was used for measuring IL-6 and the majority of results 
were under the lower limit of detectability.  
HIV, endothelial dysfunction and cardiovascular disease 
Chronic inflammation and immune activation are important risk factors for CVD, and in HIV-
uninfected individuals, atherosclerosis is now recognised as a predominantly inflammatory disorder 
(Libby, et al. 2002). Chronic inflammation and immune activation associated with untreated HIV-1 
disease have been associated with an increased incidence of CVD (Hsue, et al. 2009; Triant, et al. 
2009). The extent to which HIV-1 itself accelerates CVD independent of its effects on traditional CVD 
risk factors or ART side effects is difficult to clarify. In a cohort study of 3851 HIV-1 infected and 
1044589 HIV-uninfected individuals, myocardial infarction (MI) was increased in HIV-positive 
patients with a relative risk of 1.75 (95% CI 1.51-2.02 p<0.0001), adjusting for age, gender, race, 
hypertension, diabetes and dyslipidaemia (Triant, et al. 2007). In a recent study of internal carotid 
intima medial thickness (IMT), a marker of subclinical atherosclerosis predictive of CVD events, HIV-1 
infected individuals had a highly significant increase in carotid IMT compared to HIV-negative 
controls, even after adjusting for demographics and traditional CVD risk factors, and HIV-1 was a risk 
factor for atherosclerosis similar in magnitude to traditional CVD risk factors, such as smoking 
(Grunfeld, et al. 2009). 
The role of inflammatory processes in HIV-1 related cardiac disease has been investigated in several 
studies. In a recent study of 487 HIV-1 infected patients compared to 70,000 HIV-uninfected 
individuals, elevated CRP and HIV-1 were each independently associated with increased risk of MI, 
and patients with HIV-1 with increased CRP had a particularly increased risk of MI (OR 2.13; 95% CI 
1.92 to 2.37; p<0.0001)(Triant, et al. 2009). In a case control study comparing HIV-1 infected 
individuals who had had a cardiac event with those who had not, Ford el al. demonstrated that 
several biomarkers (D-dimer, VCAM-1, soluble tissue factor and tissue inhibitor of 
mettaloproteinase-1) predicted cardiac events when measured either a year or 4 months prior to 
the event, although traditional risk factors were also of key importance (Ford, et al. 2010). A study 
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comparing HIV-negative individuals to elite controllers showed that controllers had increased levels 
of subclinical atherosclerosis. This indicates that HIV-1 infection increases cardiac risk even in the 
absence of HIV-1 viraemia or ART (Hsue, et al. 2009). Controllers have higher levels of hs-CRP, and T-
cell activation compared to HIV-negative individuals, indicating that premature atherosclerosis in 
HIV-1 may be due to HIV-1-induced inflammation and immune activation independent of VL, and 
highlighting that although controllers have improved outcomes compared to viraemic patients, elite 
control is not a completely benign condition (Hsue, et al. 2009; Hunt, et al. 2008). 
Biological markers of endothelial and platelet activation are increased in patients with arterial 
disease and are associated with progression of atherosclerosis. A study of 52 HIV-1 infected 
individuals showed that ICAM-1 and VCAM-1 were both raised compared to HIV-negative controls, 
and that on multivariable analysis these endothelial activation markers correlated with sTNFR2, 
suggesting  that endothelial activation is related to inflammation in the setting of HIV-1 infection 
(Melendez, et al.., 2008). A study of 41 HIV-1 infected individuals showed that levels of endothelial 
markers VCAM-1, ICAM-1, as well as D-dimer and von Willebrand Factor (vWF), reduced significantly 
on commencing ART. VCAM-1 and vWF significantly correlated with HIV RNA levels (Wolf, et al. 
2002).  Another recent study compared endothelial and platelet activation markers in 56 HIV-1 
infected individuals starting ART with HIV-negative controls and HIV-1 infected patients not starting 
ART. VCAM-1, CCL2, vWF and P-selectin, were all raised in HIV-1 infected patients, and VCAM-1, vWF 
and P-selectin reduced on commencing ART (Francisci, et al. 2009). The authors concluded that HIV-
1 itself, rather than ART, causes endothelial dysfunction.  Another study showed that CCL2 levels 
correlated with HIV RNA levels, and found an independent positive association between these 
factors and aortic vessel wall area and vessel wall thickness, measured by magnetic resonance 
imaging, supporting the link between HIV-1 infection, inflammation and atherosclerotic burden 
(Floris-Moore, et al. 2009).   
A study of patients commencing ART reported a significant improvement in endothelial function 
after starting therapy, as measured by brachial artery flow-mediated dilation, indicating that 
controlling HIV-1 viraemia with ART may be a successful approach to reducing cardiac risk (Torriani, 
et al. 2008). However, few studies have assessed the effects of starting ART on non HIV-1 related 
disease outcomes. ART itself is associated with some degree of risk and as described above does not 
completely normalise inflammatory and immune activation parameters compared to HIV-negative 
individuals (Neuhaus, et al. 2010).  
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ART and cardiovascular disease 
Prolonged exposure to ART is associated with dyslipidaemia and insulin resistance, which may 
potentially accelerate the onset of CVD (Grunfeld, et al. 2008). The DAD study demonstrated 
cumulative exposure to protease inhibitors (PI) as a risk factor (Friis-Moller, et al. 2007), partly 
explained by the effects of this drug class on lipid profile. Further analyses showed that the 
nucleoside reverse transcriptase inhibitors (NRTIs), abacavir and didanosine, were also associated 
with an increased risk of MI (Sabin, et al. 2008). The mechanism by which this occurs is unclear, as 
the risk was independent of the effects of ART on lipid and metabolic profiles, and cardiovascular 
events were limited to patients currently receiving, or within 6 months of receipt of the drug, rather 
than cumulative exposure.   
A sub-analysis of the SMART study confirmed that current use of abacavir was associated with an 
excess risk of CVD, and showed that subjects on abacavir had significantly higher levels of the 
inflammatory markers, IL-6 and hs-CRP, than subjects not receiving abacavir (Lundgren 2008). A 
prospective study described hyper-reactive platelets in patients receiving abacavir, compared to 
those not receiving abacavir (Satchell C 2009). Hence, platelet activity or other inflammatory 
mechanisms may be responsible for the adverse risk seen. The association between abacavir and 
cardiovascular risk has been confirmed in some further studies (Durand 2009; Lang 2009; Martin, et 
al. 2009) but not in others (Bedimo R 2009; Benson 2009; Brothers, et al. 2009). In the Simplification 
with Fixed-dose Tenofovir/Emtricitabine or Abacavir/Lamivudine in Adults (STEAL) study, a 
randomized simplification study in which treatment-experienced patients with controlled HIV-1 
infection were switched to simplify their regimen with either fixed-dose combination of 
tenofovir/emtricitabine or abacavir/lamivudine, there was a statistically significant increase in 
cardiac events in the abacavir arm, although the study was limited by small overall numbers of 
events (Martin, et al. 2009). However, no difference in  circulating levels of inflammatory or 
coagulatory biomarkers were seen between the study arms (Martin, et al. 2010). In a review of 
compiled HIV-1 clinical trial safety data from clinical trials sponsored by the abacavir manufacturer, 
GSK, there was no evidence of excess risk related to abacavir (Brothers, et al. 2009). The role of 
abacavir in causing CVD remains controversial.  
In the FRAM study, fibrinogen levels were 11% higher for participants taking a protease inhibitor, 
compared to those not using a protease inhibitor, further suggesting that specific ART components 
may have different effects on inflammatory or pro-thrombotic processes that influence 
cardiovascular risk (Madden, et al. 2008).  
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As HIV-1 infected patients live longer due to availability of ART, the impact of non-opportunistic 
disease becomes apparent. The aforementioned studies indicate that accelerated onset of CVD in 
HIV-1 infection may be related not only to the metabolic complications of ART and a high incidence 
of traditional CVD risk factors, but also to inflammatory responses triggered by HIV-1 itself, even in 
the absence of virus, or by specific components of ART. The exact role of immune activation and 
inflammation in the pathogenesis of CVD in HIV-1 infected individuals remain to be clarified.  
1.5: Antiretroviral therapy and when to start 
There are currently 5 classes of licensed ART drugs that act at different stages of the HIV-1 life cycle. 
The most effective means of establishing durable suppression of HIV-1 replication is the 
simultaneous initiation of a combination of usually 3 or more effective agents. The goal of 
combination ART is to suppress HIV-1 replication to below the limits of detection of current plasma 
HIV RNA assays (usually <50 copies HIV RNA/ml), thereby delaying disease progression and also 
limiting potential for selection of ART resistant HIV-1 variants.  
Despite undetectable HIV RNA levels of <50 copies/ml on standard clinical assays, numerous studies 
have demonstrated ongoing viral replication on ultrasensitive assays in the plasma of ART-treated 
individuals,  persisting even in patients who have been treated for several years (Bonora, et al. 2009; 
Havlir, et al. 2003; Palmer, et al. 2008). Treatment intensification with additional ART agents in 
subjects receiving suppressive regimens does not reduce this residual HIV-1 viraemia (Dinoso, et al. 
2009; McMahon, et al. 2010). As ART agents inhibit new cycles of viral replication, but do not block 
virus production from cells that are already infected, ongoing replication may reflect long‐lived 
reservoirs of chronically-infected cells or sanctuary sites with poor ART penetration (McMahon, et al. 
2010). The clinical significance of this lower level residual viraemia during successful ART remains 
unclear. 
The use of ART has remarkably altered the clinical course of HIV-1 infection; however, the optimum 
timing for treatment initiation remains unknown. It is possible that early ART, by reducing HIV-1 
related inflammation and immune activation, could profoundly impact non-HIV-1 related disease 
outcomes, although no data are available from randomised studies addressing this question.  In the 
SMART study, treatment interruption was associated with higher rates of liver, kidney and 
cardiovascular disease, however the CD4 T-cell thresholds for starting and discontinuing ART were 
relatively low (200 and 350 cells/µl, respectively). Current UK and European guidelines suggest 
commencing long-term ART at a CD4 T-cell threshold of 350 cells/µl (EACS Version 5.2; Gazzard, et 
42 
 
al. 2008) whereas US guidelines recommend ART is commenced at a threshold of 500 cells/µl (DHHS 
2009).  
Two large cohort studies have addressed the question of starting ART at higher CD4 cells counts. The 
North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) study, found that 
mortality was significantly reduced in individuals starting treatment at above 500 cells/µl (Kitahata, 
et al. 2009). However, European data from a collaboration of cohorts (ART Cohort Collaboration) 
found little evidence of a significant improvement in survival if treatment is started above a CD4 cell 
count of 350 cells/µl (Sterne 2009).  It is possible that confounding factors such as socioeconomic 
group may have impacted on results of the NA-ACCORD study, for example, those with poor access 
to care and greater likelihood of mental health issues would be less likely to start ART early and 
other factors may influence their health.  An international RCT of early (CD4 cell count >500 cells/µl) 
vs. deferred ART (current threshold of CD4 cells count 350 cells/µl), the Strategic Timing of ART 
(START) study, began recruitment in April 2009, and has been designed to answer the question of 
the best time to start ART. The study has been powered to assess the effect of early ART on the 
development of AIDS-related outcomes and non-AIDS morbidity and mortality including 
cardiovascular disease.  Pending the results of the START study, it is important that the potential 
benefits of starting early ART are weighed against potential adverse effects such as toxicity and high 
costs.   
The use of ART in PHI has already been discussed (section 1.2). The use of short-course ART during 
PHI is under investigation in the SPARTAC trial.  
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1.6: Hypotheses and aims of this thesis 
The role of immune activation and inflammation in chronic HIV-1 infection is becoming increasingly 
apparent; however there are few available data on inflammation and immune activation in PHI, a 
time when early events are likely to impact on long-term disease outcomes. Little is known about 
which factors determine the extent of immune activation and inflammation in HIV-1 infection, and 
the mechanisms surrounding these processes are not completely understood.   
There are currently no data on whether treatment with ART in PHI impacts on levels of inflammatory 
and coagulation biomarkers. It is possible that the use of short-course ART in PHI, by influencing the 
immunological and virological events surrounding this phase of infection, will have a long-term 
impact even once ART is discontinued. This could be through several mechanisms: short-course ART 
may limit the size of the viral reservoir, lowering viral set-point and thereby reducing subsequent 
inflammatory responses, or damage to the GALT may be limited by early ART, and therefore reduce 
long-term consequences such as microbial translocation and immune activation. 
There are no data examining the effects of stopping ART that has been started in PHI on 
inflammatory processes. It is not known whether the findings of the SMART study can be 
extrapolated to the setting of PHI. In the SPARTAC study, all participants who were randomised to 
ART underwent a protocol-indicated treatment discontinuation after either 12 or 48 weeks or 
therapy. PHI represents a very different immunological stage of HIV-1 mediated disease to chronic 
infection, and biomarker changes seen in PHI may therefore differ.   
Overall aims: 
i. To explore the relationship between surrogate markers of immune activation, inflammation, 
coagulation and microbial translocation in individuals with PHI (within six months of 
seroconversion). Markers examined in this thesis are detailed in Table 1.1 
ii. To examine host and viral factors associated with these markers  
iii. To assess the impact of commencing short-course ART in PHI on IL-6 and D-dimer levels  
iv. To assess whether the effects of discontinuing ART differ for ART commenced in PHI versus 
chronic HIV-1 infection in terms of 1) biomarker changes and 2) virological rebound 
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Table 1.1. Biomarkers examined in this thesis 
 
a) Inflammatory and endothelial biomarkers  
  
Marker  Function and significance in non HIV-1 infected 
cohorts 
HIV-1 related studies 
Inflammatory 
biomarkers 
IL-6  Pro-inflammatory cytokine produced by monocytes, 
endothelial cells, and lymphocytes. 
 Strongly associated with future cardiac events in 
healthy individuals. 38% increased MI risk for each 
quartile increase in IL-6 (p=0.001) where quartile 1 
<1.04, quartile 2: 1.04 –1.46, quartile 3: 1.47–2.28, 
quartile 4: >.2.28 pg/ml) (Ridker, et al. 2000b)  
 Raised in HIV-1 infection in both ART treated and untreated individuals (Aziz, 
et al. 1998; Neuhaus, et al. 2010). 
 Increased levels 4 weeks after stopping ART initiated in chronic infection 
(SMART study) and correlated with VL. Baseline level associated with all 
cause death  (OR 12.6, p<0.0001) and CVD death (OR 2.8,p=0.003) (Kuller, et 
al. 2008) . Also associated with future  opportunistic infection (Rodger, et al. 
2009) 
hs-CRP  Acute-phase protein secreted by liver in response to 
inflammatory cytokines including IL-6. Pro-
inflammatory function, activates complement 
cascade and enhances phagocytosis.  
 Strong predictor of 1
st
 CVS events (Ridker, et al. 
2000a)  levels of <1 mg/L low, 1-3 mg/l moderate, 
and >3mg/L high risk (Ridker, et al. 2002) 
 Raised in HIV-1 infection in both ART treated and untreated individuals 
(Neuhaus, et al. 2010) 
 SMART study: baseline level associated with all cause death (OR 2.4, 
p=0.003). No change 4 weeks after stopping ART. (Kuller, et al. 2008). 
Associated with future  opportunistic infection (Rodger, et al. 2009) 
 Correlates with VL and inversely with CD4 cell count. Baseline levels in 
chronic infection predict progression to AIDS (Lau, et al. 2006). 
 Independent predictor of mortality in HIV-1 infected individuals, even in 
individuals with high CD4 cell counts (Tien, et al. 2010) 
Endothelial 
function 
ICAM-1 
(CD54) 
 Intercellular adhesion molecule, expressed on  
leukocytes and endothelial cell membranes, mediate 
the adhesion and transmigration of leukocytes to 
vascular endothelium & promotes T-cell proliferation 
and cytokine release(Springer 1990) 
 Raised levels associated with future CVD events 
(Ridker, et al. 2000a; Ridker, et al. 1998).  Risk factor 
for atherosclerotic disease progression (Blann, et al. 
1998).  
 Elevated in HIV-1, decreases with ART, no correlation with VL but correlates 
with another marker of endothelial activation, VCAM-1, which correlates 
with VL (Wolf, et al. 2002)  
 ICAM-1 and VCAM-1 increase on treatment interruption in chronic infection. 
Change in VCAM-1 and T-cell activation correlate with change in VL on 
treatment interruption (Papasavvas E 2008) 
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b) Coagulation biomarkers    
Marker Function and significance in non HIV-1 infected 
cohorts 
HIV-1 related studies 
Coagulation 
Biomarkers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
D-dimer  Fibrin degradation product and marker of 
haemostatic activation  
 Becomes elevated when cross-linked fibrin is 
produced as a result of coagulation activation 
followed by secondary fibrinolysis 
 Elevated levels associated with increased risks of 
future cardiac events (Lowe, et al. 2004; Ridker, et al. 
1994) 
 Raised in HIV-1 infection in both ART treated and untreated individuals 
(Neuhaus, et al. 2010). Decreases with ART commenced in chronic HIV-1 
infection (Baker, et al. 2010; Calmy, et al. 2009; Wolf, et al. 2002). 
 Correlates with VL (Calmy, et al. 2009; Wolf, et al. 2002) 
 SMART study: increases 4 weeks after stopping ART initiated in chronic 
infection. Baseline levels predict all cause death (OR per quartile increase 
13.3, p<0.0001) and CVS death (OR 2, p=0.06)(Kuller, et al. 2008)  
 Independent association with cardiac risk in chronic HIV-1 infection (Ford, et 
al. 2010) 
Fibrinogen  Soluble plasma glycoprotein, synthesised by the liver. 
Converted into fibrin by action of thrombin.   
 Acute-phase protein, increases with inflammation  
 Elevated fibrinogen in persons aged 25-37 is 
independently associated with subclinical CVD in the 
subsequent decade (Green, et al. 2008). 
 HIV-1 infected patients have higher levels of fibrinogen compared with 
controls. Higher fibrinogen associated with protease inhibitor based 
regimens (Madden, et al. 2008).  
 Independent predictor of mortality in chronic HIV-1 infection, even in 
individuals with higher CD4 cell counts (Tien, et al. 2010) 
Tissue 
Factor 
 Glycoprotein expressed on a variety of surfaces, 
including platelets, monocytes, and sub-endothelium 
of blood vessel wall. Activated when vascular 
endothelium is damaged to initiate the extrinsic 
coagulation pathway(Breitenstein, et al. 2010). 
 Monocyte tissue factor expression and TF activity higher in HIV-positive 
compared to HIV-negative individuals.  Production stimulated by LPS 
exposure. Monocyte tissue factor expression correlates with viraemia and 
inversely with CD4 cell count (Funderburg, et al. 2010b)  
 Soluble tissue factor predictive of cardiac events in HIV-1 infected individuals 
when measured 4 months prior to the event  (Ford, et al. 2010).  
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c) Surrogate markers of T-cell activation and microbial translocation
Marker Function and significance in non HIV-1 infected 
cohorts 
HIV-1 related studies 
Cellular 
markers of  T-
cell activation  
& 
exhaustion 
CD38  Multifunctional transmembrane glycoprotein, 
upregulated  on activated T-cells,  with role in 
increasing cytokine production, CD4 cell 
proliferation and cell to cell adhesion 
 Stronger predictor of HIV-1 disease progression than either CD4 or VL load 
when measured in chronic HIV-1 infection (Giorgi, et al. 1999; Giorgi, et al. 
2002; Liu, et al. 1997). CD8 CD38 expression independently predictive of CD4 
decline when measured within 12 months of seroconversion (Deeks, et al. 
2004), and CD4 CD38 expression independently predictive of progression to 
AIDS if measured at one year after seroconversion (Hazenberg, et al. 2003b)  
HLA-DR  MHC class II cell surface receptor, upregulated on 
activated T-cells 
 Predictive of progression to AIDS in chronic HIV-1 infection(Hazenberg, et al. 
2003b). Dual expression of CD38 and HLA-DR also predictive of progression 
to AIDs when measured in chronic infection (Cao, et al. 2009) or one year 
after seroconversion (Hazenberg, et al. 2003b) 
PD-1  Marker of T-cell exhaustion and upregulated on 
activated T-cells. Negatively regulates immune 
responses. 
 High levels of PD-1 expressed on CTL in LCMV 
infection. Antibody blockade of the PD-1 signalling 
pathway results in  rapid increase in CTL function 
and enhanced viral clearance (Barber, et al., 2006) 
 Correlates with VL and inversely with CD4 T-cell count (Day, et al.., 2006).  
 Upregulated on activated T-cells in chronic HIV-1 infection (Sauce, et al. 
2007). 
 Promotes apoptosis of HIV-1 specific CTL. Expression on HIV-1 specific CTL 
correlates with other features of functional CTL exhaustion, such as impaired 
cytokine production and reduced proliferative capacity  (Day, et al. 2006; 
Trautmann, et al. 2006).   
Surrogate 
markers of 
microbial 
translocation 
sCD14  Upregulated on activated macrophages in the 
presence of endotoxin. Mediates the interaction of 
LPS with cells. Good indicator of LPS bioactivity in 
vivo and is less subject to contamination than LPS 
assays.  
 Binds LPS via LBP, and triggers production of 
inflammatory cytokines. 
 Raised in patients with both acute and chronic HIV-1 infection compared 
with HIV-negative individuals. Directly  correlates with both LPS and LBP 
(Brenchley, et al. 2006).  
 sCD14 correlates with HIV RNA in chronic infection and inversely correlates 
with CD4 cell count. Longitudinal measurement of sCD14 in advanced HIV-1 
(n=26) showed increasing levels associated with death (Lien, et al. 1998). In 
the SMART study, plasma levels of sCD14 also predicted mortality. LPS levels 
themselves were not associated with mortality (Sandler, et al. 2010). 
LBP  Acute-phase protein produced by GI and hepatic 
endothelial cells in response to LPS, and required 
for CD14 to bind LPS.  
 As with LPS, LBP is raised in chronic infection but not in those with hyper-
acute infection, when compared to HIV-negative individuals and correlates 
with sCD14 (Brenchley, et al., 2006).  
Endotoxin 
core Ab 
 In acutely unwell individuals with sepsis, EndoCAb 
bind LPS to clear it from the circulation and titres 
decrease. Increased levels in chronic conditions of 
microbial translocation (Barclay 1995) 
 IgM EndoCAb levels inversely correlate with LPS levels in HIV-1 infected 
individuals (Ancuta, et al. 2008; Brenchley, et al. 2006; Papasavvas, et al. 
2009).  Significantly reduced IgM levels seen in acute HIV-1 compared to 
HIV-negative, and lower in chronic infection compared to both acutely 
infected  patients and HIV-negatives (Brenchley, et al., 2006) 
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Chapter 2: Materials and Methods 
2.1. Ethical approval  
Ethical approval was obtained for the studies described in this thesis, and included  approval for 
studies of immunological and inflammatory function from participants of the St Mary’s Hospital 
Seroconverter study (REC 99/1A/161E), the SPARTAC study (MREC/04/2/025) and the Darunavir/r 
Raltegravir Pharmacokinetic study (REC 08/H0718/56). Written informed consent was obtained from 
all participants. Healthy controls at St Mary’s hospital were recruited to the Communicable Diseases 
Research Tissue Bank, Wright-Fleming Institute of Imperial College London (MREC 09/H0606/106).  
2.2. Study cohorts 
Subjects with PHI 
St Mary’s Hospital Seroconverter pilot study  
One-hundred-and-five patients with PHI were recruited into a pilot study at St Mary’s Hospital, 
London, between November 1999 and October 2003. In this non-randomized open-label study 
patients were offered 3-months short-course ART initiated immediately following diagnosis of PHI. 
PHI was defined by using one of the following criteria: 
1. positive HIV-1 antibody test result within 6 months of a previous documented negative HIV-
1 antibody test;  
2. acute symptomatic seroconversion illness in the presence of an evolving HIV-1 specific 
antibody response by ELISA;  
3. positive HIV DNA PCR or positive HIV RNA quantification in the absence of an antibody 
response. 
4. HIV-positive antibody test result with an ‘incident’ detuned assay result (Optical density (OD) 
< 0.6).  
Fifteen participants declined therapy and the remaining 90 were prescribed ART. Patients choosing 
ART were prescribed either fixed dose NRTI Combivir™ (zidovudine/lamivudine) with non-nucleoside 
reverse transcriptase inhibitor (NNRTI) nevirapine (n=29); or fixed dose NRTI combination Trizivir™ 
(zidovudine/lamivudine/abacavir) with NNRTI efavirenz (n=33); or protease inhibitor (PI) based 
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regimen Combivir and Kaletra™ (lopinavir/ritonavir)(n=17). Eleven individuals received alternate 
regimens for reasons of patient choice, resistance or toxicity.  
Both treated and untreated subjects were followed monthly for two years and monitored for 
evidence of disease progression. Follow-up was then 3 monthly or according to clinical need. Fifty-six 
participants remained in clinical care at St Mary’s Hospital in July 2009 with available clinical and 
laboratory follow-up data. Frozen plasma samples from 30 participants for whom samples were 
available were included in pilot inflammatory biomarker work for this thesis (Chapter 3).  
HIV-1 specific CD4+ and CD8+ T-cell immune responses were measured as the primary study 
outcome. Secondary outcomes included CD4 cell count and VL over time, development of resistance, 
and development of opportunistic infection. Study findings have been previously published (Fidler, 
et al. 2007; Fidler, et al. 2006; Fidler, et al. 2002). The study demonstrated preserved HIV-1 specific 
CD4 T-helper responses in study participants and that short-course ART in PHI may delay CD4 cell 
decline, and concluded that larger RCT are needed to establish if short-course ART in PHI results in 
long-term clinical benefit.  
SPARTAC study 
The SPARTAC study is an international blinded RCT assessing the effect of short-course ART in PHI 
(MRC 2007). The primary end-point of the study is time taken to reach CD4 < 350 cells/µl on more 
than one occasion. Clinical data, VL data and analysis of PBMC and plasma samples from SPARTAC 
participants for studies on markers of immune activation, inflammation, coagulation and microbial 
translocation are included in this thesis (chapters 4-7).   
SPARTAC participants were randomized to one of three arms: 12 weeks short-course ART at PHI 
diagnosis, 48 weeks short-course ART at PHI diagnosis, or no treatment. Patients randomised to ART 
were recommended to receive PI based regimens with 2 NRTIs. Three-hundred-and-sixty-six patients 
were recruited between 2003 and 2007, across 7 countries: UK, Spain, Italy, Brazil, Australia, South 
Africa and Uganda. Overall baseline characteristics of study participants, a breakdown of study sites 
and details of ART regimens started are shown in Table 2.1.  
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Table 2.1. Baseline characteristics of participants enrolled in the SPARTAC trial (n=366) 
 Number or Median         (%) or [IQR] 
Sex: Male 220 (60) 
 Female 146 (40) 
Risk group: Sex between men (MSM) 205 (56) 
 Heterosexual  158 (43) 
 Not known 3 (1) 
Age (years) 32 [25, 40] 
CD4 (cells/µl) overall 559 435, 700] 
HIV RNA (copies/ml) 34,068 [4702, 150,000] 
Seroconversion-type illness reported 215 (59) 
Subtype*                        B 210 (58) 
                                        Non-B 154 (42) 
Baseline resistance*   none 321 (88) 
                                        Stanford 3-5 33 (9) 
                                        Stanford 5 12 (3) 
Time from est. SC to baseline visit (days) 79 [58, 103] 
BMI (kg/m2) 24 [22, 27] 
Hepatitis B +ve 12 (3) 
Hepatitis C +ve 4 (1) 
Study site UK 149 (40.7) 
 Ireland 2 (0.6) 
 Australia 36 (9.8) 
 Brazil 17 (4.6) 
 Italy 23 (6.2) 
 Spain 2 (0.6) 
 South Africa 118 (32.2) 
 Uganda 19 (5.2) 
Randomised to and received ART  238 (65) 
ART regimen 2 NRTI + 1 (boosted) PI 217  (91) 
 2 NRTI + 1 NNRTI  15  (6) 
 3 NRTI + 1 NNRTI 3  (1) 
 Other 3 (2 ) 
Baseline characteristics of the 366 participants enrolled in the SPARTAC trial of short-course ART in PHI are 
shown. *available in 364 participants 
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Identification of PHI in SPARTAC  
Methods of PHI diagnosis used in SPARTAC are shown in Table 2.2. All patients were estimated to be 
enrolled into the study within a maximum of 6 months from documented seroconversion. The 
majority of study participants (67%) were identified as having PHI by an HIV-positive antibody test 
within 6 months of a negative HIV-1 antibody test.  The estimated date of seroconversion was 
calculated according to method of PHI diagnosis as shown in Table 2.2.  
Table 2.2. Diagnosis of PHI and estimated date of seroconversion in SPARTAC study participants 
(n=366) 
Method of PHI diagnosis Estimated date of seroconversion 
No of 
participants (%) 
HIV-positive antibody test within 6 months 
of a negative HIV-1 antibody test 
 Midpoint between negative and 
positive test dates 
 246 (67) 
 HIV-1 antibody negative with positive RT-
PCR 
 PCR date  9 (2) 
 “Incident” test at low level (<0.6) using 
detuned assay (for subtype B virus only) 
 Assay date  72 (20) 
 Equivocal HIV-1 antibody test supported by 
a repeat test within 2 weeks showing a 
rising optical density 
 Midpoint between equivocal and 
positive test dates 
 1 (0) 
 Clinical manifestations of symptomatic  
 HIV-1 seroconversion illness supported by 
P24 antigen positivity and greater than 4 
positive bands on Western Blot 
 Date of Western Blot / antigen test  38 (10) 
  Patients were diagnosed with PHI by one of 5 methods.  The method of calculating the estimated date 
of seroconversion, and number of patients diagnosed by each method, is shown.  All patients were 
estimated to be within six months of seroconversion at study entry. 
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Clinical assessments of SPARTAC participants 
Participants attended for clinical follow-up at weeks 4, 12, 16, 24, 36, 48, 52 and 60, and then every 
12 weeks or according to clinical need.  Clinical history since last assessment, including adherence 
assessment of trial medication, HIV-1 related and non HIV-1 related adverse events, AIDS events, use 
of concomitant medication and occurrence of pregnancy, were documented. 
 Physical examination according to patient history including weight and blood pressure was 
undertaken. To standardise measurements a British Hypertension Society approved, semi-automatic 
device, the OMRON 705-CP was used to measure the patients’ blood pressure. At each scheduled 
visit 3 seated measurements were made and recorded, and average calculated. Blood for 
biochemistry, FBC, CD4 cell count and HIV RNA were taken as well as trial specific samples for 
plasma and PBMC isolation (section 2.4). Genotypic ART resistance tests were taken at baseline, 4 
weeks after discontinuing the study drugs and then annually or according to clinical need. 
Primary End-points 
The primary end-point of the study is the time from randomisation to reaching a CD4 cell count of 
<350 cells/μl measured on two consecutive occasions not more than 4 weeks apart, or time to the 
initiation of late treatment. Secondary outcomes include HIV-1 specific CD4+ and CD8+ T-cell 
responses at week 60, time from randomisation to virological failure of first regimen, development 
of new drug resistance not present at baseline, development of an AIDS defining illness or death and 
differences in blood pressure from randomisation at week 12 and week 48. The study will report in 
the second quarter of 2011.  The study remains blinded to clinical outcome and hence all data in this 
thesis referring to samples collected as part of the SPARTAC study remain blinded to randomisation 
arm and to CD4 end-point. 
A summary of the SPARTAC trial design is shown in Appendix 1. 
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Subjects with Chronic HIV-1 infection 
Darunavir/r Raltegravir Pharmacokinetic study  
Plasma samples were obtained from 15 participants with chronic HIV-1 infection enrolled in a 
prospective study, which investigated the steady state pharmacokinetic profile of 3 consecutive ART 
regimes: phase 1 - darunavir/ritonavir dosed once daily with tenofovir/emtricitabine; phase 2 - 
darunavir/ritonavir/tenofovir/emtricitabine and the integrase inhibitor raltegravir; and phase 3- 
darunavir/ritonavir/raltegravir alone. Patients receiving boosted PI based regimens were eligible for 
study entry. Four participants were female (27%) and the median age was 42 years (IQR 35.5, 49.5). 
All patients had undetectable plasma HIV-1 VLs at time of enrolment and were healthy with no 
current health complaints other than asymptomatic controlled HIV-1 infection.  
Chapter 3 examines the effect of freeze thawing on plasma levels of IL-6 and D-dimer obtained from 
20 samples taken from 15 patients over the 3 study phases (15, 3 and 2 samples from study phases 
1, 2 and 3 respectively). 
Healthy controls 
Healthy controls for IL-6 and D-dimer plasma studies (chapter 4, n=11) were recruited from the 
clinical trials centre, St Mary’s Hospital, and invited to donate blood samples to the Communicable 
Diseases Research Tissue Bank, Wright-Fleming Institute of Imperial College London. Informed 
consent was taken for venepuncture, sample storage and analysis of samples.  Healthy controls for 
plasma studies of LPS surrogate marker studies, ICAM-1 and sTF (chapter 7, n=30) were recruited 
from the Thrombosis & Vascular Biology Group, Rayne Institute, St Thomas’ Hospital, in line with 
departmental procedures for recruitment of healthy controls. Informed consent for venepuncture, 
sample storage and analysis was taken and samples were taken according to institution health and 
safety procedures. Healthy controls for PBMC samples (chapter 6, n=10) were recruited from The 
Peter Medawar Building, Oxford, in line with departmental policy for recruitment of healthy 
controls. Volunteers were recruited following informed consent and samples were taken in line with 
the Oxford University Health and Safety guidelines.  
Healthy controls were not known to be HIV-positive but were not formally tested for HIV-1 infection.   
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2.3 Statistical methods  
Data were analysed using SPSS version 17.0, except for blinded SPARTAC data analyses which were 
carried out using Stata statistical software in collaboration with SPARTAC statisticians (Medical 
Research Council). Biomarker results were log10 transformed where necessary to normalize 
distributions for analysis purposes. Baseline variables were compared between different populations 
using Mann-Whitney U tests and T Tests. Changes in biomarkers were assessed using Wilcoxon 
signed rank test and T tests. All p-values were reported from two-sided tests and significance 
inferred if p<0.05. The association of baseline characteristics with biomarker results were examined 
using linear regression. For multivariate models, variables were included if the p-value was <0.1 in 
univariate models and backwards selection was used to find significant variables. For linear 
regression analyses the regression coefficient (B) is reported and represents the rate of change of 
one variable as a function of changes in the other, i.e. the slope of the regression line. Further 
individual statistical analyses are described in each chapter. 
Power calculations for SPARTAC IL-6 and D-dimer studies (Chapter 4) were based on future planned 
analyses which will take place once the SPARTAC trial is unblinded, and which will compare 
biomarker levels across the 3 arms of the study. The sample size was calculated to power the study 
to detect a difference in biomarker levels equivalent to a one-third change in risk of death, based on 
data from the SMART study which estimated that the rises in biomarkers observed one month after 
discontinuing ART would be associated with an increased risk of death of 16% and 24% for IL-6 and 
D-dimer, respectively (Kuller, et al. 2008). The differences in biomarker levels equivalent to this risk 
and their standard errors were taken from published data from the SMART study (Kuller, et al. 2008) 
and the sample sizes corrected for the multiple comparisons across the 3 study arms.  Based on 
SMART study data, 75 patients in each arm are required to demonstrate an increase in IL-6 level 
equivalent to an increased risk of death of one-third, based on 80% power, 5% alpha and allowing 
for multiple comparisons across the arms of the trial. For D-dimer, 41 participants in each arm are 
required.  
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2.4. Laboratory Methods 
HIV-1 parameters 
CD4 cell count measurement 
For pilot seroconverter patients, pharmacokinetic study patients, and SPARTAC patients recruited at 
St Mary’s hospital, CD4 cell count was measured at the Department of Immunology, St Mary’s 
Hospital.  Samples were processed using an ST1000 automated processor and analysed by flow 
cytometry using SC500 or Navios flow cytometers.  The Becton Coulter tetra CXP panel was used. For 
SPARTAC participants at other sites, CD4 cell count was measured locally using validated QC 
approved assays. 
Plasma HIV RNA assays  
Quantification of HIV RNA for pilot seroconverter patients, PK study patients, and SPARTAC patients 
recruited at St Mary’s hospital was measured at the Department of Virology, St Mary’s Hospital using 
the VERSANT HIV RNA 3.0 Assay (bDNA) kit (Bayer Siemens, previously Chiron).  This has a lower 
limit of detectability of 50 copies/ml and upper limit of quantification of 500,000 copies/ml. HIV RNA 
for SPARTAC participants from other sites was quantified according to local procedure in diagnostic 
laboratories, using validated QC approved assays. The most sensitive assay available at the local 
laboratory was used; at some sites (eg Brazil) this had a lower limit of detection of 400 copies/ml. 
HIV-1 co-receptor usage 
Genotypic tropism was determined by the molecular diagnostics unit of the Jefferiss Trust 
laboratories, Imperial College London. RNA was extracted from stored plasma samples, reversed 
transcribed and PCR amplified using primers adjacent to the V3 loop of env. PCR products were 
sequenced in both directions and edited sequences submitted to the Geno2pheno [coreceptor] 
algorithm (www.geno2pheno.org). The false positive rate (FPR) was set at 5.7%. 
Viral genotyping for HIV-1 resistance 
HIV-1 genotyping for UK SPARTAC participants was performed by the Molecular Diagnostics Unit in 
the Jefferiss Trust laboratories, Imperial College London. HIV-1 drug resistance was determined by 
sequencing of the PR and RT genes followed by submission of sequences to the Stanford Algorithm 
http://HIV-1db.stanford.edu 
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HLA typing 
HLA type was determined for UK SPARTAC participants only at the ASHI (American Society for 
Histocompatibility and Immunogenetics) accredited HLA typing laboratory, University of Oklahoma 
Health Sciences Centre, USA. HLA type was determined using reverse sequence-specific 
oligonucleotide kits for the HLA-A, HLA-B, and HLA-C loci (Dynal Biotech). To obtain four-digit typing, 
Dynal Biotech sequence-specific priming kits were used, in conjunction with the Sequence-Specific 
Oligonucleotide type.  
Collection and storage of blood samples  
Collection of plasma 
Plasma was separated on the day of HIV-1 clinic attendance and processed in a category 3 
laboratory. Whole venous blood was collected using vacutainer tubes containing 
ethylenediaminetetraacetic acid (EDTA) for plasma samples.  Blood collection tubes were 
centrifuged at 400 x g for 10 minutes. Using a sterile transfer pipette, plasma was aliquoted into 1ml 
cryotube vials and stored at -80˚C.  
Separation and cryopreservation of peripheral blood mononuclear cells  
Whole venous blood for peripheral blood mononuclear cells (PBMCs) was collected using vacutainer 
tubes containing anticoagulant citrate dextrose (ACD) and processed on the day on clinic attendance 
in a category 3 laboratory. The PBMCs were collected by density gradient centrifugation. In brief, 
blood was diluted 1:1 in phosphate buffered saline (PBS). The diluted blood was layered onto 
Histopaque-1077 solution (Sigma-Aldrich) in a 1:1 ratio in a 50ml centrifuge tube and centrifuged at 
800 x g for 30 minutes with no brake. The white blood cell fraction was transferred to a new 50 ml 
tube using a sterile Pasteur pipette, made up to 50ml in PBS and centrifuged at 400 x g for 5 
minutes, brake 3. The supernatant was discarded and cells re-suspended in 50ml PBS and 
centrifuged at 400 x g for 5 minutes.  The cell pellet was resuspended in 2ml of Roswell Park 
Memorial Insitute solution (RPMI, Sigma-Aldrich) supplemented with 10% heat inactivated fetal 
bovine serum (FBS) and 0.5% penicillin and streptomycin. PBMCs were counted using Trypan blue 
staining and a haemocytometer. After counting, the cells were centrifuged at 400 x g for 5 minutes, 
and resuspended in freezing medium, a solution of 50% heat-inactivated FCS, 40% RPMI and 10% 
Dimethyl sulfoxide (DMSO) at a volume of 3 x 106 cell per ml. One ml aliquots were placed in 
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cryotube vials (Sarsted). The PBMCs were frozen overnight at -80˚C in Mr Frosty cryocontainers 
(Nalgene, UK) and then transferred to liquid nitrogen or -150˚C freezers. 
Cell revival 
Cryopreserved cells were rapidly defrosted in a water bath at 37˚C, diluted in RPMI with 10% FBS 
and 0.5% penicillin and streptomycin, and supplemented with 10µl of deoxyribonuclease (DNAse, 
Qiagen). DNAse was added to breakdown DNA from dead cells to prevent live/dead cells clumping 
together. The cells were twice washed by centrifuging at 400 x g for 10 minutes, and resuspended in 
RPMI/FBS solution, and counted.  Cells were re-suspended in RPMI/FCS and rested 12-16h in an 
incubator at 37o C, 5% CO2 (Sanyo, CO2 incubator) before use for flow cytometry. 
Cell counting 
Fifty microlitres of cell suspension were added to 5µl 37% formaldehyde and 45µl Trypan Blue 
(Sigma) in a 1.5ml tube. The Trypan Blue cell mixture was placed in a well of plastic haemocytometer 
(Immune Systems) and cells in 4 squares were counted. The number of cells was calculated as 
follows: average cell count x 104 x 2 (dilution factor) x 2 (resuspended volume) = total number of 
cells/ml. 
Measurement of markers of Inflammation, coagulation and endothelial activation 
IL-6  
IL-6 was measured using Quantikine HS IL-6 immunoassay (R&D systems), an ultrasensitive 
quantitative sandwich enzyme immunoassay with a range 0.02–10 pg/ml. A highly sensitive assay 
was chosen as up to 75% of the patients with chronic HIV-1 have values below the detection limit of 
less sensitive kits used in some studies (Calmy, et al. 2009). All samples and standards were assayed 
in duplicate and co-efficient of variation (CV) calculated for each pair.  If CV was >10% the reason for 
this was reviewed and the sample repeated if necessary. A standard curve was repeated for each 
ELISA plate. 
Manufacturer’s instructions were followed throughout. Frozen plasma was thawed at room 
temperature. A standard curve was prepared by making a 2-fold dilution series from the IL-6 
standard provided (10 pg/ml). Standards or samples (volume 100µl) were pipetted into the wells of a 
microplate pre-coated with a monoclonal antibody specific for IL-6. The plate was incubated for 2 
hours at room temperature on a horizontal microplate shaker and then washed 6 times using the 
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wash buffer provided.  A conjugate solution, containing an alkaline phosphatase linked polyclonal 
antibody specific for IL-6, was added to the wells in 200µl aliquots. The plate was incubated for a 
further 2 hours on the microplate shaker and washed 6 times. The provided substrate solution was 
added to the wells in 50µl aliquots and the plate incubated on the bench top for 60 minutes. An 
amplifier solution was added, and colour development stopped with 50µl sulphuric acid (1M). The 
absorbance of each well was immediately determined using a microplate reader (Biotrak 2, 
Amersham sciences) set to 490nm, with background wavelength correction set to 620nm.  
Hs-CRP 
Hs-CRP levels were evaluated using a chemiluminescent immunoassay (Immulite 2500 Hs-CRP, 
Siemens Healthcare Diagnostics) at St George’s Hospital NHS trust laboratories. An automated 
analyser was used (Immulite 2500). 
D-dimer 
D-dimer was measured in the diagnostic haematology laboratory at St Mary’s Hospital, Imperial 
College Healthcare NHS Trust using an immuno-turbidimetric assay (Innovance D-dimer, Siemens 
Healthcare Diagnostics). An automated analyser was used (Sysmex CS2100i) 
Fibrinogen 
Fibrinogen was measured in the diagnostic haematology laboratory at St Mary’s Hospital, Imperial 
College Healthcare NHS Trust. Clotting time after addition of bovine thrombin (Thrombin reagent, 
Siemens) to diluted plasma was compared to a calibration curve using reference plasma (Standard 
Human Plasma, Siemens). An automated analyser was used (Sysmex CS2100i) 
Soluble tissue factor 
Soluble tissue factor (TF) was measured using Quantikine Human Coagulation Factor III / Tissue 
Factor Immunoassay R&D systems. All samples and standards were assayed in duplicate and 
manufacturer’s instructions were followed throughout. Frozen plasma was thawed at room 
temperature. Samples were diluted 2-fold by diluting 150µl plasma in to 150µl of provided diluent.  
A standard curve was prepared by making a 2-fold dilution series from the standard provided (500 
pg/ml). Standards or samples (volume 100µl) were pipetted into the wells of a micro plate pre-
coated with a monoclonal antibody specific for TF. The plate was incubated for 2 hours at room 
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temperature on a horizontal microplate shaker and then washed 4 times using the wash buffer 
provided.  The provided conjugate solution, containing a polyclonal antibody against TF, conjugated 
to horseradish peroxidise, was added to the wells in 200µl aliquots. The plate was incubated for a 
further 2 hours on the microplate shaker and washed 4 times. The provided substrate solution was 
added to the wells in 200µl aliquots and the plate incubated on the bench top for 30 minutes. Colour 
development stopped with 50µl sulphuric acid (1M). The absorbance of each well was immediately 
determined using a microplate reader (Dynax MRX) set to 450 nm, with background wavelength 
correction set to 540 nm. Results were analysed using Revelation software Version 4.06 (Dynax). 
Soluble ICAM-1 
Soluble ICAM-1 was measured using Quantikine sICAM-1 / CD54 Immunoassay (R &D systems). All 
samples and standards were assayed in duplicate and manufacturer’s instructions were followed 
throughout. Frozen plasma was thawed at room temperature.  Samples were diluted 20-fold by 
diluting 20µl sample into 380µl diluent. A standard curve was prepared by making a 2-fold dilution 
series from the standard provided (50ng/ml). The provided conjugate solution (containing a 
monoclonal antibody against sICAM-1 conjugated to horseradish peroxidise) was first added to the 
wells of a micro plate pre-coated with a monoclonal antibody specific for sICAM-1 in 100µl aliquots. 
Standards or samples (volume 100µl) were then added. The plate was incubated for 1.5 hours at 
room temperature on a horizontal microplate shaker and then washed 4 times using the wash buffer 
provided.  The provided substrate solution was added to the wells in 200µl aliquots and the plate 
incubated on the bench top for 30 minutes. Colour development stopped with 50µl sulphuric acid 
(1M). The absorbance of each well was immediately determined using a microplate reader (Dynax 
MRX) set to 450 nm, with background wavelength correction set to 540 nm. Results were analysed 
using Revelation software Version 4.06 (Dynax). 
Surrogate markers of microbial translocation 
Assays measuring LPS are highly subject to contamination and require specific procedures when 
collecting and storing plasma in order to ensure accurate results (Redl, et al. 1992).  Blood should be 
collected, and plasma stored in pyrogen-free containers, and subjects should be fasting when 
undergoing venepuncture (Personal communication Daniel Douek 2009). As SPARTAC samples have 
not been collected specifically for this purpose, surrogate markers of LPS activity, including soluble 
CD14, LPS-Binding Protein and Endotoxin Core Antibody, were measured in this study. In particular, 
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no information on dietary status at the time of venepuncture was available from SPARTAC 
participants. 
sCD14 
Soluble CD14 was measured using Quantikine Human sCD14 Immunoassay (R&D systems). All 
samples and standards were assayed in duplicate and manufacturer’s instructions were followed 
throughout. Frozen plasma was thawed at room temperature.  Plasma was diluted 200-fold by 
diluting 10µl plasma into 1990 µl of provided diluent. A standard curve was prepared by making a 2-
fold dilution series using the standard provided (16000 pg/ml). Standards or samples (volume 100µl) 
were pipetted into the wells of a microplate pre-coated with a monoclonal antibody specific for 
sCD14. The plate was incubated for 3 hours at room temperature on the bench top and then washed 
4 times using the wash buffer provided.  The provided conjugate solution containing polyclonal 
antibodies against sCD14 conjugated to horseradish peroxidise, was added to the wells in 200µl 
aliquots and the plate incubated for a further hour. After washing 4 times, the substrate solution 
provided was added to the wells in 200µl aliquots and the plate incubated for 30 minutes whilst 
protecting from light. Colour development stopped with 50µl sulphuric acid (1M). The absorbance of 
each well was immediately determined using a microplate reader (Dynax MRX) set to 450nm, with 
background wavelength correction set to 540nm. Results were analysed using Revelation software 
Version 4.06 (Dynax). 
LPS-Binding Protein (LBP) 
LBP was measured using LBP Human ELISA test kit (Hycult biosciences). All samples and standards 
were assayed in duplicate and manufacturer’s instructions were followed throughout. Plasma was 
diluted 1000 fold by diluting 10µl in 90µl of provided diluents, and then further diluting 10µl of 
resulting solution in 990 µl of diluent. A standard curve was prepared by making a 1.5-fold dilution 
series using the standard provided (50 ng/ml). The provided microplate pre-coated with antibody to 
LBP was prewashed 4 times before adding 100ul standard or sample. The plate was incubated on the 
benchtop at room temperature for 1 hour and further washed 4 times. One-hundred microlitres of 
biotinylated tracer antibody solution was then added and the plate incubated a further hour at room 
temperature. After washing 4 times 100ul provided conjugate solution containing streptavidin 
peroxidise was then added.  Following further one hour incubation and washing 4 times, 100ul of 
substrate solution was added. Colour development was stopped after 30 minutes by adding 100ul 
60 
 
oxalic acid, and the absorbance of each well determined using a microplate reader (Dynax MRX) set 
to 450nm. Results were analysed using Revelation software Version 4.06 (Dynax). 
Endotoxin-core antibodies (EndoCAb) 
Endotoxin-core IgM antibodies were measured using EndoCAb ELISA kit (Hycult biosciences). All 
samples and standards were assayed in duplicate and manufacturer’s instructions were followed 
throughout.  Samples were diluted 100 fold by diluting 10µl in 990µl of diluent. A standard curve was 
prepared by making a 2 fold dilution series using the standard provided (3.50 MMU/ml). 100µl 
standard or sample was added to the provided microplate pre-coated with endotoxins. The plate 
was incubated at 37°c (Dynax MRX) for 1 hour and further washed 4 times. 100µl of horseradish 
peroxidise conjugated antibody solution was then added to the wells and the plate incubated a 
further hour at 37°c. After washing 4 times 100µl provided substrate solution was added. Colour 
development was stopped after 30 minutes at room temperature by adding 100µl oxalic acid. The 
absorbance of each well was determined using a microplate reader (Dynax MRX) set to 450nm. 
Results were analysed using Revelation software Version 4.06 (Dynax). 
Flow cytometry techniques and markers of T-cell immune activation 
Cells were stained with a panel of antibodies for CD3, CD4, CD8, immune activation markers HLA-DR 
and CD38 and T-cell exhaustion markers PD-1, TIM-3 and LAG-3.  TIM-3 and LAG-3 were added as 
part of another project in order to maximise the use of the SPARTAC PBMC resource, and results for 
these markers are not described in this thesis.  Antibodies used and corresponding fluorochromes 
are shown in Table 2.3 
Antibody optimisation 
The optimal antibody concentration for each marker was determined by performing titrations of 
different antibody concentrations as demonstrated in Appendix 2. For activation markers CD38 and 
HLA-DR, PBMCs from healthy individuals were stimulated overnight at 37°c with 5µg/ml 
Phytohaemaglutin in RPMI/FCS in order to induce T-cell activation.   
Cell staining 
An antibody solution was made up by adding a 2µl aliquot of each antibody per patient sample 
(dilution 1:50 from stock) to 83.5µl PBS per sample, with the exception for CD38/QDot 605 where 
0.5µl was used (dilution 1:200).  This resulted in a total volume of 100µl per patient sample.  Final 
61 
 
antibody concentrations are shown in Table 2.3. A separate solution of isotype control and PBS was 
made up for negative samples.  
For each patient, 250,000 live cells were used in each positive FACS reaction and 100,000 cells used 
for the negative control. PBMCs were centrifuged at 500 x g (1600 rpm, ALC multispeed centrifuge 
PK131) for 10 minutes and supernatant removed. One-hundred microlitres of the antibody solution 
were added to the positive samples and 100µl of isotype control solution to the negative control 
sample. The solution was gently mixed to re-suspend the cell pellet and incubated at 4C for 30 
minutes. Following the 30 minute incubation period, 1ml of PBS was added to the cell/antibody mix, 
and the cells centrifuged for 10min at 500 x g. The supernatant was then poured off, and the cells 
fixed using 200µl 1% paraformaldyhyde solution in PBS. 
Compensation controls 
Positive compensation beads, polystyrene microparticles which bind immunoglobulin, and negative 
beads which have no binding but are used detect background fluorescence, were used to optimize 
fluorescent compensation settings by providing distinct positive and negative stained populations. 
Compensation controls were set up for each colour. One drop of positive compensation beads (BD 
Biosciences) were added to individual FACS tubes each assigned a colour and one drop of negative 
beads (BD Biosciences) was added to a negative control tube. Two microlitres of the antibody used 
for each colour was added to individual positive tubes. The solution was incubated at 4C for 10-20 
min, then 1ml PBS added, the solution centrifuged at 500 x g for 10 minutes and fixed with 1% 
paraformaldehyde in PBS. 
Determination of negative gates  
Negative gates for analysis were established using Fluorescence minus 1 (F-1). Due to a paucity of 
cells from SPARTAC patients’ samples, cells from healthy controls were used for F-1. 250,000 cells 
were placed into each tube and the cell antibody solution was prepared as described above. One 
antibody was omitted from each tube in order to establish negative gates for analysis of that 
particular antibody.  
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Sample Analysis 
Samples were analysed within 6h of fixation. Flow cytometry was carried out using a four-laser, 18-
color benchtop flow cytometer, LSR 11 equipped with a blue, red and violet lasers; (BD biosciences). 
The LSRII was standardised on a daily basis using cytometry setup and tracking beads (BD 
biosciences) to ensure reproducibility of data.  Compensation between flourochromes was regularly 
updated using compensation beads prepared as described above. Data were analysed using FloJo 
software version 8.8.6 (TreeStar, Inc.). T-cell analysis was performed on a gated population of 
lymphocytes as defined from forward versus side scatter 2 dimensional dot-plots for each sample. 
An example of the gating strategy and the placement of negative gates are shown in Figure 2. 1. The 
percentage of CD8 and CD4 cells expressing CD38 and HLA-DR were calculated, in addition to the 
median fluorescent intensity (MFI).  In addition the percentage of CD8 or CD4 cells with dual CD38 
HLA-DR expression, and percentage expressing PD-1, was calculated. 
 
 
 Table 2.3. Antibodies and fluorochromes used for T-cell activation study  
  
Antibody Fluorochrome Clone Company Final Concentration 
(g/100l) 
CD3 Pacific Orange UCHT1 BD Biosciences 0.4 
CD4 Alexa 700 RPA-T4 BD Biosciences 0.4 
CD8 PE-Cy5 (PerCP) SK1 BD Bioscience 0.4 
Live/Dead Pacific Blue n/a (Dye) Invitrogen 2l/100l 
CD38 Qdot 605 HIT-2 Invitrogen 0.4 
HLA-DR PE-Cy7 LN3 eBiosciences 0.4 
PD-1  APC  MIH4 eBiosciences 0.5 
LAG-3* FITC  17B4 LifeSpan Biosc 2 
TIM-3* PE 344823 R and D 0.05 
Antibodies used, fluorochromes, and final concentration of antibody used for flow cytometry are shown. *TIM-3 
and LAG-3 were added as part of another project in order to maximise the use of the SPARTAC PBMC resource 
and results are not described in this thesis. PerCP -Peridinin chlorophyll protein; PE – Phycoerythrin; FITC - 
Fluorescein isothiocyanate; APC - Allophycocyanin 
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Figure 2. 1. Examples of gating strategy and placement of negative gates  
Side  
scatter 
Side  
scatter 
Side  
scatter 
CD8 
CD3 CD4 Live / dead stain Forward scatter 
F-1: no HLA-DR included, negative gates are shown F-1: no CD38 included, negative gates are shown 
CD4 
CD38 
Gating strategy and Fluorescence minus one (F-1) results are demonstrated.  For F-1, the antibody of interest was omitted from the cell antibody mix in order to 
establish the placement of negative gates for that particular antibody during analysis 
 
CD4 CD8 CD8 
CD38 HLA-DR HLA-DR 
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Chapter 3: Pilot study assessing inflammatory and pro-coagulatory biomarkers in PHI and effects 
of freeze thawing 
Introduction 
Uncontrolled viral replication in chronic HIV-1 infection is associated with raised levels of 
inflammatory and pro-coagulatory biomarkers which are reduced upon commencing ART (Baker, 
et al. 2010; Calmy, et al. 2009). Data from the SMART trial indicates that subclinical inflammation 
after stopping ART in chronic HIV-1 infection may be associated with significant morbidity and 
mortality (Kuller, et al. 2008; Rodger, et al. 2009). Whether these findings can be applied to PHI 
warrants further investigation. The full extent of the inflammatory response in PHI, and effect of 
starting and stopping ART in this setting are unknown. We investigated the levels of pro-
inflammatory and coagulatory biomarkers in stored samples obtained from patients with PHI, and 
assessed feasibility of analysing frozen samples, with a plan to expanding this pilot study to the 
SPARTAC trial participants, if successful.  
The aims of this chapter were to: 
i. explore the feasibility of testing plasma for inflammatory and pro-coagulatory biomarkers 
after longer term freezing  
ii. measure levels of inflammatory and pro-coagulatory biomarkers in PHI, to assess the 
effect of ART in these patients and to assess the relationship between inflammatory 
markers and long-term clinical outcome in a pilot study 
Results 
3.1. Pilot work to assess the effect of long-term freeze-thawing on IL-6 and D-dimer assays.  
To assess the potential impact of freezing for a one year period on IL-6 and D-dimer assays, 20 
plasma samples were obtained from 15 patients with chronic HIV-1 infection enrolled into a 
pharmacokinetic study, on separate clinic visits.  The patient cohort enrolled in this study is 
described in methods chapter 2.2.  All patients had HIV RNA levels <50 copies/ml at enrolment and 
were in good health.   
For IL-6, EDTA plasma samples were collected according to the methods described in chapter 2.4, 
aliquoted into more than one vial, and immediately frozen at -20°c. Samples were batched and 
assayed within one month.  A further aliquot was analysed after a one year period. For D-dimer a 
fresh citrate sample was taken and sent straight to the haematology laboratory according to 
routine NHS procedure for assessing D-dimer.  A further EDTA plasma sample was collected and 
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immediately frozen at -20oc.  This sample was assayed after a one year period.  Details of the 
assays used for IL-6 and D-dimer are described in methods chapter 2.4.   
Table 3.1 shows median IL-6 and D-dimer levels and Spearman rank correlation between initial 
samples and those stored for one year.  For IL-6, there was a highly significant correlation between 
results from initial samples and those assayed after one year of freezing (Rank correlation 
coefficient 0.94).  Scatter plots of biomarker results measured within one month of sampling and 
then repeated after a 1 year period are shown in Figure 3.1a and demonstrated the relationship 
between initial and subsequent assay results.   Agreement between samples was further assessed 
by constructing Bland Altman plots (Bland and Altman 1986). Figure 3.2a shows a Bland Altman 
plot for IL-6.  The mean difference between the two IL-6 measurements is -0.1pg/ml (95% CI -0.25, 
0.03).  IL-6 measurements after one year fall within 0.50pg/ml below or 0.72pg/ml above the 
measurement within one month of freezing, indicating good agreement between initial and 
subsequent assays. 
For D-dimer, there was a strong correlation between fresh sample results and those repeated after 
one year, but the strength of relation between the ranks was weaker (Rank correlation coefficient 
0.79). The relationship between initial biomarker results on fresh samples and those repeated 
after one year is shown Figure 3.1b. Initial D-dimer results tended to be higher than those from 
samples that had been frozen for a year.  A Bland Altman plot for D-dimer is shown in Figure 3.2b. 
The mean difference between the measurements is 0.04 mg/L (95% CI 0.01, 0.07). From the 
calculated limits of agreement, the majority of D-dimer measurements after one year are within 
0.18 mg/L below and 0.09 mg/L above the measurement taken one month after freezing. 
 
Table 3.1.  IL-6 and D-dimer results measured within one month and after one year of freezing 
(n=20) 
 
Initial biomarker result 
Median (IQR) 
Repeated after 1 year 
Median (IQR) 
Spearman rank 
Coefficient 
p-value for 
correlation 
IL-6 pg/ml 1.41 (1.01, 2.05) 1.52  (1.18, 2.21) 0.94 <0.0001 
D-dimer mg/L 0.19 (0.16, 0.38) 0.13 (0.11, 0.29) 0.79 <0.0001 
 
20 EDTA plasma samples for IL-6 were batched and frozen at -20°c.  The initial sample was measured within 
one month of sample being taken and second sample measured after one year. For D-dimer a fresh sample 
was assayed within hours of being taken and a second sample frozen at -20°c and assayed after a year. 
Spearman’s rank correlation coefficient for agreement between initial and subsequent samples is shown 
alongside median values and IQR.   
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Scatter plot of biomarker results measured within one month of sampling and then repeated after a 1 year period, 
frozen at minus 20°c. The line of equality (x=y, solid line), indicating exact agreement between the two 
measurements, and best fit line showing relationship between the 2 measurements (dashed line) are shown.    
Figure 3.1. Scatter plot showing the relationship between initial biomarkers levels and assays 
repeated after one year (a) IL-6 and (b) D-dimer 
  
(a) 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
(b) 
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Figure 3.2.  Bland-Altman plot showing level of agreement between frozen samples for (a) IL-6 and 
(b) D-dimer 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
  
Bland Altman plots were constructed to assess agreement between first and second biomarker measurements. The mean 
of the 2 measurements (x axis) is plotted against the difference between the 2 measurements (y axis).  The horizontal lines 
demonstrate the mean difference and limits of agreement (2 Standard Deviations of mean difference). 
For IL-6, the limits of agreement are -0.72 and 0.50pg/ml therefore initial IL-6 measurement may be up to 0.5 pg/ml above 
or 0.72 pg/ml below the measurement after one year of freezing. For D-dimer, the limits of agreement are -0.09 and 0.18, 
and initial D-dimer measurements can be expected to be within 0.18 mg/L above and 0.09 mg/L below the measurement 
taken after 1 year after freezing.    
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Summary of freeze thaw analysis 
These data confirm that analysis of stored frozen plasma samples for IL-6 and D-dimer is a valid 
methodology to estimate these biomarkers in HIV-1 infected cohorts.  Freezing at -20°c for a one 
year period has little effect on IL-6 results. It should be noted that D-dimer results after one year of 
freezing are slightly lower that results from fresh citrated samples.  
3.2. Pilot study of inflammatory and pro-coagulatory biomarkers in PHI 
Prior to use of stored samples from the SPARTAC study, evaluation of the baseline and subsequent 
levels of biomarkers in PHI were assessed using stored plasma samples from a previous 
seroconverter study, described in methods chapter 2.2. Frozen plasma samples from 30 participants 
for whom serial samples were available were included in this analysis. Baseline samples had been 
stored a median of 6.3 years (IQR 5.7, 6.7 years; range 5.4, 7.2 years).  
In this non-randomized open-label study patients were offered 3-months short-course ART initiated 
immediately following diagnosis of PHI. Plasma levels of IL-6, hs-CRP, D-dimer and fibrinogen were 
measured at 4 time points: baseline, or the nearest time point to PHI diagnosis, 12 weeks, or just 
before stopping therapy in those who received treatment, a median of 8 weeks after stopping (range 
4 to 12 weeks after stopping), and a median of 9 months after stopping (range 8 to 10 months). 
Samples at equivalent time points from seroconversion were analyzed in those who did not receive 
therapy.   
Baseline characteristics 
Baseline characteristics and antiretroviral regimen of the 30 included participants are shown in Table 
3.2. Overall the median age was 34 years (range 27-65) and 87% were male. Twenty-five subjects 
received ART in PHI and 5 declined.  Patients who opted to receive therapy had significantly higher 
baseline HIV RNA than those who declined therapy (p=0.04, 95% CI 2.3, 92.8), and had a higher 
incidence of seroconversion symptoms, although this was not statistically significant (p=0.07, 95% CI-
0.8, 0.03). The ART regimen started reflected prescribing practice at the time of the study. Over half 
of patients were commenced on quadruple therapy consisting of Trizivir™ and efavirenz. Nearly one 
third commenced a PI based regimen comprising of Combivir™ and Kaletra™. 
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Table 3.2. Baseline characteristics and ART regimen started in 30 patients diagnosed with PHI 
 
 Received ART 
n=25 
Declined ART 
n=5 
Median age (range) 33 (27,65) 40 (29,56) 
Male (%) 23 (92) 3 (60) 
Median CD4 cells/µl (IQR) 
Median VL copies/ml (IQR)    
530 (310, 570) 
122534 (9980, 381860) 
448 (420, 630) 
5577 (1317, 34948) 
Symptomatic at presentation 20 (80) 3 (60) 
ART regimen started: 
Combivir™ / Nevirapine (%) 
Trizivir ™/ Efavirenz (%) 
Combivir™ / Kaletra™ (%) 
 
4 (16) 
14 (56) 
7 (28) 
 
 
N/A 
 
 
 
 
 
Assessment of biomarker levels in pilot study participants  
Samples were available for 27/30 patients at time point 1, for 100% patients at time points 2-4. 
Assay failure occurred for 7/27 fibrinogen samples and 1/27 D-dimer samples at time point 1. This 
was due to the automated analyser being unable to recognize the sample.  One fibrinogen sample 
failed at each of time points 2 and 3, and one D-dimer assay failed at time point 4.    All IL-6 and hs-
CRP assays were successful. No assays failures occurred in the 5 control patients. 
Median levels and interquartile range (IQR) of IL-6, hs-CRP, D-dimer and fibrinogen at each time 
point are shown for ART treated patients in Table 3.3 alongside VL and CD4 cell count data.  At 
baseline, there was a significant correlation between log10 transformed IL-6 and D-dimer (Pearson 
correlation coefficient 0.4, p=0.04), and between IL-6 and fibrinogen levels (both log10 transformed, 
Pearson correlation 0.5, p=0.02). hs-CRP was significantly correlated with fibrinogen (both log10 
transformed, Pearson correlation 0.9, p=0.001).  There was no association between biomarker levels 
at baseline and CD4 cell count or VL in this analysis. 
 
 
Baseline characteristics, incidence of symptoms related to seroconversion, and ART regimen started in 
30 patients diagnosed with PHI with available serial plasma samples.  
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Table 3.3.  Inflammatory biomarkers and HIV-1 parameters in 25 patients with PHI who received 3 
months ART at diagnosis  
 
Time point Week 0 
(1st clinic visit) 
Week 12 
 (on ART) 
Week 20  
(8 weeks after 
stopping ART) 
Week 48  
(9 months after 
stopping ART) 
IL-6 pg/ml         median 
                          (IQR) 
2.17 
(1.01,10.9) 
1.13 
(0.64,1.76) 
0.76 
(0.48,1.37) 
1.15 
(0.72,1.67) 
D-dimer mg/L   median 
                            (IQR) 
0.38 
(0.17, 1.87) 
0.24 
(0.12, 0.39) 
0.24 
(0.16, 0.48) 
0.32 
(0.12,0.49) 
hs-CRP mg/L    median 
                           (IQR)            
0.70 
(0.2, 2.1) 
0.70 
(0.25, 2.0) 
0.80 
(0.50, 1.75) 
1.00 
(0.33,1.90) 
Fibrinogen g/L median 
                           (IQR) 
1.83  
(1.53, 2.17) 
1.71 
(1.48, 2.30) 
2.1 
(1.97, 2.31) 
2.0 
(1.8, 2.33) 
VL copies/ml    median 
                            (IQR) 
122,534 
(9980, 381859) 
50  
(50-50) 
10946 
(3223,36758) 
20582 
(3734, 116969) 
CD4 cells/µl  median 
                            (IQR) 
420 
(310, 570) 
670 
(550,765) 
650 
(450,730) 
445 
(342,690) 
 
Median levels and IQR of IL-6, D-dimer, CD4 cell count and VL (VL) in 25 individuals diagnosed with PHI are 
shown across 4 study time points. Patients were started on ART at week 0 and discontinued at week 12.  
Plasma samples were available for 22 patients at week 0 and for 25 patients all other time points. Assay failure 
occurred for 7/27 fibrinogen samples and 1/27 D-dimer samples at time point 1.  One fibrinogen sample failed 
at each of time points 2 and 3, and one D-dimer assay failed at time point 4.  IL-6: n=22 week 0, n=25 weeks 
12-48; D-dimer: n=21 week 0, n=25 weeks 12 and 20, n=24 week 48; hs-CRP: n=22 week 0, n=25 weeks 12-48; 
fibrinogen: n=15 week 0, n=24 week 12 and 20, n=25 week 48 
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Changes over time in patients receiving ART (n=25) 
All patients receiving ART achieved a plasma HIV RNA of <100 copies/ml by 12 weeks of ART, and 23 
(92%) achieved an HIV RNA of <50 copies/ml by this time point. Figure 3.3 demonstrates biomarker 
changes for log10 transformed results across the 4 study time points in patients receiving ART.  
Changes in biomarkers were assessed using Wilcoxon signed rank test. There was a statistically 
significant decrease in plasma IL-6 concentration in treated patients corresponding with viral 
suppression 12 weeks after starting ART (p=0.01).  Following interruption of ART, at week 20, there 
was a further decline in IL-6 (p=0.002) despite a rebound in plasma HIV RNA.  At one year, or 9 
months after stopping ART, IL-6 levels had rebounded when compared to week 20 (p=0.04), but 
were not significantly higher than those whilst virally suppressed (p=0.4) and remained significantly 
lower than baseline values (p=0.01).  There was a significant reduction in D-dimer after 12 weeks of 
ART (p=0.01). Once ART was stopped D-dimer levels appeared static at 8 weeks (p=0.3). At 9 months 
there was no significant rise in D-dimer when compared to week 20 (p=0.7) and levels remained 
significantly lower than baseline (p=0.02). There was no significant change in hs-CRP across the 4 
time points in treated individuals (change on starting ART p=0.8, change on stopping ART p=0.7, 
change at 9 months compared to week 20 p=0.6). There was no change in fibrinogen on starting ART 
(p=0.4), however there was a rise on stopping ART (p=0.046).  At 9 months there was no further 
significant changes compared to week 20 (p=0.4) although levels remained significant higher than 
while suppressed on ART (p=0.005) and similar to baseline levels (p=0.3).  
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Log10 transformed biomarkers (median, IQR and upper and lower adjacent values) in 25 patients treated with ART for 3 months at Primary HIV-1 diagnosis are shown across 4 
study time points. ART was prescribed at HIV-1 diagnosis (week 0) and discontinued at week 12. Changes in biomarkers were assessed using Wilcoxon signed rank tests.  
(a) IL-6; n=22 week 0, n=25 weeks 12-48 (b) D-dimer; n=21 week 0, n=25 weeks 12 and 20, n=24 week 48 (c) hs-CRP; n=22 week 0, n=25 weeks 12-48 (d) fibrinogen; n=15 
week 0, n=24 week 12 and 20, n=25 week 48 
 
(a) 
Figure 3.3. Pro-inflammatory and coagulatory biomarkers in patients receiving 3 months ART at PHI diagnosis 
(b) 
(c) 
(d) 
p=0.01 p=0.002 p=0.04 p=0.01 p=0.3 p=0.7 
p=0.8 p=0.7 p=0.6 p=0.4 p=0.05 p=0.4 
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Changes over time in untreated participants with PHI (n=5)  
There were no significant changes in IL-6, D-dimer, hs-CRP or fibrinogen levels across the time points 
in the 5 patients who declined ART. Although not significant, median levels of biomarkers levels did 
decrease at week 12 compared to baseline (Table 3.4).  It was not possible to compare biomarker 
changes in those receiving therapy to those who declined due to small numbers of untreated 
patients.  
 
Table 3.4.  Inflammatory biomarkers and HIV-1 parameters in untreated patients with PHI 
 
Time point Week 0 
(1st clinic visit) 
Week 12 Week 20 Week 48 
IL-6 pg/ml         median 
                          (IQR) 
1.21 
(0.52, 2.09) 
0.64 
(0.47, 1.81) 
1.38 
(0.55, 3.85) 
1.42 
(0.50, 1.92) 
D-dimer mg/L   median 
                            (IQR) 
0.24 
(0.12, 0.35) 
0.23 
(0.15, 0.31) 
0.14 
(0.1, 0.39) 
0.13 
(0.12, 0.42) 
hs-CRP mg/L     median 
                           (IQR)            
1.0 
(0.30, 2.9) 
0.50 
(0.25, 1.70) 
0.30 
(0.20, 1.05) 
1.50 
(0.60, 1.70) 
Fibrinogen g/L  median 
                           (IQR) 
2.13 
(1.86, 2,21) 
1.88 
(1.79, 2.01) 
1.91 
1.81, 1.93) 
2.27 
(1.90, 2.37) 
VL copies/ml      median 
                            (IQR) 
5577 
(1317, 34948) 
11935 
(8326, 47135) 
15767 
(4170, 53144) 
35823 
(3661, 37484) 
CD4 cells/µl       median 
                            (IQR) 
530 
(448, 630) 
630 
(540, 720) 
510 
(405, 665) 
500 
(395, 670) 
Median levels and IQR of IL-6, D-dimer, CD4 cell count and VL (VL) in 5 individuals with PHI who declined 
therapy are shown across 4 study time points  
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Long-term follow-up 
Subjects were followed up for a median 5.35 years (IQR 4.9, 5.4 years); total 160.5 person years 
follow-up. 24/27 (88%) of subjects with baseline biomarker levels commenced on long-term ART.  
The median time to starting ART was 2.9 years (IQR 1.6, 5.1 years). Cox proportional hazards 
regression was used to assess whether baseline biomarkers, CD4 cell count and VL were associated 
with time to starting long-term ART (Table 3.5). Variables were log10 transformed for analysis 
purposes. A one log increase in VL was associated with a 36% increase risk of starting ART (Hazard 
Ratio 1.36, 95% CI 1.12, 1.64 p=0.002).  There were no association between biomarker levels at 
baseline and starting ART in this analysis, which is limited by small numbers. 
 
Table 3.5. Relationship between baseline parameters and time to starting long-term ART in 27 
participants with PHI 
Variable Hazard Ratio 95% CI p-value  
VL  1.36 1.12, 1.64 0.002  
CD4 0.48 0.17, 1.34 0.16  
IL6 0.99 0.93, 1.06 0.8  
D-dimer 1.03 0.87, 1.25 0.4  
Hs-CRP 0.98 0.9, 1.04 0.6  
Fibrinogen 0.66   0.25, 1.74 0.4  
Hazard ratio, 95% CI and p-value are shown for effect of baseline parameters at time of PHI diagnosis (VL, CD4 
cell count and biomarker levels) on time to starting long-term ART. 27 participants with available results at 
baseline were included.  
 
Summary of pilot seroconverter study 
Frozen plasma samples obtained from participants enrolled in a pilot study of short-course ART in 
PHI and stored for a median of 6.3 years, were successfully analysed for inflammatory and 
coagulation biomarkers. Levels of IL-6 and D-dimer significantly declined in parallel with starting ART 
in PHI, however a decline was also observed in untreated individuals at week 12. On discontinuing 
ART there was a delay in rebound of plasma biomarkers. Hs-CRP levels did not change significantly 
over the course of the study.  A high proportion of fibrinogen assays failed.  There was a significant 
rise in fibrinogen on stopping ART. Baseline HIV RNA was the only variable associated with time to 
starting long-term ART in this pilot study. 
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Discussion  
Several factors have been shown to influence the outcome of assays measuring cytokine and 
coagulation markers. Differences in methods of sample collection and processing of samples, 
including type of anticoagulant used, may affect assay results and limit comparability between 
laboratories (Aziz, et al. 1998; De Jongh, et al. 1997). Although multiple freeze-thaw cycles should be 
avoided, long-term freezing is thought to be a reliable method of sample storage (Aziz, et al. 1999a). 
Aziz et al. (1999) demonstrated that many cytokine and immune activation analytes, measured in 
HIV-1 infected samples, were stable under several different storage conditions, and concluded that 
batch testing of frozen stored samples for cytokine assessment was feasible. A study measuring 
short and long-term stability of D-dimer assays in citrated plasma samples showed short-term 
stability for at least 24h at room temperature and at 4–8°C as well as long-term stability for samples 
stored up to 3 years at ≤-60°C (Bohm-Weigert, et al. 2010). However, the effects of long-term 
freezing (up to 7 years) on plasma biomarker assays for IL-6 and D-dimer, and the effects of shorter 
term freezing on specific assays used in this thesis are unknown.  
This study demonstrates the feasibility of measuring biomarker levels from frozen plasma that has 
been stored for up to 7 years. Firstly, we assessed the effect of freezing for a one year period on IL-6 
and D-dimer results. Samples were assayed within one month of collection for IL-6 and repeated 
after one year of sampling. Results were highly correlated and showed good agreement. D-dimer 
was measured immediately using fresh citrated plasma and repeated after 1 year from frozen EDTA 
plasma.  Although there was a highly significant correlation between the measurements, D-dimer 
results were lower after one year. This could reflect a difference in anticoagulant between 1st and 2nd 
measurements in this analysis or be related to the temperature of storage (-20oc versus -60°c 
compared to the study by Bohn-Weigert et al.). This potential difference should be taken into 
account when comparing D-dimer results between studies using fresh citrated plasma, commonly 
used for D-dimer measurement in routine NHS care, and frozen plasma collected by other methods 
for research purposes.  
This analysis is limited by several factors. For logistical reasons, samples were stored at -20oc and 
may be better preserved at colder temperatures. In addition we were only able to assess the effects 
of freezing over a one year period due to time constraints, although samples assessed in this thesis 
were stored for longer time periods. For D-dimer a different anticoagulant was used for the 1st and 
second assays, and measuring initial D-dimer levels from EDTA plasma may have been preferable. 
Due to cost and logistic restraints associated with measuring individual IL-6 samples by ELISA, assays 
were batched and measured within one month. We were therefore unable to measure this 
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biomarker from fresh plasma. However, this study provides reassuring data that although these 
biomarkers may be moderately affected by freezing and storage conditions, results are highly 
correlated and generally comparable.  
We next analysed samples obtained from a pilot study where ART was offered to individuals with 
PHI. This pilot biomarker study demonstrates the feasibility of measuring biomarkers from EDTA 
plasma samples which have been frozen for a longer time period (median 6.3 years). Results were 
obtained for the majority of samples for D-dimer, IL-6 and hs-CRP.  A high proportion of samples 
measuring fibrinogen failed, in particular samples at the earliest time point, indicating that this assay 
is less amenable to such long-term storage. Following this pilot work, the effects of short-course ART 
in PHI on IL-6 and D-dimer were further investigated in a larger powered study, SPARTAC (chapter 4). 
Fibrinogen analysis was not undertaken in the SPARTAC population based on the problems identified 
in this pilot study. Hs-CRP was not analysed in SPARTAC samples due to cost constraints. 
This pilot study shows significant changes in IL-6 and D-dimer after 12 weeks on therapy. This work is 
underpowered to give a clear evaluation of the effects of treatment in PHI; hence it is not possible to 
draw firm conclusions from these data. Although there were no significant changes over time in 
untreated patients, it appears that reductions in biomarkers levels also occur in untreated patients 
at 12 weeks.  The small numbers of untreated subjects mean that it is not possible to evaluate the 
natural history of biomarker changes in untreated PHI or infer whether the changes seen in this 
study in treated patients are due to ART or due to the natural history of HIV-1 infection.  
In this pilot study, levels of IL-6 and D-dimer do not immediately rebound following interruption of 
short-course ART commenced in PHI, although they did begin to rise by week 48.  Biomarkers did not 
rebound to pre-treatment levels and this may reflect high levels of IL-6 and D-dimer at the time of 
PHI associated with intense viral replication and immune activation. Larger studies are needed to 
assess the natural history of these biomarkers in PHI. The unexpected delayed rise observed in IL-6 
and D-dimer compared with the reported change in these markers from the SMART study may be 
confounded by the small numbers in the study. In addition, the ART regimens used in the pilot study 
may impact on delayed biomarker changes: nearly 60% of pilot study participants were started on 
NNRTI based regimens which have longer plasma half life, compared to PI based regimens. It is 
possible that there may be a prolonged effect of the drug, even on ART discontinuation.  In later 
studies, such as SPARTAC, NNRTI based regimens were not the preferred regimen due to the risk of 
developing resistance associated with essential monotherapy during the NNRTI washout period, as 
well as known toxicities associated with nevirapine in patients with higher CD4 cells counts, and 
higher numbers of female patients particularly at African sites, meaning efavirenz was not 
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recommended. We observed a significant rise in fibrinogen levels on discontinuing ART, in keeping 
with the SMART study findings of raised biomarkers on stopping ART, although fibrinogen was not 
specifically measured in SMART.   
No significant changes were seen in hs-CRP over time in this study. This may be due to small 
numbers in the study, the short duration of treatment or due to a lack of hs-CRP response to ART. 
Calmy et al.(2009) saw no change in hs-CRP on starting and stopping ART. In the SMART study there 
was a decrease in hs-CRP, compared to baseline, in individuals commencing ART who achieved HIV 
RNA<400 copies/ml at six months (Baker, et al. 2010), but no difference in hs-CRP was seen at one 
month in individuals undergoing treatment interruption compared to those on continuous therapy 
(Kuller, et al. 2008) .  
The level of T-cell activation in PHI is predictive of disease progression (Deeks, et al. 2004) , and a 
recent study of 40 South African women found a small panel of plasma cytokines (IL-7, eotaxin and 
IL-1α) in PHI to be associated with rate of CD4 cell loss (Roberts, et al. 2010). We assessed the 
impact of HIV-1 parameters and baseline biomarker values on long-term disease progression as 
assessed by time to starting ART. It is known that HIV RNA levels in PHI and at viral set point predict 
disease progression (Lyles, et al. 2000; Mellors, et al. 1995) and in this analysis HIV RNA in PHI was 
significantly associated with time to starting ART. There was no association between baseline 
biomarker levels and time to starting ART. However, this analysis is limited by small numbers and 
will be expanded to a larger cohort of individuals with PHI (SPARTAC) once long-term follow-up data 
from these individuals are available.   
In this non randomized study, clear baseline differences between those who decline and accept 
therapy are observed, despite the small number of patients who declined therapy.  Patients who 
declined therapy had lower plasma VL at baseline and had a trend towards fewer symptoms. Many 
ART studies in PHI are in non-randomized cohorts, and these data demonstrate the importance of a 
randomized study to assess effects of short-course ART in PHI, in order to eliminate bias associated 
with reason for starting or stopping therapy.  Therefore, in order to gain a clear understanding of the 
effects of PHI on IL-6 and D-dimer, and to assess the effects of stopping and starting ART in this 
study, this work was expanded to the SPARTAC study in Chapter 4. SPARTAC has the largest existing 
cohort of randomized participants recruited in early infection, and its randomized design represents 
an ideal setting in which to investigate effects of treatment in PHI on immunological mechanisms 
and outcomes. This presents an opportunity to investigate inflammatory responses associated with 
PHI and the effects of short-course ART on pro-inflammatory and coagulatory biomarkers.  
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Chapter 4: Interleukin-6 and D-dimer in PHI and the effect of ART  
Introduction 
Individuals with chronic HIV-1 infection, both treated and untreated, have raised levels of IL-6 and D-
dimer compared with HIV-negative controls (Neuhaus, et al. 2010). Previous studies in HIV-1 
infected and HIV-negative individuals demonstrate that raised levels of these biomarkers are 
associated with considerable morbidity and mortality (Ford, et al. 2010; Kuller, et al. 2008; Ridker, et 
al. 1994; Ridker, et al. 2000b; Rodger, et al. 2009).  
The SMART trial investigated the effect of treatment interruption in chronic HIV-1 infection. Episodic 
use of ART, guided by CD4 cell count, was compared to the current practice of continuous therapy. 
The study found that risk of opportunistic disease or death was more than twice as great (HR 2.6, 
p<0.001) in those who discontinued ART (drug conservation arm) compared to those who continued 
therapy (viral suppression arm). The drug conservation arm was associated with an 84% (p=0.007) 
increased risk of all-cause mortality including an increased risk of fatal cardiovascular events (El-
Sadr, et al. 2006).  Interruption of ART in chronic HIV-1 infection was associated with significant rises 
in IL-6 and D-dimer four weeks following ART discontinuation (Kuller, et al. 2008).  Kuller et al. 
hypothesized that the observed adverse outcome following ART interruption was due to activation 
of inflammatory and fibrinolytic pathways, secondary to increases in HIV RNA. Increases in IL-6 and 
D-dimer were significantly associated with magnitude of VL rebound and in a case control analysis 
comparing those who survived to those who died, baseline biomarker levels were predictive or all 
cause mortality. These findings have led to a recommendation that ART is not discontinued in 
chronic HIV-1 disease (Gazzard, et al. 2008). 
It is unknown whether interruption of ART initiated in PHI elicits the same response in IL-6 and D-
dimer levels as seen in SMART. Acute HIV-1 infection is associated with an intense cytokine storm 
which may promote ongoing immune activation, viral replication and CD4 cell loss (Stacey, et al. 
2009).  This stage of infection is associated with massive viral replication, predominantly in the gut, 
where it is estimated that over one-half of the body's effector CD4 T-cell reserves are irreversibly 
lost (Mattapallil, et al. 2005). In chronic HIV-1 infection, long-term immune activation, in addition to 
viral replication and / or ART exposure have been linked to ongoing inflammation, with clinical 
implications including an increased risk of CVD (Grunfeld, et al. 2009). This has been demonstrated in 
studies linking increased carotid IMT in HIV-1 infected individuals to high CRP levels (Hsue, et al. 
2009). PHI represents a very different stage of HIV-1 mediated disease to chronic infection, and the 
absence of long-term immunological damage means that biomarker changes seen in PHI may differ 
to those seen in chronic disease.  IL-6 and D-dimer are known to confer an increased risk of mortality 
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in chronic HIV-1 infection; however there are no data examining factors associated with these 
biomarkers in early HIV-1 infection, or assessing the impact of short-course ART initiated in PHI. It is 
possible that interrupting therapy following treatment in PHI is a safe intervention due to the short 
duration of HIV-1 infection and short exposure to ART, and that short-course ART itself in PHI has a 
beneficial effect attenuating levels of immune activation and inflammation following discontinuation 
of therapy. Conversely, it may be that high levels of immune activation and inflammation triggered 
by PHI confer an increased risk of biomarker rebound when treatment is discontinued.  
The SPARTAC trial is currently investigating the impact of short-term ART in PHI on long-term disease 
progression. Three-hundred-and-sixty-six participants identified as having PHI were randomised to 
one of three arms: no treatment, 12 weeks ART or 48 weeks ART. Therefore all subjects who were 
randomised to one of the 2 treatment arms (n=238) underwent protocol-indicated treatment 
interruption following completion of short-course therapy.  
The aims of this chapter were to:  
i. summarise baseline IL-6 and D-dimer levels in PHI, and to compare biomarker levels in PHI 
to those at SPARTAC week 60 and to HIV-negative individuals 
ii. assess factors associated with IL-6 and D-dimer in PHI 
iii. evaluate changes in biomarker levels after 12 weeks on ART commenced in PHI and assess 
factors  associated with change in biomarker on starting ART  
iv. evaluate changes in biomarker levels after stopping therapy initiated in PHI and assess 
factors associated with change in biomarker on cessation of ART 
v. compare biomarker changes associated with stopping ART commenced in PHI to those seen 
in the SMART trial.  
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Results 
4.1. IL-6 and D-dimer in PHI  
Stored plasma samples from the baseline SPARTAC study visit were used to assess levels of IL-6 and 
D-dimer in PHI.  225 participants were enrolled into SPARTAC outside Africa and data from trial 
participants in Europe, Australia, and Brazil, were included. No data from African sites were included 
due to constraints in shipping samples in time for this analysis, and in addition, to focus inclusion 
towards MSM cohorts with clade B HIV-1 infection in order to enable more accurate comparison 
with the SMART population.  Baseline samples from 201 participants were available. 
Baseline characteristics of SPARTAC participants included in biomarker analysis 
Baseline characteristics of 201 individuals with available plasma for biomarker analysis are shown in 
Table 4.1. Subjects were predominantly MSM with subtype B virus. The median estimated time from 
seroconversion at randomisation, calculated by randomisation date minus the estimated 
seroconversion date, was 71.5 days.  The median CD4 cell count at baseline was 550 cells/µl and 
median VL was 44,407 copies/ml.  Of note, 13 (6.5%) participants had VL <400 copies/ml prior to 
initiation of ART. The majority of individuals (64%) were recruited from UK sites with 18%, 9.5% and 
8.5% recruited from Australia, Italy and Brazil respectively.  
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Table 4.1. Baseline characteristics in 201 SPARTAC participants  
 Number or Median       (%) or [IQR] 
Sex: Male 192 (96) 
 Female 9 (4) 
Risk group: MSM 181 (90) 
 Heterosexual  18 (9) 
 Not known 2 (1) 
Age (years) 34.7 [29.4,42.6] [range 19.6, 62.9] 
Subtype             B 178 (92) 
                            Non-B 16 (8) 
Time from est. SC to baseline visit (days) 71.5 [49, 94]  
BMI (kg/m2) 23.5 [21.7, 25.4] 
Systolic blood pressure (mmHg) 125 [117, 135] 
Diastolic blood pressure (mmHg) 76 [68, 82] 
CD4 (cells/µl) overall 550 [432, 711] 
 <350  19 (9.5) 
 350-499  53 (26.5) 
 500+  128 (64) 
HIV RNA  Overall 44407 [6371, 165855] 
(copies/ml) <400 13 (6.5) 
 400-9,999 44 (22) 
 10,000-99,999 72 (36) 
 >100,000 71 (35.5) 
Log10 HIV RNA (copies/ml)  4.7 [3.8, 5.2] 
SPARTAC site    UK 129 (64) 
                           Brazil 17 (8.5) 
                            Australia 36 (18) 
                            Italy 19 (9.5) 
Baseline demographics of 201 SPARTAC participants are shown alongside estimated time from seroconversion, 
CD4 cell count and VL. The time from seroconversion at randomisation was estimated by randomisation date 
minus the estimated seroconversion date. Subtype unavailable for 7 participants, CD4 cell count and VL 
unavailable in 1 participant 
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IL-6 and D-dimer at baseline SPARTAC visit (week 0), week 60 and in healthy controls 
In order to investigate longitudinal changes in IL-6 and D-dimer in SPARTAC participants, a 
comparison of biomarker levels between week 0 to week 60 was undertaken.  Baseline plasma 
samples at week 0 of the study were available from 201 individuals and from 193 individuals at week 
60.  SPARTAC participants were randomised to either no treatment, 12 weeks ART or 48 weeks ART; 
therefore all individuals had discontinued the ART given as a trial intervention by week 60. Due to 
the blinded nature of the SPARTAC trial, week 60 results were analysed together regardless of 
randomisation arm, and the impact of different lengths of ART used in the SPARTAC study (12 or 48 
weeks therapy) will be addressed at the end of the trial once the data is unblinded. Biomarker levels 
in 11 healthy individuals were analysed to assess whether these biomarkers are higher in HIV-1 
infected individuals compared to HIV-negative controls.  
Median levels and IQR are shown in Table 4.2 and log10 transformed data are demonstrated visually 
by box-plot graphs in Figure 4.1. The median levels of IL-6 and D-dimer were 1.43 pg/ml and 0.34 
mg/L respectively at PHI (baseline) and 1.45 pg.ml and 0.33mg/L respectively at week 60. Differences 
in biomarkers at week 60 were compared to week 0 using the Wilcoxon signed rank test. There was 
no difference in either IL-6 or D-dimer levels between week 0 and week 60.  IL-6 and D-dimer at 
week 0 and week 60 were compared to healthy controls using Mann-Whitney U tests.  IL-6 was 
significantly higher at both week 0 (p=0.01) and week 60 (p=0.02) than in healthy controls.  Levels of 
D-dimer were also significantly higher at both week 0 and week 60 than in healthy controls (week 0 
p=0.045; week 60 p=0.03). 
 
Table 4.2.  IL-6 and D-dimer at SPARTAC week 0, week 60 and healthy controls 
 Week 0 Week 60 Healthy controls 
 N Median [IQR] N Median [IQR] N Median [IQR] 
IL-6 pg/ml 201 1.43 0.9, 2.4 193 1.45 0.9, 2.5 11 0.54 0.2, 1.7 
D-dimer mg/L 192 0.34 0.2, 0.5 192 0.33 0.2, 0.5 11 0.2 0.15, 0.3 
Median values and IQR are shown for IL-6 and D-dimer at week 0, week 60 and in healthy controls. Plasma 
samples were available for 201 individuals at week 0 and 193 individuals at week 60.  D-dimer assay failure 
occurred in 9 samples at week 0 and 1 sample at week 60.  
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Figure 4.1. IL-6 and D-dimer levels at SPARTAC week 0 (PHI), week 60 and in healthy controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box-plots showing median, IQR and upper and lower adjacent values for IL-6 and D-dimer in SPARTAC 
participants at week 0 and week 60, and in HIV-negative controls.  Week 0 was compared to week 60 using 
Wilcoxon signed ranks test for paired samples. Mann-Whitney U tests were used to compare healthy controls 
to SPARTAC participants 
 
p=0.02 
p=0.03 
p=0.01 
p=0.045 
p=0.6 
p=0.9 
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4.2 Factors associated with IL-6 and D-dimer in PHI (SPARTAC week 0) 
The association between baseline IL-6 and D-dimer and baseline characteristics (age, sex, duration of 
infection, CD4 cell count, HIV RNA, systolic blood pressure, diastolic blood pressure and BMI) was 
examined using linear regression. Due to skewed distributions, both IL-6 and D-dimer were log10 
transformed to achieve normality for analysis purposes. The association between baseline log10 IL-6 
and log10 D-dimer and other baseline variables is shown in Table 4.3.  
Baseline log10 IL-6 was significantly associated with age and HIV RNA levels. A 1 log increase VL was 
associated with a 16% increase in IL-6 and a 10 year increase in age associated with a 16% increase 
in IL-6.  Baseline log10 D-dimer was associated with HIV RNA and age on univariate analysis, with a 
trend towards lower levels in female participants, individuals with higher CD4 cell counts, and higher 
levels closer to seroconversion.  On multivariate analysis HIV RNA and age remained significant. A 
17% rise in D-dimer was seen for every 10 year increase in age and a 31% increase in D-dimer was 
seen for every 1 log increase in HIV RNA.   
To further explore the relationship between plasma VL at baseline and biomarker levels, analysis of a 
further breakdown of the biomarkers by baseline VL was undertaken. IL-6 and D-dimer were 
assessed according to VL strata as shown in Figure 4.2.  For IL-6, patients with HIV RNA >400 
copies/ml had increased biomarker levels with increasing VL strata. Thirteen individuals had HIV RNA 
<400copies/ml at baseline, in the absence of ART, and these individuals had higher than expected  
IL-6 levels.  For D-dimer there was a linear relationship between increasing D-dimer and increasing 
VL strata.  
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Table 4.3. Linear regression models for baseline IL-6 and D-dimer 
.  
Marker Baseline variable 
Univariate Multivariate 
B 
Coefficient 
p 
value 
95% CI 
B 
Coefficient 
p 
value 
95% CI 
Log 10 
IL-6 
Age (+10 years) 0.07 0.01 0.01, 0.12  0.06 0.03 0.004, 0.11 
 Sex (female) -0.028 0.8 -0.27, 0.22    
(n=201) BMI (+1 kg/m2) -0.005 0.6 -0.02, 0.01    
 Time from SC (+1 week) 0.002 0.8 -0.009, 0.01    
 Systolic BP (+ 1 mmHg) 0.000 0.9 -0.004, 0.004    
 Diastolic Bp (+ 1 mmHg) 0.001 0.7 -0.004, 0.006    
 CD4 (+100 cells) -0.02 0.1 -0.04, 0.004    
 Log10 HIV RNA (+ 1 log) 0.07 0.007 0.02, 0.12 0.06 0.01 0.004, 0.11 
 Age (+10 years) 0.07 0.001 0.03, 0.14 0.05 0.02 0.01, 0.09 
 Sex (female) -0.19 0.06 -0.39, 0.01    
Log 10 
D-dimer 
BMI (+1 kg/m2) 0.001 0.9 -0.1, 0.02    
(n=192) Time from SC (+1 week) -0.008 0.09 -0.02, 0.001    
 Systolic BP (+ 1 mmHg) 0.002 0.17 -0.001, 0.006    
 Diastolic Bp (+ 1 mmHg) 0.001 0.6 -0.003, 0.005  
 
 
 
 
  CD4 (+100 cells) -0.02 0.09 -0.04, 0.003 
 Log10 HIV RNA (+ 1 log) 0.12 <0.001 0.08, 0.15 0.1 <0.001 0.07, 0.15 
 
Factors associated with IL-6 and D-dimer at baseline study visit are shown. IL-6 and D-dimer were log10 
transformed to achieve normality. B (regression coefficient), 95% confidence interval and p-value are given. 
For multivariate models, variables were included if the p-value was <0.1 in univariate models.  
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Figure 4.2.  IL-6 and D-dimer levels by VL strata in individuals with PHI 
 
a) IL-6 
 
b) D-dimer 
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IL-6 and D-dimer levels (median and IQR) are shown for each VL strata. IL-6 and D-dimer are log10 
transformed. 
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4.3 Effect of ART on IL-6 and D-dimer levels 
In order to investigate the effects of short-course ART on IL-6 and D-dimer levels in PHI, data from 
the two treatment arms of SPARTAC were combined and analysed. Participants were included in this 
analysis if they were randomised to start therapy for either 12 or 48 weeks as per the SPARTAC study 
protocol, if it was confirmed that they received ART and if available longitudinal stored plasma was 
available for biomarker analysis. IL-6 and D-dimer levels were analysed from stored EDTA plasma 
samples at baseline, 12 weeks after starting ART, at ART cessation (combined week 12 and week 48 
data according to arm), and 4 weeks after cessation (combined week 16 and week 52 data according 
to arm). The time point of 4 weeks after stopping therapy was chosen in order to allow comparison 
with the published SMART trial data of treatment interruption in chronic HIV-1 infected subjects. 
Effect of 12 weeks ART on IL-6 and D-dimer levels 
Excluding African sites, 150 participants were randomised to start therapy for either 12 or 48 weeks 
as per the SPARTAC study protocol and were confirmed to have received ART. Of these, plasma 
samples were available at both week 0 and week 12 in 115 individuals.  Paired baseline and week 12 
biomarker levels for these individuals are presented in Table 4.4.  
103 (90%) of participants suppressed HIV RNA <400 copies/ml at week 12. Differences in biomarkers 
at week 12 were compared to zero using the Wilcoxon signed rank test. On commencing ART, there 
was significant decline of 0.22pg/ml in the median IL-6 and a significant decline of 0.05 mg/L in the 
median D-dimer from baseline to week 12. 
The association of change in biomarkers after 12 weeks on ART with baseline covariates (age, sex, 
risk group, duration of infection, CD4 cell count, log10 HIV RNA, systolic blood pressure, diastolic 
blood pressure, change in CD4 cell count, HIV RNA suppression at week 12, and change in HIV RNA) 
was studied using linear regression to adjust for baseline and time dependant variables. Table 4.5 
shows factors associated with change in IL-6 and D-dimer after 12 weeks of ART.   
On univariate analysis, there was a trend toward an association between change in HIV RNA and 
change in IL-6 with larger change in HIV RNA being associated with larger fall in IL-6 levels. On 
multivariate analysis, a higher baseline CD4 cell count was associated with a larger decrease in Log10 
IL-6 at week 12.  Baseline IL-6 levels were strongly associated with change in IL-6, with an increase of 
1 log10 IL-6 being associated with a -0.07pg/ml greater decrease in log10 IL-6 after 12 weeks (an 
additional 17% decrease in absolute IL-6).  
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For D-dimer, on univariate analysis, HIV RNA, BMI and both systolic and diastolic blood pressure 
were significantly associated with change in D-dimer level on commencing ART. Higher HIV RNA 
levels were associated with a greater reduction in HIV RNA, and those with higher blood pressure 
and higher BMI had smaller reductions in D-dimer levels. In addition baseline D-dimer values were 
strongly associated with change in D-dimer, and there was a trend towards an association between 
change in D-dimer and change in HIV RNA levels. On multivariate analysis, BMI remained significant 
with a higher baseline BMI being associated with a smaller decrease in log10 D-dimer. In addition 
baseline levels of D-dimer remained highly significant predictors of change in D-dimer on ART. An 
increase of 1 log10 in baseline D-dimer was associated with a -0.06pg/ml greater decrease in log10 D-
dimer after 12 weeks (an additional 15% decrease in absolute D-dimer). The changes in both log10 IL-
6 and log10 D-dimer from baseline to week 12 were very strongly associated with baseline values 
with higher baseline values resulting in a greater decrease than lower values.   
 
Table 4.4. IL-6 and D-dimer after 12 weeks on ART (n=115) 
Marker N  Baseline + 12 weeks Change from baseline p-value 
Med IQR Med IQR  Med IQR 
IL-6  115 1.39 [0.83, 2.39] 1.17 [0.67, 1.75] -0.22 [-0.99, 0.35] 0.01 
Log10 IL-6  115 0.14 [-0.08, 0.38] 0.07 [-0.17, 0.24] -0.14 [-0.30, 0.18] 0.01 
D-dimer  112 0.34 [0.20, 0.51] 0.31 [0.17, 0.43] -0.05 [-0.16, 0.06] 0.003 
Log10 D-dimer  112 -0.47 [-0.69, -0.29] -0.51 [-0.76, -0.37] -0.08 [-0.22, 0.09] 0.003 
Log10 transformed and absolute levels of IL-6 and D-dimer (median and IQR), and median change after 12 
weeks ART, are shown. Participants from both SPARTAC treatment arms are included (patients randomised to 
either 12 of 48 weeks ART). Note D-dimer assay failure occurred in 3 participants 
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Table 4.5. Linear regression models for change in IL-6 and D-dimer after 12 weeks on ART 
 
 
Baseline variable (or change 
at week 12) 
Univariate Multivariate 
B p-value 95% CI B p-value 95% CI 
Log10  
IL-6 
Baseline Log10 IL-6 (+ 0.1) -0.07 <0.001 [-0.08,   -0.05] -0.07 <0.001 [-0.08,-0.05] 
Sex (Female) 0.19 0.40 [-0.27, 0.65]    
Risk group (MSW) 
                  (Not known) 
0.14 
0.23 
0.29 
0.42 
[-0.12, 0.40] 
[-0.33, 0.79] 
   
Age (+10 years) 0.00 0.61 [-0.01, 0.01]    
BMI (+1 kg/m2) 0.01 0.32 [-0.01, 0.04]    
Time from SC (+1 week) 0.00 0.73 [-0.02, 0.01]    
Systolic BP (+ 1 mmHg) 0.00 0.85 [-0.01, 0.01]    
Diastolic BP (+ 1 mmHg) 0.00 0.31 [-0.01, 0.00]    
CD4 (+100 cells) -0.03 0.10 [-0.07, 0.01] -0.04 0.009 [-0.07,-0.01] 
Log10 HIV RNA (+ 1 log) 0.06 0.10 [-0.01, 0.14]    
Change CD4 (+100) 0.00 0.83 [-0.04, 0.04]    
Change Log10 HIV RNA (+1) -0.07 0.07 [-0.14, 0.01]    
HIV RNA < 400 wk 12 -0.01 0.91 [-0.25, 0.23]    
Log10  
D-dimer 
Baseline Log10 D-dimer (+0. 1) -0.06 <0.001 [-0.08, -0.04] -0.06 <0.001 [-0.07,-0.04] 
Sex (Female) 0.18 0.37 [-0.22, 0.59]    
Risk group (MSW) 
                     (Not known)                 
-0.02 
0.21 
0.88 
0.40 
[-0.24, 0.21] 
[-0.29, 0.71] 
  
 
Age (+10 years) 0.00 0.28 [0.00, 0.01]    
BMI (+1 kg/m2) 0.04 0.01 [0.01, 0.06] 0.03 0.01 [0.01, 0.05] 
Time from SC (+1 week) 0.01 0.21 [-0.01, 0.02]    
Systolic BP (+ 1 mmHg) 0.01 0.04 [0.00, 0.01]    
Diastolic BP (+ 1 mmHg) 0.01 0.04 [0.00, 0.01]    
CD4 (+100 cells) 0.02 0.39 [-0.02, 0.05]    
Log10 HIV RNA (+ 1 log) -0.07 0.03 [-0.14, -0.01]    
Change CD4 (+100) 0.00 0.95 [-0.03, 0.04]    
Change Log10 RNA (+1) 0.06 0.07 [0.00, 0.12]    
HIV RNA < 400 wk 12 0.17 0.11 [-0.04, 0.38]    
Results from linear regression models looking at the change in Log10 IL-6 and Log10 D-dimer from baseline to 
week 12, and their associations with baseline variables, are shown. IL-6 and D-dimer were log10 transformed to 
achieve normality. B (regression coefficient), 95% confidence interval and p-value are given. For multivariate 
models, variables were included if the p-value was <0.1 in univariate models.  
 
90 
 
4.4 IL-6 and D-dimer after the cessation of ART in individuals achieving VL<400 copies/ml on 
treatment 
To assess the effect of stopping ART on IL-6 and D-dimer data from the two treatment arms were 
blinded and analysed together. IL-6 and D-dimer were assessed at end of treatment (either week 12 
or 48 depending on arm) and 4 weeks after stopping ART. 104 participants had available plasma at 
the end of ART for biomarker analyses.  In order to standardise comparisons only those participants 
with HIV RNA < 400 copies /ml on treatment were included in this analysis. 96 (92%) participants had 
suppressed HIV RNA <400 copies/ml at the end of therapy and analyses were restricted to these 
individuals.  Of these, 88/96 (92%) had plasma available for analysis 4 weeks after stopping ART.   
Table 4.6 presents paired biomarker data for the individuals included in this analysis and 
demonstrates the effects of starting and stopping ART in these participants. Median (IQR) biomarker 
levels are shown at beginning of therapy, after 12 weeks of ART, at the end of therapy and 4 weeks 
after stopping. Differences in biomarkers at 12 weeks compared to start of ART, and at 4 weeks after 
the end of treatment compared to end of treatment, were assessed using the Wilcoxon signed rank 
test. As previously demonstrated, there was a significant decline in IL-6 and D-dimer from baseline 
to week 12 of therapy. It should be noted that although the median values for D-dimer are the same 
at baseline and week 12, there was a reduction in mean d-dimer levels at week 12, indicating a 
skewed distribution of these data (mean [SD] D-dimer 0.43 [0.42] mg/L at baseline versus 0.41[0.75] 
mg/L at week 12; mean log10 D-dimer -0.48 [0.29] mg/L at baseline vs. -0.54 (0.32)mg/L at week 12).     
There was a significant increase of 0.23pg/ml [IQR -0.18, 0.91] in IL-6 from the end of ART to 4 weeks 
after treatment cessation and a significant increase of 0.04mg/L [IQR -0.06, 0.15] in the D-dimer over 
the same period.  The median [IQR] increase 4 weeks after stopping compared to baseline levels 
prior to starting therapy was 0.02 [-0.94, 0.78] for IL-6 (p=0.88) and -0.01 [-0.19, 0.12] for D-dimer 
(p=0.36) i.e. overall for the population tested biomarker levels for IL-6 and D-dimer returned to 
baseline levels by 4 weeks after stopping treatment. 
Median biomarker changes on stopping and starting ART in these individuals are further 
demonstrated in Figure 4.3.  
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Table 4.6. IL-6 and D-dimer on starting and stopping ART in individuals with HIV RNA <400 copies/ml at time of stopping ART 
Marker 
Start of ART (Baseline) 12 weeks after starting ART  
p-
value1 
 
End of ART  4 weeks after stopping ART 
p-
value2 
Med IQR Med IQR   Med IQR Med IQR  
IL-6  1.37 [0.82, 2.01] 0.94 [0.64, 1.53] 0.002  1.04 [0.70, 1.56] 1.45 [0.74, 2.08] 0.003 
Log10  
IL-6  
0.14 [-0.09, 0.30] -0.03 [-0.19, 0.18] 0.004 
 
0.02 [-0.16, 0.19] 0.17 [-0.12, 0.32] 0.001 
D-dimer  0.32 [0.20, 0.50] 0.32 [0.18, 0.43] 0.04  0.28 [0.18, 0.38] 0.33 [0.19, 0.41] 0.03 
Log10  
D-dimer  
-0.49 [-0.71, -0.30] -0.49 [-0.74, -0.37] 0.03 
 
-0.55 [-0.74, -0.42] -0.48 [-0.72, -0.39] 0.06 
 
Median biomarker levels on stopping and starting ART are shown in individuals achieving VL<400 copies/ml on therapy with available plasma samples. Biomarkers were 
measured at baseline (n=96), 12 weeks after starting ART (n-94), at end of ART (either week 12 or week 48 depending on arm (n=96), and 4 weeks after stopping therapy 
(n=88). 
1 
P-value for difference between baseline and week 12. 
2 
P-value for difference between end of ART and + 4 weeks. D-dimer assays failed in 2 participants at end of 
ART and 2 failed at 4 weeks after stop. 
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Figure 4.3. The effect of starting and stopping ART in PHI on IL-6 and D-dimer* 
  
P=0.002 P=0.003 
P=0.88 
P=0.04 P=0.03 
P=0.36 
Plasma IL-6 and D-dimer levels on starting and stopping ART are shown in 88 individuals who achieved HIV 
RNA<400 copies/ml by end of ART. Biomarkers were measured at baseline (PHI), 12 weeks after starting ART, 
at end of ART and 4 weeks after stopping therapy. P-values were derived using Wilcoxon signed rank tests. 
*Note end of ART data includes results from either week 12 or week 48 depending on randomisation arm. 
 
 * 
 * 
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Factors associated with change in IL-6 and D-dimer on stopping ART 
Factors associated with change in biomarker 4 weeks after stopping ART were assessed using linear 
regression. Table 4.7 presents results from univariate and multivariate regression analyses for 
change in IL-6 and D-dimer on stopping ART, based on covariates at the end of treatment. The 
increase in biomarkers does not appear to be associated with any variables at cessation of ART other 
than the biomarker value at the end of ART.  A lower value of IL-6 or D-dimer at the end of ART is 
associated with a larger increase after cessation.  BMI was associated with change in D-dimer on 
univariate analysis, with a lower BMI at the cessation of ART being associated with a larger increase 
in D-dimer after cessation of therapy, but this lost significance in the multivariate model. The 
association between the change in log10 IL-6 and log10 D-dimer with the change in Log10 HIV RNA and 
CD4 cell count is also shown. From the models there does not appear to be any association with the 
change in VL and the increase in either biomarker. It should be noted that the change in VL is equal 
to absolute VL at 4 weeks, as all participants included in this analysis were suppressed at the end of 
ART. The relationship between VL strata and change in biomarker is investigated further in Figure 
4.4. It appears that there may be an upwards trend across lower VLs for log10 IL-6 but that those who 
virologically rebounded to 50,000 copies/ml had smaller than expected increases in log10 IL-6. For D-
dimer those with low levels of virological rebound (<400 copies/ml) on stopping ART had larger than 
expected rebound in D-dimer.  
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Table 4.7. Linear regression models for change in IL-6 and D-dimer 4 weeks after cessation of ART 
compared to end of ART 
 
Change 
in 
marker 
End of ART variable (or 
change 4 weeks after stop) 
Univariate Multivariate 
B p-value 95% CI B p-value 95% CI 
Log10  
IL-6 
Log10 IL-6 (+ 0.1) -0.05 <0.001 [-0.07,-0.03] -0.05 <0.001 [-0.07,-0.03] 
Sex (Female) -0.05 0.82 [-0.45, 0.36]    
Risk group (MSW) 
                   (Not known) 
0.04 
-0.09 
0.77 
0.71 
[-0.21, 0.29] 
[-0.59, 0.41] 
   
Age (+10 years) 0.00 0.86 [-0.01, 0.01]    
BMI (+1 kg/m2) -0.01 0.46 [-0.04, 0.02]    
Time from SC (+1 week) -0.10 0.29 [-0.29, 0.09]    
CD4 (+100 cells) 0.00 0.96 [-0.03, 0.03]    
 Change in CD4 (+100) 0.00 0.71 [-0.04, 0.02]    
 Change in log10 HIV RNA (+1) -0.03 0.44 [-0.10, 0.04]    
Log10  
D-dimer 
Log10 D-dimer (+ 0.1) -0.05 <0.001 [-0.07,-0.03] -0.05 <0.001 [-0.07,-0.02] 
Sex (Female) 0.11 0.56 [-0.28, 0.51]    
Risk group (MSW)  
                   (Not known) 
0.11 
-0.15 
0.38 
0.54 
[-0.13, 0.34] 
[-0.63, 0.33] 
   
Age (+10 years) 0.00 0.64 [-0.01, 0.01]    
BMI (+1 kg/m2) -0.03 0.04 [-0.06, 0.00] -0.02 0.17 [-0.05, 0.01] 
Time from SC (+1 week) 0.07 0.47 [-0.12, 0.25]    
CD4 (+100 cells) -0.01 0.27 [-0.04, 0.01]    
 Change in CD4  (+100) 0.00 0.72 [-0.03, 0.02]    
 Change in Log10 HIV RNA (+1) 0.05 0.18 [-0.13, 0.31]    
 
 
 
 
 
  
Linear regression analysis of factors associated with change in IL-6 and D-dimer 4 weeks after stopping 
ART. IL-6 and D-dimer were log10 transformed to achieve normality. B (regression coefficient), 95% 
confidence interval and p-value are given. For multivariate models, variables were included if the p-value 
was <0.1 in univariate models.  
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Figure 4.4. Change in IL-6 and D-dimer 4 weeks after stopping ART by change in VL
b) Change in Log10 D-dimer  
a) Change in Log10 IL-6  
Change in IL-6 and D-dimer levels on discontinuing ART (median and IQR) are shown for each VL strata. 
Although there was no overall association in this cohort between change in biomarkers and change in HIV 
RNA, there does appear to be a relationship for IL-6 for all except the highest VL strata, and for D-dimer 
in all but the lowest VL strata. 
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4.5. Comparison with the SMART study 
Comparison of techniques used to measure IL-6 and D-dimer assays in SPARTAC and SMART. 
Prior to performing a comparison of biomarker changes associated with stopping ART in the SMART 
versus the SPARTAC study, a comparison of  the techniques used in the two studies  was undertaken 
in order evaluate the potential inter-laboratory variation and to assess differences between the 
commercial assays used.  Samples were identified from 10 SPARTAC patients where 2 or more vials 
of EDTA plasma were available at the same time point. Samples from SPARTAC week 252 were used 
due to the large availability of plasma at this time point. Plasma from one vial was analysed by the 
methods described in methods chapter 2.4 (IL-6 ELISA, R&D systems HS600B; D-dimer 
immunoturbidimetric assay Innovance, Dade Behring). The second vial was sent in dry shippers 
containing liquid nitrogen to Laboratory for Clinical Biochemistry Research, University of Vermont, 
the laboratory that had undertaken the biomarker evaluations in the SMART trial, where a  
chemiluminescent assay was used for IL-6  (R&D systems Q6000B) and an immunoturbidimetric 
assay was used for D-dimer (STA-R analyzer, Stago, Parsipanny, NJ).    
Table 4.8 demonstrates median results for IL-6 and D-dimer when measured in SPARTAC and SMART 
study laboratories. Spearman rank coefficient for correlation between the samples is also shown. IL-
6 assays results were highly correlated (Spearman Rank coefficient 0.83, p=0.003), however 
correlation between D-dimer assays was poor (Spearman Rank coefficient 0.52, p=0.11).  On 
parametric testing, Pearson correlation for log10 transformed results showed highly significant 
correlation between IL-6 assays measured at the two sites (coefficient 0.97, p<0.0001, and a less 
strong but still significant correlation between D-dimer assays (coefficient 0.77, p=0.014). 
The relationship between the results from the 2 laboratories is shown in Figure 4.5.  Despite the high 
correlation between IL-6 results from the 2 laboratories, all IL-6 results measured by SPARTAC 
methodology fall below the line of equality indicating that results from samples measured for the 
SPARTAC study were consistently lower than those measured in the SMART laboratory.  For D-dimer, 
all SPARTAC laboratory measurements lie above the line of equality indicating that results were 
consistently higher.  Bland Altman plots were constructed to further assess agreement between 
biomarker measurements at SPARTAC and SMART laboratories (Figure 4.6). For IL-6, the limits of 
agreement are -2.30 and -0.36 pg/ml, indicating that IL-6 results for SPARTAC are consistently lower 
than when measured in the SMART laboratory. For D-dimer, the limits of agreement are -0.01 and 
0.35, indicating that that D-dimer measurements may be between -0.01 mg/L lower and 0.35 mg/L 
higher in the SPARTAC laboratory.  Thus lack of agreement is demonstrated for both biomarkers.  
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It was therefore not possible to undertake a direct comparison between absolute levels of 
biomarkers between the two study populations as there was a significant difference between the 
assays employed.  
 
Table 4.8. IL-6 and D-dimer results measured from same samples in SPARTAC and SMART 
laboratories 
 
  
 
SPARTAC biomarker  
result 
Median (IQR) 
SPARTAC sample 
processed in SMART lab  
Median (IQR) 
Spearman rank  
Coefficient 
p-value for 
correlation 
 
IL-6 pg/ml 0.99 (0.28, 2.05) 2.24 (1.19, 3.22) 0.83 
 
0.003 
 
D-dimer mg/L 0.29 (0.18, 0.36) 0.08 (0.04, 0.15) 0.52 0.11 
IL-6 and D-dimer were measured in SPARTAC and SMART laboratories. Spearman’s rank correlation coefficient is 
shown alongside median values and IQR.   
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Scatter plot of biomarker results measured in SPARTAC and SMART laboratories. The line of equality (x=y, solid 
line), indicating exact agreement between the two measurements, and best fit line showing relationship between 
the 2 measurements (dashed line) are shown.    
Figure 4.5. Scatter plot showing the relationship between biomarkers levels in SPARTAC samples 
measured at Imperial College, London and repeated in the SMART study laboratory, Vermont USA 
 
(a) 
 
 
 
 
 
 
 
 
 
 
(b) 
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Figure 4.6. Bland-Altman plot showing level of agreement between SPARTAC and SMART 
laboratories measuring (a) IL-6 (b) D-dimer 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
  
Bland Altman plots were constructed to assess agreement between biomarker measurements at SPARTAC and SMART 
laboratories. The mean of the 2 measurements (x axis) is plotted against the difference between the 2 measurements (y 
axis).  The horizontal lines demonstrate the mean difference and limits of agreement (2 Standard Deviations of mean 
difference).For IL-6, the limits of agreement are -2.30 and -0.36 pg/ml, indicating that IL-6 measurement in the SPARTAC 
laboratory is consistently lower than in the SMART laboratory and demonstrating lack of agreement. For D-dimer, the limits 
of agreement are -0.01 and 0.35, indicating that that D-dimer measurements may be between -0.01 mg/L lower and 0.35 
mg/L higher in the SPARTAC laboratory, again demonstrating lack of agreement.    
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Comparison between SPARTAC and SMART study findings 
In view of the lack of agreement between assays used in the SPARTAC versus SMART trials, it was 
not possible to perform a direct comparison of individual patient data between SPARTAC and SMART 
studies. However, proportional change in biomarker values on stopping therapy in SPARTAC were 
compared with published results from the SMART study. Standard errors and 95% CI were calculated 
using bootstrapping techniques and two-sided p-values using t-tests. 
In published manuscripts the SMART study reported a 43% and 27% rebound in IL-6 and D-dimer, 
respectively, 4 weeks after stopping ART. Corresponding figures from SPARTAC were 22% (95% CI: 0, 
46%, p-value for difference from 43%: 0.09) for IL-6 and 14% (95% CI: 0, 29%, p-value for difference 
from 27%: 0.10) for D-dimer.  Thus rebound for both biomarkers appears to be lower when 
treatment was stopped in the SPARTAC study compared to the SMART, although this was not 
statistically significant.  For IL-6 this should be interpreted with caution due to SPARTAC values being 
lower than SMART values in the comparison between laboratories.  
4.6 Summary of results in this chapter 
In this chapter we demonstrate that levels of IL-6 and D-dimer are raised in HIV-1 infected 
individuals in both PHI and at week 60, compared to healthy controls.  In PHI, these biomarkers 
correlate with HIV RNA levels and age. There was a significant reduction in both biomarkers on 
commencing ART, however levels rebounded to baseline within 4 weeks of stopping ART.  Due to 
differences in the assays used, a direct comparison with individual patient data from the SMART 
study was not possible. Comparing proportional change in biomarkers on stopping ART between the 
two studies, there was a trend towards lower biomarker rebound in SPARTAC compared with SMART 
(p≤0.1). 
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Discussion 
This is the first study to examine levels of IL-6 and D-dimer in a large cohort of individuals with PHI 
and to assess the effect of starting and stopping ART commenced in this setting on these 
parameters.  Individuals with chronic HIV-1 infection have raised levels of IL-6 and D-dimer 
compared with HIV-negative controls (Neuhaus, et al. 2010), and stopping ART is associated with 
rises in these biomarkers (Kuller, et al. 2008); however there are few data at the time of PHI. In view 
of the adverse events demonstrated in the SMART trial, it is important to demonstrate the impact of 
stopping ART commenced in PHI on biomarker levels. As all SPARTAC participants randomised to 
receive ART undergo protocol-indicated cessation of therapy after 12 or 48 weeks, this cohort 
circumvents any biases that may be introduced by either clinical or patient-clinician led choice to 
start or stop ART initiated at PHI.  
IL-6 and D-dimer levels were significantly higher at both week 0 (PHI) and week 60 than in healthy 
controls. This is consistent with results from previous studies showing raised IL-6 and D-dimer in 
chronic HIV-1 infection compared to HIV-negative individuals (Neuhaus, et al. 2010), and another 
study of 14 South African women with available plasma samples before and after HIV acquisition, 
showing rises in IL-6 during acute infection (Roberts, et al. 2010).  Baseline levels of IL-6 and D-dimer 
in PHI were comparable to those seen at week 60 and in individuals on chronic suppressed ART 
(chapter 3.1 freeze thaw analysis), and slightly lower than those seen at baseline in individuals 
choosing to take ART in the pilot study (chapter 3.2 seroconverter study) although higher than those 
who declined ART in that study. Acute HIV-1 infection is associated with an intense cytokine storm 
(Stacey, et al. 2009), however participants recruited to SPARTAC represent later stages of PHI up to 6 
months after seroconversion and may have missed this cytokine peak. Whether short-course ART 
impacted on IL-6 and D-dimer levels at week 60 is currently unknown. Although all individuals have 
stopped treatment by week 60, due to the blinded nature of the SPARTAC trial, week 60 results were 
analysed together regardless of randomisation arm and represent a heterogeneous population in 
terms of treatment history.  
In the SMART study, baseline D-dimer levels were significantly higher in untreated individuals 
compared to those with HIV RNA <400 copies/ml on ART (p<0.001), but baseline IL-6 levels did not 
vary according HIV RNA (Kuller, et al. 2008).  In untreated SMART participants at baseline there was 
no correlation between HIV RNA levels and IL-6 or D-dimer(Baker, et al. 2010). In contrast, both IL-6 
and D-dimer were significantly associated with HIV RNA levels in PHI. When divided by HIV RNA 
strata, there was a linear relationship between VL strata and D-dimer levels. Interestingly, for IL-6, 
higher than expected levels were seen in the 13 individuals with VL <400 copies/ml at baseline. 
These individuals may represent natural elite controllers and when the trial is unblinded it will be 
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possible to examine the specific characteristics of these participants in more detail. A recent study of 
individuals with HIV-2 infection showed that in those with detectable HIV-2 RNA, VL correlates 
directly with level of immune activation, yet in those with natural elite control, a wide range of levels 
of immune activation is seen demonstrating that control of HIV RNA may not necessarily equate to 
low levels of immune activation and subsequent inflammation (Leligdowicz, et al. 2010).     
Both IL-6 and D-dimer in PHI were also associated with age, with increased age being associated with 
higher biomarker levels.  These data are consistent with observations in chronic infection (Kuller, et 
al. 2008). It is well-established that older subjects experience faster rates of CD4 cell decline  
(Touloumi, et al. 1998) and high levels of inflammation and immune activation, independent of HIV 
RNA levels, may in part explain this enhanced disease progression. The predictive value of baseline 
IL-6 and D-dimer levels in PHI on disease outcome measures (rate of CD4 cell decline, HIV-1 related 
events and AIDS diagnoses, and HIV-1 unrelated events such as CVD) is currently unknown but will 
comprise an interesting analysis once the trial is unblinded.  
Participants in SPARTAC were randomised 1:1:1 to one of the three arms.  For the assessment of the 
effects of ART on IL-6 and D-dimer, the two treatment arms (12 and 48 weeks ART) were combined 
and analysed together. No comparison was made between the two treatment arms as the SPARTAC 
study is still ongoing.  It is possible that the length of treatment could impact on immune 
inflammatory processes although there are no current data comparing relative lengths of treatment 
on biomarkers levels. It is also unknown how the changes in biomarkers observed in patients 
receiving ART compare with individuals with PHI who did not receive treatment. Once the SPARTAC 
study is unblinded in 2011, the randomized nature of the study will allow a direct comparison of 
biomarker levels in treated compared to untreated individuals, allowing us to assess the natural 
history of IL-6 and D-dimer changes in patients with PHI.   
As no comparison can be made with the control arm of SPARTAC until the study is unblinded, we 
cannot yet confirm whether the observed reductions were definitely due to the effect of ART or the 
natural history of biomarker changes following PHI. Recent analyses of SMART participants who 
were either naive to ART or not on ART at the time of randomisation showed significant reductions 
in D-dimer in individuals with chronic HIV-1 infection starting ART compared to those deferring ART 
(Baker, et al. 2010), consistent with other studies in chronic HIV-1 (Wolf, et al. 2002) and with our 
findings in PHI. However, no reductions were observed in IL-6 and hs-CRP in ART treated individuals 
compared to untreated individuals who deferred ART (p=0.12 and p=0.17 for IL-6 and hs-CRP, 
respectively, at six months). It should be noted that only 62% of individuals commencing ART in the 
analysis by Baker et al. suppressed HIV RNA to <400 copies/ml at six months, which may explain 
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these findings, and significant reductions were seen in IL-6, hs-CRP and D-dimer at six months 
compared to baseline in those achieving viral suppression (Baker, et al. 2010).  
In this analysis, IL-6 and D-dimer levels fell significantly within 12 weeks of starting ART in PHI, but 
rebounded to baseline levels 4 weeks after stopping therapy.  The clinical significance of these 
findings, in the setting of PHI, is not yet known. Factors associated with larger decrease on starting 
ART were also associated with a larger increase on stopping ART and there was no difference 
between baseline levels and those 4 weeks after stopping treatment.  A high biomarker level pre-
ART was associated with a larger fall of biomarker on commencing ART, and a low value on ART 
associated with a higher rise on stopping ART.  Likewise, high BMI was associated with a smaller fall 
in D-dimer on starting and also a smaller rise on stopping, indicating that those with high BMI have 
less response to ART in terms of biomarker changes.  Interestingly, in the SMART study, higher BMI 
was associated with higher levels of both IL-6 and D-dimer at baseline (Kuller, et al. 2008) and in the 
recent analysis by Baker et al, lower BMI was associated with greater reductions in hs-CRP, 
consistent with our finding for D-dimer (Baker, et al. 2010). In our analysis, high baseline CD4 cell 
count was associated with a larger fall in IL-6 on starting ART, suggesting a possible benefit of 
starting early ART, however there was no association between CD4 cell count at time of stopping 
ART and biomarker rebound. Baseline biomarker levels were associated with higher HIV RNA, 
however change in VL on stopping ART was not associated with change in either biomarker.  This is 
in contrast to the SMART study where rise in VL on stopping ART was significantly associated with 
change in IL-6 and D-dimer levels. The study is limited by small numbers of available plasma at later 
time points of stopping and starting ART, and the lack of association may be due to small numbers in 
each VL stratum.    
We performed a comparison of the laboratory techniques used between SPARTAC and the SMART 
trial, with samples from the same patient and time points analysed in the two laboratories. Although 
highly correlated, IL-6 results were consistently lower when measured in the SPARTAC study than in 
the SMART laboratory, indicating poor agreement between samples. For D-dimer, SPARTAC results 
were consistently higher. In a series of studies at the University of California, Los Angeles, which 
measured cytokines and soluble markers of activation in HIV-1 infected patients, substantial 
differences were found when ELISA kits from different manufacturers were used and analytic results 
from different lots of ELISA kits supplied by a single manufacturer also differed by up to 50% (Aziz, et 
al. 1999a). These studies highlight the need for quality control procedures when samples are 
analysed in more than one laboratory. Our study confirms a marked variation in performance 
characteristics between laboratories and demonstrates the need for caution when comparing results 
between different published studies.  
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The assays used in the SPARTAC trial were chosen after careful consideration on the basis of kit 
sensitivity and feasibility with available laboratory facilities, and expert opinion was that the assays 
used would be comparable between SPARTAC and SMART (personal communication Elaine Cornell, 
University of Vermont, USA).  In SPARTAC, standard operating procedures mean that all samples 
have been treated in the same way, although the effect of shipping from different sites is not 
known. Several quality control procedures were undertaken as described in methods chapter 2.4. 
Interestingly both IL-6 assays were from the same manufacturer. As D-dimer is a routinely used 
clinical test, SPARTAC D-dimer samples were measured in an accredited NHS laboratory. The 
discrepancy between results comparing the techniques used by the two studies may indicate 
differences in the assays used or possibly differences in laboratory techniques or storage conditions. 
The effect of shipping samples is unclear.  However this comparison of techniques is limited by the 
small number of samples included and a larger sample would give a better indication of the 
discrepancy between laboratories.    
Although it was disappointing not to be able to undertake a direct comparison between SPARTAC 
RCT and SMART using individual patient data, the crude comparison with published data may give an 
indication of level of biomarker rebound after treatment interruption of ART initiated in PHI versus 
chronic HIV-1 infection. Although we found no significant differences in biomarker rebound when 
compared to the SMART study, there was a trend towards lower levels of IL-6 and D-dimer rebound 
compared to that observed in chronic infection. For IL-6 this comparison must be interpreted with 
caution as IL-6 results were consistently lower in SPARTAC than those in SMART in the comparison of 
techniques used in the two studies.  However as the comparison of techniques showed consistently 
higher D-dimer results for SPARTAC, our results indicate that D-dimer rebound is likely to be lower 
on discontinuing ART commenced in PHI (SPARTAC) compared to that commenced in chronic 
infection (SMART). PHI represents a very different immunological stage of HIV-1 mediated disease to 
chronic infection, and biomarker changes may therefore differ. It is also possible that the clinical 
consequences of biomarker rebound may differ between chronic and PHI due to the short duration 
of HIV-1 infection at ART initiation and short exposure to ART.   
In conclusion we observed raised levels of IL-6 and D-dimer in PHI and at week 60 compared to 
healthy controls. Both biomarkers were related to age and HIV RNA levels. A significant reduction in 
IL-6 and D-dimer occurred on commencing ART in PHI. On discontinuation of therapy, both 
biomarkers rebounded to baseline levels but did not rebound beyond baseline levels at week 4. 
Once the SPARTAC trial is unblinded in 2011, the clinical significance of these findings will be 
investigated.  
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Chapter 5: HIV-1 VL dynamics following cessation of ART started in PHI or during chronic infection  
Introduction  
The level of HIV-1 VL is a strong predictor of disease progression when measured in both early (Lyles, 
et al. 2000) and chronic HIV-1 infection (Mellors, et al. 1997; Mellors, et al. 1996; Phillips and 
Pezzotti 2004). In addition, VL is also a critical determinant of risk of onward HIV-1 transmission 
(Quinn, et al. 2000). The level of viral rebound following cessation of ART therefore has important 
consequences. 
Interruption of ART started in chronic infection is no longer a recommended management strategy 
(El-Sadr, et al. 2006) and viral rebound following treatment cessation reaches levels comparable to 
pre-treatment values (El-Sadr, et al. 2006; Oxenius, et al. 2002; Wit, et al. 2005). In spite of effective 
therapies, the early establishment of a stable, inaccessible reservoir of latently infected resting 
memory CD4 T-cells is hypothesised to be the major source contributing to rebound viraemia after 
cessation of ART (Siliciano and Siliciano 2006; Trono, et al. 2010).   
Early treatment with ART during PHI may reduce the number of infected cells and prevent the 
establishment of a larger viral reservoir, conferring enhanced control of viral replication when 
therapy is stopped. Small studies quantifying the viral reservoir in treated PHI participants confirm 
that although a reduction in reservoir size is observed after even short-course ART initiated in PHI, 
complete abolition of viral replication is not achieved and the viral reservoir may be re-expanded 
even after short-term rebound of viraemia (Lillo, et al. 2002). Initial control of plasma viraemia after 
stopping ART in PHI had been reported in some studies (Hecht, et al. 2006; Rosenberg, et al. 2000; 
Steingrover, et al. 2008), but durable long-term effects were not observed in others (Desquilbet, et 
al. 2004; Fidler, et al. 2002; Hecht, et al. 2006; Kaufmann, et al. 2004; Koegl, et al. 2009; Streeck, et 
al. 2006). An observational study comparing treatment interruption in 24 patients with PHI with 46 
patients initiating ART in chronic infection, showed delayed or absent viral rebound following 
cessation of ART commenced in PHI and significantly lower median time to viral rebound, suggesting 
different viral dynamics between PHI and chronic infection (Steingrover, et al. 2008).    
In addition to considering the influence of short-course ART during PHI on viral rebound post-ART 
interruption, it is important to address the clinical safety of this strategy. In the SMART study, the 
level of plasma HIV RNA rebound following cessation of ART was highly correlated with increases in 
inflammatory and pro-coagulatory biomarkers, and biomarker levels were predictive of mortality 
(Kuller, et al. 2008). Based on these observations, the consequences of discontinuing treatment 
commenced in early infection on levels of plasma viraemia are important. 
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 It is possible that ART started in PHI may confer enhanced virological control once ART is stopped 
compared with stopping ART initiated in chronic HIV-1 disease. Moreover, sustained reductions in VL 
set-point resulting from ART given in PHI could dampen immune activation and inflammatory 
consequences of HIV-1 infection, leading to a long-term improvement in clinical outcome. Possible 
mechanisms resulting in reduced viral rebound after treatment in PHI compared with chronic 
infection could include a smaller size viral reservoir in PHI, preserved immunological function 
conferring enhanced natural viral control, or lower levels of inflammation and immune activation, 
thereby limiting viral replication which preferentially occurs in activated cells.     
The aims of this chapter were to:  
i. describe viral dynamics associated with stopping and starting ART in PHI 
ii. compare the level of plasma VL when ART is discontinued in patients starting treatment in   
PHI (SPARTAC) to those in whom ART was commenced in chronic HIV-1 Infection (SMART).   
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Results  
5.1 Patient characteristics 
Viral dynamics associated with starting and stopping ART were examined in SPARTAC participants 
who were randomised to either one of the two treatment arms.  Data from the two treatment arms 
from all SPARTAC centres were combined and analysed together. Individual patient data from 
SMART study participants were obtained from the International Network for Strategic Initiatives in 
Global HIV Trials (INSIGHT) group. Viral dynamics following treatment interruption were then 
compared between SPARTAC and SMART trial participants.  
In the SMART study, participants with a CD4 cell count >350 cells/µl were randomised to either a 
Drug Conservation (DC) or Viral Suppression (VS) arm.  SPARTAC and SMART study participants were 
included in this analysis if they underwent protocol-indicated ART cessation, i.e. if they were 
receiving ART at time of randomisation to the DC arm in SMART, or randomised to one of the two 
treatment arms in SPARTAC, and had a CD4 cell count and plasma VL available when ART was 
stopped. The closest CD4 cell count and VL to the time of ART cessation were used, up to 24 weeks 
and 12 weeks before stopping for CD4 cell count and VL respectively and no more than 2 weeks after 
stopping treatment.  Viral load measurements were scheduled at 4, 12, 24, 36, 48 and 4, 8, 16, 32, 
40, 48 weeks after stopping ART in the SPARTAC and SMART studies, respectively, and were defined 
by those closest to the scheduled visits (allowing a +/-2 week window around the week 4 and 6 visits 
and a +/-4 week window around subsequent visits). Enrolment into SMART was stopped on 11th 
January 2006 due to the results of an interim analysis which indicated clear superiority of the VS 
arm, and it was recommended that participants in the DC arm re-initiate ART  at this point (El-Sadr, 
et al. 2006). 
In SPARTAC, 243 participants were randomised to one of the two treatment arms, and 238 of these 
initiated therapy. Of these, 11 were excluded because they did not stop ART (n=6), were on ART for 
<15 days (n=4) or did not have a VL at ART stop (n=1). Of 2290 SMART participants receiving ART at 
the time of randomisation to the DC arm, 256 were excluded from this analysis because ART was not 
stopped (n=42, 25 of whom were randomised in the month prior to 11th January 2006), stopped ART 
after 11th January 2006 (n=20), did not have a VL at ART stop (n=1) or did not have any subsequent 
treatment-naïve VLs at scheduled visits (n=193, 153 of whom had only stopped in the month prior to 
11th January 2006). Analyses also were restricted to participants who had suppressed VL to <400 
copies/ml at the time of ART stop, as this was the limit of the least sensitive assay used across both 
trials. Forty-three SPARTAC and 384 SMART participants had VL ≥400 copies/ml at ART stop.  VL data 
were log10-transformed and values <400 copies/ml were treated as equal to 400 for all participants 
to avoid confounding by trial as a greater proportion of VLs were measured using this detection limit 
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in the PHI compared to chronically infected participants. In addition analyses were restricted to 
those in whom HIV-1 had been sexually transmitted, as few were from other risk groups in SPARTAC 
compared to SMART. In SPARTAC no participants were known to have acquired HIV-1 through 
injecting drug use (IDU) and 1% had unknown route of transmission, compared to 8% and 5% for IDU 
and unknown in SMART. Therefore a further 125 SMART participants who reported IDU as their 
transmission risk, and 2 SPARTAC and 75 SMART participants with other or unknown route of HIV-1 
transmission, were excluded.  Overall, 182 PHI and 1450 chronically infected participants were 
included in this analysis.  
SPARTAC participants recruited from the following sites were included: UK and Ireland n=86 (47.3%), 
South Africa n=54 (29.7%), Australia n=19 (10.4%), Italy n=12 (6.6%), Brazil n=9 (4.9%), and Spain n=2 
(1.1%). Participant demographics, ART exposure and CD4 cell count at time of treatment 
discontinuation for included SPARTAC and SMART participants are shown in Table 5.1. Compared to 
participants with chronic infection, SPARTAC participants were younger (median 34 versus 44 years), 
more likely to be female (33% versus 24%), had considerably less ART exposure (6% versus 44% ever 
exposed to ≥3 classes) and were more likely to be on a protease inhibitor regimen at the time of ART 
stop (94% versus 36%). At ART stop, CD4 cell count was slightly higher among SPARTAC compared to 
SMART participants (707 versus 646 cells/µl). Among SMART participants, 77% had a nadir CD4 cell 
count of <350 cells/µl. Two SMART participants had CD4 cell count <350 cells/µl at ART stop 
(contrary to SMART inclusion criteria), but both were measured on the day of ART stop and both 
participants had previous CD4 cell count >350 cells/µl within the previous 6 weeks. The estimated 
time since first initiating ART was 3 (3, 11) versus 72 (48, 96) months for SPARTAC compared to 
SMART participants, respectively. As SMART participants were enrolled into the trial with prevalent 
HIV-1 infection, duration of HIV-1 infection and time since first initiation of ART were often not 
known. The intervals available for the chronically infected participants can, therefore, be regarded 
as the minimum values. 
Follow-up data for this analysis was included from the date of first stopping ART and was censored 
at the last available VL measurement, the 48 week visit, when ART was re-initiated, or 11th January 
2006 for SMART participants, whichever was earliest. Due to the premature stop of the SMART trial, 
559 (39%) of chronically infected participants were censored on 11th January 2006. A further 17 (9%) 
and 463 (32%) SPARTAC and SMART participants respectively were censored before their 48 week 
visit due to ART re-initiation. The median follow-up was 48 (IQR 45, 49) and 27 (IQR 12, 43) weeks 
for the PHI and chronically infected participants, respectively, and the median number of RNA 
measurements included per individual was 6 (IQR 5, 6) and 4 (IQR 3, 6) for SPARTAC and SMART 
respectively. 
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Table 5.1. Characteristics of participants at time of stopping ART in the SPARTAC and SMART trials.  
  SMART 
Chronic HIV infection 
N=1450 
SPARTAC 
PHI  
N=182 
Sex, female 350 (24%) 60 (33%) 
Age, years 44 (38, 51) 34 (28, 42)  
HIV-1 exposure   
 MSM 890 (61%) 114 (63%) 
 Sex between men & women (male) 222 (15%) 8 (4%) 
 Sex between men & women (female) 338 (23%) 60 (33%) 
Time since first diagnosed HIV-positive, months 96 (60, 144)  6 (4, 13)  
Number of ART drugs, ever 5 (4, 7)  3 (3, 3)  
Number of ART classes, ever   
 1 48 (3%) 0 (0%) 
 2 763 (53%) 171 (94%) 
 ≥3 639 (44%) 11 (6%) 
ART type at stop   
 NNRTI based 674 (46%) 8 (4%) 
 PI based 521 (36%) 171 (94%) 
 3 NRTI 132 (9%) 2 (1%) 
 3 class 84 (6%) 0 (0%) 
 NRTI sparing 3 (<1%) 0 (0%) 
 Suboptimal ART 36 (2%) 1 (1%) 
Nadir CD4 cell count up to ART stop, cells/µl 230 (132, 340)  - 
 <200 592 (41%) - 
 200-349 515 (36%) - 
 350-499 226 (16%) - 
 ≥500 117 (8%) - 
CD4 cell count at ART stop, cells/µl  646 (495, 848)  707 (586, 919) 
         CD4 nadir <200 cells/µl 
568 (456, 724)  - 
          CD4 nadir 200-349 cells/µl 
618 (494, 784)  - 
          CD4 nadir 350-499 cells/µl 
806 (646, 993) - 
          CD4 nadir ≥500 cells/µl 
948 (784, 1176)  - 
 
Participant characteristics for those randomised to discontinue ART, at the time of ART cessation, are shown for the 
SPARTAC and SMART trials. Values are median (IQR) for continuous variables and n (%) for categorical variables. CD4 
values are shown for closest up to 24 weeks before ART was stopped.  
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5.2 Time to VL reaching pre-ART levels in SPARTAC participants 
Among SPARTAC participants, the time to reach pre-ART VL levels following treatment interruption 
was estimated using survival methods. Pre-ART VLs in PHI participants were estimated as the mean 
of all available VLs before ART initiation (9%, 85%, 5%, 1% participants had 1, 2, 3 and 4 pre-ART VLs 
available, respectively). The median (IQR) pre-ART VL was 4.5 (IQR 3.9, 5.1) log10 copies/ml. Eleven 
participants had pre-ART VL <400 copies/ml and were, therefore, not included in this analysis. Nine 
participants were censored before reaching pre-ART levels due to ART re-initiation (one at 5 week 
and the remainder at least 25 weeks after ART stop; the median pre-ART VL was somewhat higher in 
these participants at 5.5 log10 copies/ml). A total of 71 (42% of 171) participants were observed to 
rebound to pre-ART VL levels, at a median 50 (95% CI 48, 51) weeks after treatment interruption. A 
quarter of participants had rebounded to pre-ART levels by 15 (95% CI 12, 26) weeks.  
5.3 VL rebound at 4 weeks after ART stop by PHI versus chronically infected participants 
Viral load at 4 weeks after stopping ART was compared between SPARTAC (PHI) and SMART (chronic 
infection). Using linear and ordered logistic regression, respectively, differences in absolute levels 
and in the proportions with VL <400, 400-3499, 3500-9999, 10,000-49,000 or ≥50,000 copies/ml 
were examined at 4 weeks after stopping ART. Table 5.2 shows factors associated with HIV RNA level 
at four weeks after stopping ART on linear regression. Four weeks after stopping therapy, VL levels 
were 0.45 (95% CI 0.26, 0.64) log10 copies/ml lower among PHI compared to chronically infected 
participants (p<0.001; median 3.7 [IQR 2.7, 4.3] versus 4.4 [IQR 3.0, 5.0] log10 copies/ml 
respectively). There was a trend towards an association between lower CD4 cell count at time of 
stopping ART and higher week 4 VL, p=0.08). Persons infected through heterosexual sex had 
significantly lower week 4 VL than MSM (p<0.001), but with no evidence that this effect differed 
between chronic infection and PHI (p=0.4). There was no association between age at time of 
treatment discontinuation and VL at week 4 after stopping ART (p=0.6). The proportions of 
participants with VL <400 copies/ml four weeks after stopping therapy were similar between the PHI 
and chronic infection populations (22% versus 21%, respectively; p=0.6). Table 5.3 shows the 
number of participants within each VL stratum for SPARTAC and SMART participants. The 
proportions of participants with VL rebound to 400-3499, 3500-9999, 10,000-49,999 and ≥50,000 
copies/ml were 22, 23, 16 and 17% among SPARTAC participants compared to 12, 8, 18 and 40% 
among the SMART participants, indicating higher levels of VL rebound in chronically infected 
individuals (adjusted p<0.001).  
  
111 
 
Table 5.2. Factors associated with viral load four weeks after stopping ART  
 Coefficient (95% CI) p value 
PHI, versus chronic HIV-1 infection -0.45 (-0.64, -0.26) <0.001 
Age at ART stop, per 10 years 0.01 (-0.04, 0.07) 0.6 
Sex/risk group, versus men infected through sex with men  <0.001 
 Male, infected through sex with women -0.14 (-0.30, 0.03)  
 Female, infected through sex with men -0.33 (-0.47, -0.20)  
CD4 cell count at ART stop, per 100 cells/µl -0.02 (-0.04, 0.002) 0.08 
Linear regression model of factors associated with HIV RNA levels (log10 copies/ml) 4 weeks after stopping ART 
in SPARTAC vs. SMART participants respectively. The regression coefficient (95% CI) and p-value are given for 
each variable  
 
 
 
 
 
 
Table 5.3. Level of viral load 4 weeks after stopping ART in PHI and chronic infection. 
 
VL (copies/ml) Chronic HIV-1 infection 
N=1327* 
PHI 
N=156* 
<400 284 (21%) 35 (22%) 
400-3499 161 (12%) 34 (22%) 
3500-9999  110 (8%) 36 (23%) 
10,000-49,999 235 (18%) 25 (16%) 
≥50,000 537 (40%) 26 (17%) 
Number of SMART (chronic HIV-1 infection) and SPARTAC (PHI) participants with VL within each VL stratum are 
shown 4 weeks after stopping ART. Values are n (%).*participants with a week 4 VL available. 
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5.4 VL rebound up to 48 weeks after stopping ART in PHI and chronic infection 
Differences in VL levels and slopes over 4-48 weeks after stopping ART were examined using linear 
mixed models. In addition the time averaged viral burden, reflecting circulating virus at a given time 
point, was estimated by calculating the area under the VL curve (AUC), over the whole period after 
stopping ART, and dividing by time. Models were adjusted for the effect of sex/risk group (MSM, 
heterosexual men (MSW), and heterosexual women), age and CD4 cell count at ART stop.  No 
adjustments were made for time on ART, as this is confounded by duration of infection and, 
therefore, by trial, nor for ART class which was also confounded by trial. Differences in the effects of 
participant characteristics at ART stop, and nadir CD4 cell count up to ART stop, were investigated 
for PHI compared to chronically infected participants, where appropriate, using interactions.  
Over 48 weeks after stopping ART, the median VL remained lower in the PHI group compared to 
chronically infected group, demonstrated in Figure 5.1a. Modelling VL 4-48 weeks after stopping 
ART, there was evidence to suggest that the chronic infection participants rebounded more rapidly 
than the PHI participants (p<0.0001). Results of this model are demonstrated in Figure 5.1b.  The 
predicted VL for a representative participant with PHI (male infected through sex between men, 
aged 40 years and with CD4 cell count 600 cells/µl at ART stop) at weeks 4, 12 and 36 after stopping 
ART were 3.36 (3.27, 3.45), 3.53 (3.43, 3.63) and 4.04 (3.88, 4.20) log10 copies/ml, respectively, 
compared to 3.75 (95% CI 3.71, 3.79), 4.10 (4.05, 4.14) and 5.13 (5.05, 5.21) log10 copies/ml, 
respectively for chronic infection. 
The median (IQR) time-averaged viral burden was 1.12 (0.56, 1.69) and 1.55 (1.03, 1.99) log10 
copies/ml amongst participants with PHI and chronic infection, respectively. After adjustment, total 
viral burden was, on average, 0.28 (95% CI 0.17, 0.39) log10 copies/ml lower for PHI compared to 
chronically infected participants (p<0.001). 
The associations between longer-term VL rebound and sex/risk group, CD4 cell count and age at ART 
stop were qualitatively similar to those for the week 4 VL rebound. There was evidence of higher VL 
over 48 weeks among MSM compared to MSW and with lower CD4 cell count (0.03 [-0.04, -0.01] per 
100 cells, p<0.001), but no difference in these effects by PHI/chronic infection status (p=0.2 and 0.3 
respectively). Older age at time of stopping ART was associated with higher VL rebound, although 
the magnitude of this effect was small (0.04 [0.01, 0.08] log10 copies/ml per 10 years, p=0.02) and 
there was no difference by PHI/chronic infection status (p=0.4). 
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Figure 5.1 
a) VL up to 48 weeks after stopping ART in PHI versus chronic infection  
 
 
 
 
 
 
 
 
 
 
 
 
b) Predicted VL over 4-48 weeks after stopping ART in PHI versus chronic infection on mixed effect 
model 
 
  
a) Plasma VL in PHI vs. Chronic HIV-1 infection (CHI) from 0 to 48 weeks after treatment cessation is shown, 
alongside pre-treatment VL for PHI 
b) Predicted VL over 4-48 weeks after ART stop by PHI versus chronic infection (CHI), based on a representative 
participant (male infected through sex with men, aged 40 years and with CD4 cell count 600 cells/µl at time of 
ART stop) 
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5.5 VL rebound up to 48 weeks after stopping ART, categorising the chronically infected 
participants by nadir CD4 cell count 
At time of stopping ART, SMART participants were categorised according to their nadir CD4 cell 
count, in order to assess whether any differences over 48 weeks between the populations could be 
explained solely by CD4 T-cell levels. Compared to PHI participants, the VL rebound after 4 weeks, up 
to 48 weeks, was significantly higher in the chronically infected participants with CD4 T-cell nadir 
<500 cells/µl, and lower CD4 T-cell nadir was associated with faster rebound (Figures 5.2 a and b). 
For every 8 weeks, on average the VL in PHI participants increased by 0.17 (95% CI 0.14, 0.20) log10 
copies/ml compared to 0.71 (0.60, 0.81), 0.46 (0.36, 0.57), 0.33 (0.21, 0.44) and 0.15 (0.01, 0.29) 
log10 copies/ml in chronically infected participants with nadir CD4 cell counts of <200, 200-349, 350-
499 and ≥500 cells/µl, respectively. Predicted VL at week 4 and 36 after stopping ART are 
demonstrated in Table 5.4. and were lower in PHI and for higher nadir CD4 cell count. 
We observed a similar relationship for the time-averaged AUC: chronically infected participants with 
a lower nadir CD4 cell count had higher viral burden, compared with PHI participants (0.39 [95% CI 
0.27, 0.51], 0.29 [0.18, 0.41] and 0.20 [0.06, 0.33] log10 copies/ml higher viral burden for nadir CD4 
cell counts <200, 200-349 and 350-499 cells/µl respectively). There was no difference in viral burden 
between chronically infected participants with nadir CD4 cell count ≥500 cells/µl and PHI 
participants (0.04 [-0.12 to 0.20] log10 copies/ml). 
 
Table 5.4. Predicted VL in PHI and chronic infection, stratified by nadir CD4 cell count 
 Week 4 VL  
log10 copies/ml (95% CI) 
Week 36 VL  
log10 copies/ml (95% CI) 
SPARTAC 3.33 (3.24, 3.42) 4.01 (3.85, 4.18) 
SMART, nadir CD4 ≥500 3.46 (3.34, 3.57) 4.34 (4.11, 4.56) 
SMART, nadir CD4 350-499 3.61 (3.52, 3.69) 4.71 (4.53, 4.88) 
SMART, nadir CD4 200-349 3.72 (3.66, 3.77) 5.01 (4.89, 5.14) 
SMART, nadir CD4 <200 3.88 (3.83, 3.94) 5.82 (5.68, 5.96) 
 
 
 
Predicted VL at week 4 and week 36 from mixed effect model for PHI (SPARTAC) vs. Chronic infection 
(SMART), with participants with chronic infection categorised by nadir CD4 cell count (cells/µl), based on a 
representative participant (MSM, aged 40 years, CD4 cell count 600 cells/µl at time of stopping ART). 
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Figure 5.2  
a) VL up to 48 weeks after stopping ART, with participants with chronic HIV-1 infection categorised 
by nadir CD4 cell count   
 
 
 
 
 
 
 
 
 
 
b) Predicted VL on mixed effect model over 4-48 weeks after stopping ART  
 
  
a) Plasma VL in PHI (SPARTAC) versus chronic infection (CHI; SMART) is shown.  CHI is categorised by nadir CD4 cell count. 
b) Results from mixed effect model for VL over 4-48 weeks after stopping ART with CHI participants categorised by nadir 
CD4 cell count (cells/µl), based on a representative participant (MSM, aged 40 years, CD4 cell count 600 cells/µl at time of 
stopping ART).  
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5.6 Effect of CD4 cell count at ART stop on VL rebound 
There was evidence of an interaction between nadir CD4 cell count in SMART participants and CD4 
cell count at time of stopping ART, in relation to VL rebound over 48 weeks (p=0.04 and 0.0006 in 
the linear mixed model for VL up to 48 weeks and the linear regression for AUC, respectively). 
Among chronically infected participants with a nadir CD4 cell count <200 cells/µl, lower CD4 cell 
nadir in association with higher CD4 cell count at stop resulted in higher viral load AUC after 
stopping ART, with a trend for such an association in participants with CD4 cell count <350 cells/µl.  
For participants with nadir CD4 cell counts of <200 and 200-349 cells/µl, a CD4 cell count of 100 
cells/µl higher at ART stop was associated with an AUC 0.05 (95% CI 0.03, 0.08) and 0.02 (-0.002, 
0.05) log10 copies/ml higher, respectively. In contrast, among chronically infected participants with 
nadir CD4 cell count of ≥350 cells/µl, there was no evidence of an association between CD4 cell 
count at stop and subsequent AUC (0.002 [-0.03, 0.04] and -0.01 [-0.05, 0.03] log10 copies/ml per 100 
cells/µl higher CD4 cell count at stop, for participants with nadir CD4 cell counts of 350-499 and ≥500 
cells/µl, respectively). Among PHI participants, there was evidence to suggest that a higher CD4 cell 
count at time of stopping ART was associated with lower AUC (0.04 [95% CI 0.003, 0.08] log10 
copies/ml lower per 100 cells/µl higher CD4 cell count at stop). The effect on AUC of PHI versus 
chronic infection/nadir CD4 cell count remained robust with or without adjustment for the CD4 cell 
count at time of stopping ART. 
5.7 Summary of results in this chapter 
In the SPARTAC trial, 42% of participants rebounded to pre-ART VL levels, at a median of 50 weeks 
after stopping therapy. Four weeks after stopping ART, although the proportion of participants with 
detectable VL ≥400 copies/ml was similar, VL levels were significantly lower in SPARTAC compared to 
those in SMART participants, and remained lower up to 48 weeks. Lower CD4 cell nadir in the 
SMART study was associated with higher VL after stopping ART, and VL rebound for SMART 
participants with CD4 cell nadir >500 cells/µl was comparable to that seen in SPARTAC. 
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Discussion 
This is the first study to compare the viral dynamics between PHI and chronic infection in individuals 
undergoing a randomised protocol-indicated interruption of ART.  We observed that viral rebound 
after stopping ART initiated in PHI was lower than that observed in chronic infection, 4 weeks after 
treatment interruption. This difference was sustained over 48 weeks of follow-up. In addition, the 
time averaged viral burden was significantly lower in PHI patients versus the chronically infected 
population.  These data are consistent with those from Steingrover et al. (2008) who reported 
differences in VL rebound when comparing treatment interruption in PHI to a non-randomised 
cohort of individuals who started ART in chronic infection.  However, whereas Steingrover observed 
delayed or absent viral rebound in PHI, a similar proportion of PHI and chronically infected subjects 
in our study had HIV RNA levels  >400 copies/ml at 4 weeks, and stopping ART either during PHI or 
chronic infection was associated with a rebound in VL in most individuals, although to lower levels in 
PHI. This discrepancy may be due to the small numbers investigated and the non-randomised nature 
of the treatment interruption in the Steingrover cohort, or due to inherent differences between the 
study populations.  
The stage of infection prior to commencing therapy was predictive of viral dynamics after 
withdrawing treatment, indicating that the ability to control viral replication after discontinuation of 
ART is related to preservation of the immune response.  When chronic infection participants were 
stratified by CD4 cell count at time of stop ART, nadir CD4 cell count prior to starting ART predicted 
the capacity to control viral replication, with lower nadir CD4 cell count associated with higher VL 
after ART stop. Viral rebound was higher across all CD4 cell strata when compared with rebound in 
PHI. Interestingly, in chronic infection  patients with CD4 cell nadir <350, there was an association 
between CD4 cell count at stop and degree of viral rebound as measured by area under VL time 
curve, with higher CD4 cell count at stop being associated with higher AUC. Thus, the degree of viral 
rebound could be related to degree of immune reconstitution occurring on ART, or to the number of 
CD4 target cells available for viral infection upon stopping ART (Douek, et al. 2002) in those with 
severely depleted CD4 T-cell resources prior to commencing ART. In contrast, this effect was not 
apparent in PHI and higher CD4 cell count at stop was associated with lower VL rebound, indicating 
different VL dynamics between chronic and PHI.  
These data may reflect differences in the size of the viral reservoir which is likely to be considerably 
smaller in those commencing ART early. Strain et al (2005) showed that in patients treated in PHI, 
within 6 months of infection, a more pronounced reduction in the size of the latent reservoir was 
seen compared with those treated in chronic infection (Strain, et al. 2005). Another  study of NNRTI 
based ART during recent HIV-1 infection found that ART in PHI reduces HIV-1 DNA to levels 
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comparable to those seen in long-term non-progressors, and these effects were not apparent if 
therapy was started during chronic infection (Pires, et al. 2004). The size of the latent viral reservoir 
in patients with chronic HIV-1 infection has been shown to predict viral rebound after structured 
treatment interruption (Yerly, et al. 2004). Together, these findings suggest an association between 
timing of initiation of ART and decay of the HIV-1 reservoir, and highlight the potential benefits of 
early ART.  
We observed higher viral rebound in MSM compared with heterosexual study participants.  This 
difference remains unexplained. In SPARTAC, MSM were more likely to have subtype B virus than 
heterosexual participants. Some VL assays have been reported to underestimate HIV RNA in 
individuals with non-B subtypes (Holguin, et al. 2008), although this is not thought to affect more 
recent VL assays. However, subtype data were not available for SMART so are not included in this 
analysis. Another explanation could be gender differences in VL, as VL has previously been noted to 
be lower in women than in men in individuals with higher CD4 cell counts of >350 cells/µl, and most 
participants this analysis would fall into this CD4 cell category (Donnelly, et al. 2005). Our data are in 
agreement with findings from the CASCADE cohort which showed that among men, those infected 
heterosexually and by injecting drug use had on average 56% lower HIV RNA levels than homosexual 
men (Touloumi, et al. 2004). However, as no significant differences in HIV-1 progression are known 
to occur according to risk group (CASCADE 2000), the clinical relevance of this finding is not clear.  
As the majority of studies examining short-course ART in PHI are observational in nature, potential 
bias associated with reason for stopping or starting therapy is likely to confound the results. In our 
analysis, participants underwent protocol-indicated cessation of ART, and the randomised reason for 
treatment interruption in both chronic infection and PHI populations will reduce bias in this analysis. 
However this study does have some limitations. No adjustment for ART duration was made, 
although length of ART was significantly longer for the chronic infection (SMART) participants 
compared to the PHI (SPARTAC) participants.  This would have had the effect, in any case, of 
exaggerating the difference in VL rebound between the two populations. In addition, we were 
unable to compare the two ART arms of the SPARTAC trial, as follow-up is currently blinded. Of note, 
the SPARTAC participants randomised to the 12 weeks of ART may contribute disproportionately to 
those SPARTAC PHI participants with detectable VL at ART stop, who were then excluded from the 
analysis. Longitudinal analysis of both SMART and SPARTAC populations is confounded by exclusion 
of data due to informative censoring, for example, when individuals initiated long-term ART. This 
potential source of bias was accounted for to some extent in the mixed effect models. However, the 
result of failing to account for this completely would result in an underestimate of the observed 
difference between the two populations, due to the higher number of SMART patients reinitiating 
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therapy compared to SPARTAC.  Finally, we did not examine CD4 cell count evolution in this analysis, 
or the relationship between VL rebound and clinical disease progression, because the SPARTAC trial 
is ongoing. 
 In both SMART and SPARTAC, VL was not assayed until 4 weeks post-treatment interruption.  More 
frequent testing would give a true indication of immediate viral dynamics following ART cessation. It 
is possible that initial viral rebound will peak immediately following treatment interruption, prior to 
VL quantification in this study. However, models comparing rate of viral replication after withdrawal 
of treatment to initial acute infection show the rate in initial acute infection to be nearly five times 
faster (Little, et al. 1999). Although treatment discontinuation in PHI was associated with viral 
rebound, this was not observed to rebound to pre-ART levels until a median of 50 weeks, and it is 
unlikely that potentially greater increases would have been observed if VL had been measured 
sooner after treatment cessation. 
Data from African heterosexual transmission studies have shown that for individuals in HIV 
serodiscordant relationships, where the HIV-infected partner’s VL is less than 1500 copies RNA/ml, 
HIV-1 transmission is rare (Quinn, et al. 2000; Wawer, et al. 2005). In our study, the majority of 
participants in both SMARTAC and SMART had viral rebound at one month to levels sufficient to 
pose a risk of onward transmission. An additional goal of treating individuals with PHI may be to limit 
the enhanced risk of onward viral transmission and the role of ART as a public health tool to limit 
HIV-1 transmission is receiving heightened attention. The high VL in infected blood during acute HIV-
1 infection is reflected in genital tract secretions, and seminal and cervical VLs strongly correlate 
with plasma VLs for the first 6 months of infection, and are significantly higher than levels in chronic 
infection (Miller, et al. 2010; Morrison, et al. 2010).  Specific characteristics of recently transmitted 
viral variants make PHI particularly infectious (Keele and Derdeyn 2009; Ma, et al. 2009). It is 
unknown how long after transmission these characteristics remain or whether they are preserved 
after intermittent ART. Targeting individuals with ART during PHI could have a marked impact on 
HIV-1 transmission, but it is crucial that strategies investigating the use of short-term ART as a 
prevention measure examine the consequences of ART discontinuation and viral rebound on onward 
transmission. In the SMART study, individuals did not reduce high risk sexual behaviour, despite 
treatment interruption and detectable VL (Burman, et al. 2008). In a recent study looking at onward 
HIV-1 transmission amongst individuals treated in PHI who stopped ART, there were at least five 
new primary infections originating from these patients within 16-61 weeks after stopping early 
ART(Rieder, et al. 2010).The level of viral rebound following cessation of ART in PHI should therefore 
be anticipated when designing a strategy aimed at limiting secondary transmission, and it is likely 
that long-term ART would be preferable with this goal in mind.  
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Treatment interruption in the SMART study was associated with adverse clinical outcome and this 
strategy is no longer recommended in chronic infection (El-Sadr, et al. 2006). The levels of plasma 
HIV RNA in PHI correlates with biomarkers of inflammation, coagulation and immune activation 
(Chapter 4 and 6). Levels of viral rebound may therefore affect risk, not only of HIV-1 disease 
progression and development of opportunistic infection, but also of conditions not traditionally 
related to HIV such as CVD. The clinical effects of short-course treatment in PHI currently remain 
unknown; however the differences in VL dynamics between PHI and chronic infection demonstrated 
in this analysis indicate that the consequences of treatment interruption may differ. Such differences 
may reflect immunological status, immune activation and reservoir size. This observed difference in 
plasma VL rebound between PHI and chronic infection may translate into differences in levels of 
immune activation and inflammation on discontinuation of ART commenced in PHI versus chronic 
infection, and supports the hypothesis that treatment interruption following ART in PHI may not be 
associated with same adverse clinical effects as seen in the SMART trial.  
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Chapter 6:  T-cell Immune Activation in PHI 
HIV-1 infection induces a state of chronic immune hyper-activation which is thought to contribute 
towards the immunological destruction that precedes clinical disease (Cadogan and Dalgleish 2008). 
In untreated HIV-1 infected patients, the level of T-cell immune activation is an independent 
predictor of disease progression (Bofill, et al. 1996; Deeks, et al. 2004; Hazenberg, et al. 2003b; Liu, 
et al. 1997) and in some studies has been shown to be a stronger predictor of disease progression 
than CD4 cell count or VL (Giorgi, et al. 2002; Liu, et al. 1997).  
Following HIV-1 acquisition, massive depletion of CCR5 positive CD4 memory T-lymphocytes occurs, 
focused primarily in the GI mucosa through cytopathic and apoptotic mechanisms, resulting in 
depletion of T-cell reservoirs (Cadogan and Dalgleish 2008; Douek 2007; Mattapallil, et al. 2005). It 
has been hypothesized that this irreversible GALT damage creates a permanently imbalanced 
immunological environment instigating chronic homoeostatic events as the immune system 
struggles to replaces its losses, leading to a high turnover of T-cells, continuous T-cell activation, and 
a gradual loss of peripheral CD4 cells (Cadogan and Dalgleish 2008). In addition, damage to gut 
mucosal surfaces allows translocation of microbial products across the gut epithelium and into the 
systemic circulation, resulting in persistent antigenic stimulation of the immune system and 
hypothesized to be a major cause of HIV-associated immune activation (Brenchley, et al. 2006).  
Deeks et al. (2004) showed that the level of T-cell activation is established early in the course of HIV-
1 infection and varies widely between individuals, but is generally stable within a given person. It is 
possible that short-course ART given during PHI will reduce long-term immune activation even after 
discontinuation of ART, by rapidly limiting VL and thereby altering the immunological events 
described above. This hypothesis will be tested after the SPARTAC study has been unblinded. To gain 
some understanding of the processes occurring during PHI, we undertook an in-depth analysis of 
different markers of CD8 and CD4 T-cell activation, and assessed both viral and host factors 
associated with these parameters.  
CD38 and HLA-DR are cell surface molecules which are known to be upregulated upon antigenic 
activation in vivo and are commonly used as markers of T-cell activation. In addition, the relationship 
between expression of PD-1, a marker of T-cell exhaustion which is also upregulated on activated T-
cells, with other markers of activation was investigated. PD-1 expression in chronic infection has 
been associated with impaired functional capacity of CTL such as reduced cytokine production and 
loss of viral control (Day, et al. 2006). PD-1 positive cells undergo high rates of apoptosis and have 
limited proliferative capacity (Petrovas, et al. 2006) and the interactions between PD-1 and its 
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ligands are thought to be involved in negative regulation of immune activation (Cai, et al. 2004; 
Freeman, et al. 2000; Latchman, et al. 2001). The role of PD-1 in PHI has not been fully explored.  
The aims of this chapter were to: 
i. compare immune activation in PHI to those at SPARTAC week 60 and to healthy controls 
(methods chapter 2.3). 
ii. explore the relationship between different markers of immune activation, PD-1 expression, 
inflammation and coagulation in individuals with PHI. 
iii. assess host and viral factors associated with immune activation and PD-1 expression in PHI 
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Results 
6.1 Immune activation in PHI, at week 60 and in healthy controls 
PBMC samples for T-cell activation assays were available from the UK recruited SPARTAC 
participants at week 0 and week 60. In order to investigate the effect of duration of infection on 
markers of T-cell activation, a comparison was undertaken between week 0 and week 60 of the 
study. Due to the blinded nature of the SPARTAC trial, week 60 results were analysed together 
regardless of randomisation arm, although ultimately a comparison between the 3 arms of SPARTAC 
will be undertaken at week 60 to assess the effect of short-course ART on immune activation after 
discontinuing treatment. All individuals had discontinued treatment given as a trial intervention by 
week 60. PBMC samples from 10 healthy individuals were analysed to assess whether T-cell 
activation was higher in HIV-1 infected individuals compared to healthy controls.  
One-hundred-and-forty-nine SPARTAC participants were recruited in the UK and baseline 
characteristics of these individuals are shown in Table 6.1. The majority of participants were MSM 
with subtype B virus.  The median age was 34 years (range 19-60).  The median estimated time from 
seroconversion at the baseline study visit was 73 days (range 8 to 156 days).   
The following T-cell activation markers were assessed on both CD8 and CD4 T-cells: CD38 expression 
(both proportion of cells expressing CD38 (CD38%) and Median Fluorescent Intensity (MFI), HLA-DR 
expression (both HLA-DR% and HLA-DR MFI), proportion of cells with dual expression of CD38 and 
HLA-DR (CD38 HLA-DR%), and proportion of cells expressing PD-1 (PD-1%).  
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Table 6.1. Baseline characteristics of UK SPARTAC participants  
Baseline variable  Number or Median  (%) or [IQR]  
Sex: Male 143 (96) 
 Female 6 (4) 
Risk group: MSM 139 (93) 
 Heterosexual 9 (6) 
 Other / unknown 1 (1) 
Age (years) 34 [28,41] 
Estimated time from seroconversion (days) 73 [47,93] 
BMI 23.3 [21.6, 25.4] 
Systolic blood pressure 127 [116, 135] 
Diastolic blood pressure 76 [68, 82] 
Clade                              B 134 (90) 
                                       non-B 15 (10) 
Viral tropism *             R5 135/146 (92) 
                                       X4 11/146 (8) 
CD4 (cells/µl) overall 540 [406, 669] 
<350 18 (12) 
350-499 42 (28) 
>500 89 (60) 
HIV RNA (copies/ml) overall 57050  [11774, 195,517] 
                                       <400 7 (5) 
                                       400-9999 26 (17) 
                                       10000-99999 55 (37) 
                                     >100000 61 (41) 
HLA type*                     B*57 +ve 10/120 (7) 
                                       B*27 +ve 14/120 (10) 
Baseline characteristics of UK recruited SPARTAC participants (n=149) are shown. *Tropism available in 146 
participants; HLA typing was available for 120 participants only 
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CD8 T-cell activation  
Baseline PBMC samples at week 0 were available from 122 individuals and from 124 individuals at 
week 60. Results for 122 and 124 participants at week 0 and 60, respectively, are shown except for 
PD-1 where results for 120 and 114 participants were available at week 0 and week 60, respectively 
(results for PD-1 were disregarded due technical problems with the APC laser during analysis of one 
batch of 12 samples). Median values and IQR are shown in Table 6.2 and data are further 
demonstrated on box-plot graphs in Figure 6.1.   
In PHI (week 0) the median percentage of CD8 cells expressing CD38 (CD8 CD38%) was 41.5%, 
median percentage of CD8 cells expressing HLA-DR (CD8 HLA-DR%) was 32% and median dual 
expression of CD38 and HLA-DR activation markers (CD8 CD38 HLA-DR%) was 17.3%. Median PD-1% 
expression on CD8 cells was 4.5%. Differences in immune activation at week 60 were compared to 
week 0 using the Wilcoxon signed rank test. At week 60 there was a significant reduction in the 
percentage of CD8 cells expressing CD38 (p<0.0001), in CD38 MFI (p<0.0001), and in the percentage 
of CD8 cells co-expressing CD38 and HLA-DR (p<0.0001).  There was a trend toward reduced CD8 
HLA-DR% expression at week 60 (p=0.08) although no change was observed in HLA-DR MFI (p=0.2).   
Figure 6.2 shows flow cytometry plots in a single representative individual and demonstrates a clear 
population of activated CD8 cells at week 0 which has reduced in size considerably by week 60. 
There was no change in CD8 PD-1 expression between week 0 and week 0. 
Levels of immune activation in HIV-1 infected individuals were compared with healthy controls using 
Mann-Whitney tests. All markers of CD8 T-cell activation were significantly higher at week 0 when 
compared to healthy controls (p≤0.001 for all). At week 60, CD38 activation (both percentage 
expression and MFI) was not significantly higher than in healthy controls, although HLA-DR% 
expression, HLA-DR MFI, dual HLA-DR CD38 % expression, and PD-1 expression remained 
significantly elevated (p≤0.001 for all).   
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Table 6.2. T-cell activation and PD-1 expression in SPARTAC participants and in healthy  controls 
 Parameter Week 0 Week 60 Healthy control 
  N Median [IQR] N Median [IQR] N Median [IQR] 
CD8 cells CD38% 122 41.5 29, 59.5 124 26.8 12.4, 37.5 10 21.2 17.7, 28.9 
CD38 MFI 122 402 269, 630 124 276.5 153.5, 437.5 10 219 140, 323 
HLA-DR % 122 32.0  18.9, 43.8 124 31.5 20.0, 42.7 10 9.8 3.4, 10.4 
HLA-DR MFI 122 178.5 109, 303 124 187 113.5, 303 10 63.5 36.1, 75.5 
CD38 HLA-DR % 122 17.3 8.5, 30.9 124 9.6 4.1, 16.8 10 1.9 0.8, 4.7 
PD-1% 120 4.5 2.9, 7.2 114 5.2 2.3, 7.9 10 2.2 1.3, 2.8 
CD4 cells CD38% 122 52.3 38, 65.3 124 45.1 29.7, 57.1 10 44.1 29.1, 57.7 
CD38 MFI 122 463 310, 594 124 362 229, 560.5 10 263 177, 587 
HLA-DR % 122 10.8 6.7, 15.4 124 11.2 6.8, 18.3 10 5.7 1.7, 8.2 
HLA-DR MFI 122 51.5 35.9, 64.4 124 56.0 35.9, 81.7 10 43.8 21.1. 50.4 
CD38 HLA-DR % 122 5.3 3.3,  9.0 124 5.0 2.2, 8.8 10 3.4 0.9, 4.5 
PD-1% 120 8.4 5.9, 10.9 114 7.5 4.4, 10.7 10 1.8 1.0, 2.3 
  
Median values and IQR for markers of CD8 and CD4 T-cell activation are shown at SPARTAC baseline visit (PHI), SPARTAC week 60 and in healthy controls  
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Figure 6.1. CD8 T-cell activation and PD-1 expression in SPARTAC participants and in healthy controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p=0.7 p<0.0001 p<0.0001 p=0.08 
p<0.0001 p<0.0001 
p=0.8 p=0.001 
p=0.001 p<0.0001 
p<0.0001 p<0.0001 
Boxplots showing median, IQR and upper and lower adjacent values for CD8 T-cell activation markers in SPARTAC participants at week 0 (n=122) and week 60 (n=124), and in 
healthy controls (n=10).  For PD-1 n=120 at week 0 and n=114 at week 60. Week 0 was compared to week 60 using Wilcoxon signed ranks test for paired samples. Mann-Whitney U 
tests were used to compare HIV-negative controls to SPARTAC participants 
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Flow cytometry dot-plots of single and dual expression of HLA-DR and CD38 on CD8 cells at Week 0 (HIV-1 seroconversion) and Week 60 are shown in the same individual.  
Cell are gated on CD8. There is a clear  population of activated CD8 cells, expressing both CD38 and HLA-DR, which has reduced consideraly by week 60 
 
 
 
 
Week 0 
Week 60 
CD8 CD8 
CD4 HLA-DR CD38 CD38 
HLA-DR CD38 CD4 
CD38 
HLA-DR 
HLA-DR 
CD8 CD8 
CD8 
CD8 
Figure 6.2. Flow cytometry plot demonstrating CD8 T-cell activation in a single representative individual at week 0 and week 60 
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CD4 T-cell activation  
 
In PHI, the median percentage of CD4 cells expressing CD38 (CD4 CD38%) was 52.3%, median 
percentage of cells expressing HLA-DR (CD4 HLA-DR%) was 10.8% and median dual expression of 
CD38 and HLA-DR% (CD4 CD38 HLA-DR) was 5.3%. Median CD4 PD-1% expression was 8.4%. Results 
at week 0, week 60 and in healthy controls are shown in Table 6.2 and data are further 
demonstrated on box-plot graphs in Figure 6.3.   
Compared to week 0, at week 60 there was a significant reduction in CD38% expression on CD4 cells 
(p=0.009) and a significant reduction in CD4 CD38 MFI (p=0.03). There was a trend towards reduced 
PD-1 % expression (p=0.08). There was no significant change in HLA-DR % expression (p=0.9), HLA-
DR MFI (p=0.2) or dual expression of HLA-DR and CD38 (p=0.1) between weeks 0 and 60.  
HLA-DR expression, dual CD38 HLA-DR% expression and PD-1% expression were significantly 
elevated when compared to healthy controls at both week 0 and week 60 (Figure 6.3). HLA-DR MFI 
was also significantly elevated at week 0 and 60 compared to healthy controls (p=0.03 and p=0.01 
for week 0 and week 60, respectively).  There was no significant difference between CD4 CD38% 
expression or CD38 MFI in HIV-1 infected individuals compared to healthy controls in this cohort.  
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Figure 6.3. CD4 T-cell activation levels in SPARTAC participants and in healthy controls 
p<0.0001 
p<0.0001 
p=0.006 
p=0.04 
p=0.002 
p=0.002 
p=0.8 
p=0.2 
p=0.009 
p=0.9 
p=0.1 
p=0.08 
Box-plots showing median, IQR and upper and lower adjacent values for CD4 T-cell activation markers in SPARTAC participants at week 0 (n=122) and week 60 (n=124), and in 
healthy controls (n=10). For PD-1 n=120 at week 0 and n=114 at week 60.  Week 0 was compared to week 60 using Wilcoxon signed ranks test for paired samples. Mann-Whitney U 
tests were used to compare healthy controls to SPARTAC participants 
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6.2 Relationship between markers of T-cell immune activation, PD-1 expression, and inflammatory 
biomarkers in PHI  
The relationship between markers of T-cell immune activation, PD-1 expression, and inflammatory 
biomarkers in individuals with PHI were examined. With the exception of CD4 and CD8 cell CD38% 
expression which were normally distributed, activation marker results were skewed. Therefore non-
parametric testing was used to assess the associations between variables, although results from 
parametric Pearson correlations of both the absolute and log-transformed variables gave similar 
results. Table 6.3 shows Spearman Rho correlations between different markers of immune 
activation.  Different measures of CD8 T-cell activation were correlated strongly with each other 
(p<0.0001 for all).  CD8 PD-1 expression correlated with all markers of CD8 activation (p<0.0001 for 
all).  
Different measures of CD4 T-cell activation also correlated with each other (p<0.0001 for all). CD4 
PD-1 expression was not associated with CD4 CD38 activation, but did correlate with dual CD4 CD38 
HLA-DR expression (p=0.003).   
CD8 T-cell activation markers (CD38, HLA-DR and dual expression) were correlated with all markers 
of CD4 T-cell activation (p<0.0001 for all). CD8 PD-1% expression correlated with CD4 PD-1% 
expression, and with CD4 CD38% expression and dual CD4 CD38 HLA-DR% expression.  CD4 PD-1% 
expression was also associated with CD8 CD38% expression and dual CD8 CD38 HLA-DR% expression.     
 The relationship between markers of immune activation and IL-6 and D-dimer were also examined 
(Table 6.3).  Biomarker results for IL-6 and D-dimer were available in 129 and 120 UK participants, 
respectively, of whom 111 and 105 also had cells available for T-cell activation studies. There was a 
significant correlation between IL-6 and CD8 CD38, CD8 CD38 MFI and dual CD8 expression of CD38 
and HLA-DR (p=0.008, p=0.004 and p=0.01, respectively). D-dimer correlated with CD8 CD38% 
expression, dual CD8 CD38 HLA-DR% expression and CD8 PD-1 expression (p=0.003, p=0.03, p=0.02, 
respectively).  There was no significant correlation between CD4 T-cell activation markers and IL-6 or 
D-dimer. 
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Table 6.3. Relationship between different markers of CD8 and CD4 T-cell activation, IL-6 and D-dimer
 
  CD8 cells CD4 cells Plasma 
Biomarkers 
 Parameter  CD38 
%  
CD38 
MFI  
HLA-DR 
%  
HLA-DR 
MFI  
CD38 HLA-
DR  %  
PD-1 
% 
CD38 
%  
CD38 
MFI  
HLA-DR 
%  
HLA-DR 
MFI  
CD38 HLA-
DR %  
PD-1% IL-6 D-dimer 
CD8 
cells 
CD38 %                                  coefficient  
                                                p-value 
 0.78 
0.000  
0.39 
0.000  
0.39 
0.000 
0.76 
0.000  
0.54 
0000 
0.63 
0.000  
0.50 
0.000  
0.17 
0.06  
0.18  
0.048 
0.51  
0.000  
0.33 
0.000 
0.25 
0.008 
0.30 
0.003 
CD38 MFI                              coefficient 
                                               p-value 
0.79 
0.000  
 0.56 
0.000  
0.56 
0.000  
0.73 
0.000  
0.40 
0.000 
0.67 
0.000  
0.71 
0.000  
0.33 
0.000  
0.25 
0.006  
0.62  
0.000  
0.07 
0.5 
0.27 
0.004 
0.16 
0.1 
HLA-DR %                             coefficient 
                                              p-value 
0.39  
0.000  
0.56  
0.000  
 0.96  
0.000  
0.81 
0.000  
0.31 
0.000 
0.38 
0.000  
0.40 
0.000 
0.74 
0.000 
0.64 
0.000  
0.73 
0.000  
0.09 
0.3  
0.12 
0.2 
0.03 
0.75 
HLA-DR MFI                        coefficient 
                                              p-value 
0.39  
0.000  
0.56  
0.000  
0.96  
0.000  
 0.78 
0.000  
0.31 
0.000 
0.40  
0.000  
0.42  
0.000  
0.72 
0.000  
0.63  
0.000  
0.71  
0.000  
0.05 
0.59 
0.14 
0.13 
0.03 
0.72 
dual CD38 HLA-DR %         coefficient 
                                              p-value 
0.76  
0.000  
0.73 
0.000  
0.0.81 
0.000  
0.78  
0.000  
 0.45  
0.000 
0.50  
0.000  
0.45 
0.000 
0.55  
0.000  
0.50 
0.000  
0.70  
0.000  
0.24 
0.009 
0.23 
0.01 
0.21 
0.03 
PD-1%                                  coefficient 
                                              p-value 
0.54 
0.000 
0.40 
0.000 
0.31 
0.000 
0.31 
0.000 
0.45 
0.000 
 0.26 
0.000 
0.14 
0.12 
0.16 
0.07 
0.18 
0.048 
0.28 
0.002 
0.45 
0.000 
0.07 
0.5 
0.23 
0.02 
CD4 
cells 
CD38  %                              coefficient 
                                             p-value 
0.63 
0.000  
0.68  
0.000  
0.38  
0.000 
0.40  
0.000 
0. 5 
0.000 
0.26 
0.004 
 0.90  
0.000  
0.36 
0.000 
0.41  
0.000  
0.65 
0.000  
0.14 
0.13 
0.06 
0.50 
-0.01 
0.9 
CD38 MFI                           coefficient 
                                             p-value 
0.50 
0.000  
0.71  
0.000  
0.40  
0.000  
0.42 
0.000  
0.45  
0.000  
0.14 
0.12 
0.90  
0.000  
 0.39 
0.000  
0.41 
0.000 
0.63  
0.000  
-0.05 
0.6 
0.1 
0.3 
-0.09 
0.4 
HLA-DR %                           coefficient 
                                             p-value 
0.17 
0.06  
0.33  
0.000  
0.74  
0.000  
0.72  
0.000  
0.55  
0.000  
0.16 
0.07 
0.36 
0.000 
0.39  
0.000 
 0.89  
0.000  
0.87  
0.000  
0.16 
0.08 
0.08 
0.4 
0.11 
0.28 
HLA-DR  MFI                      coefficient 
                                             p-value 
0.18  
0.048 
0.25  
0.006  
0.64  
0.000  
0.63 
0.000  
0.50  
0.000  
0.18 
0.048 
0.41  
0.000  
0.41  
0.000  
0.89  
0.000  
 0.81  
0.000  
0.19 
0.04 
0.05 
0.64 
0.07 
0.46 
dual CD38HLA-DR %       coefficient 
                                           p-value 
0.51  
0.000  
0.62 
0.000  
0.73  
0.000  
0.71 
0.000  
0.70 
0.000  
0.28 
0.000 
0.65  
0.000  
0.64  
0.000  
0.87 
0.000  
0.81 
0.000  
 0.27 
0.003 
0.16 
0.09 
0.15 
0.13 
PD-1%                               coefficient 
                                           p-value 
0.33 
0.000 
0.07 
0.5 
0.09 
0.3 
0.05 
0.06 
0.24 
0.009 
0.45 
0.000 
0.14 
0.13 
-0.05 
0.6 
0.16 
0.08 
0.19 
0.04 
0.27 
0.003 
 -0.002 
0.98 
0.13 
0.18 
Plasma 
Biomarkers 
IL-6                                    coefficient 
                                           p-value 
0.25 
0.008 
0.27 
0.004 
0.12 
0.2 
0.14 
0.13 
0.24 
0.01 
0.07 
0.5 
0.06 
0.5 
0.1 
0.3 
0.08 
0.4 
0.05 
0.6 
0.16 
0.09 
-0.002 
0.98 
 0.28 
0.002 
D-dimer                           coefficient 
                                          p-value 
0.29 
0.003 
0.16 
0.11 
0.03 
0.7 
0.03 
0.7 
0.21 
0.03 
0.23 
0.02 
-0.01 
0.9 
-0.09 
0.4 
0.11 
0.29 
0.07 
0.46 
0.15 
0.13 
0.13 
0.18 
0.28 
0.002 
 
The association between different CD8 and CD4 cell markers of T-cell activation, and plasma biomarkers IL-6 and D-dimer, are shown. Non parametric Spearman rho correlation coefficients 
are given, although parametric Pearson correlations were similar. Significant p-values are shown in bold.  N=122 for T-cell activation markers, N=120 for PD-1, N=111 for IL-6 and N=105 for 
D-dimer. Percentage (%) expression on CD8 and CD4 T-cells and median fluorescent intensity (MFI) are given for CD38 and HLA-DR.  
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6.3 Viral and Host factors associated with T-cell activation in PHI  
Viral factors and immune activation 
Viral load  
The relationship between VL and markers of CD8 and CD4 cell activation was investigated. There was 
a highly significant association between HIV RNA levels and all markers of CD8 T-cell activation 
(CD38% and HIV RNA: Spearman rho=0.51, p<0.0001; CD38 MFI and HIV RNA: rho= 0.52 p<0.0001; 
HLA-DR% and HIV RNA: rho=0.29, p=0.001; HLA-DR MFI and HIV RNA: rho=0.31, p=0.001; dual CD38 
HLA-DR% and HIV RNA: rho=0.54 p<0.0001).  
There was a highly significant association between PD-1 expression and HIV RNA levels (Spearman 
rho=0.4, p<0.0001). Due to the known relationship between PD-1 expression and T-cell activation, it 
is possible that this observed correlation between PD-1 expression and HIV RNA may be related to 
the correlation between CD38 expression and HIV RNA, i.e. the effect of VL on PD-1 expression is 
mediated through the effect of VL on CD38 expression. In order to control for this, unadjusted 
Pearson correlations between log10-transformed PD-1 and log10 VL were undertaken, and compared 
to partial correlations, controlling for CD38 expression. Unadjusted Pearson correlation showed a 
highly significant relationship between log10 PD-1 and log10 VL (coefficient 0.4, p<0.0001).  On 
controlling for CD38%, the strength of this correlation reduced substantially (coefficient 0.18, 
p=0.044) indicating that the relationship between PD-1 and VL is at least in part mediated through 
upregulation of PD-1 in response to immune activation.  However controlling for HLA-DR expression 
did not significantly alter the strength of the association between log10 VL and log10 PD-1 (coefficient 
0.3, p<0.0001). 
The relationship between immune activation and HIV RNA was further examined according to VL 
strata.  There was a rise in CD8 T-cell activation and CD8 PD-1 expression with each VL stratum 
(Figure 6.4).  
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Figure 6.4. Effect of VL on level of CD8 T-cell activation in UK SPARTAC patients at baseline 
 
 Box-plots showing CD8 T-cell activation markers CD38%, HLA-DR% and dual CD38 HLA-DR%, and PD-1% expression 
(median, IQR and upper and lower adjacent values) for individuals as divided by VL strata (VL<400 n=7; VL 400-9999 
n=26; VL 10,000-99999 n=55, VL>100,000 n=60) 
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The association between CD4 cell activation and HIV RNA levels was less robust. There was a trend 
towards a correlation between CD4 CD38 expression and HIV RNA levels (CD38% and HIV RNA: 
Spearman rho 0.17, p=0.06; CD38 MFI and HIV RNA: rho=0.17, p=0.06) and similar results for HLA-DR 
expression (HLA-DR% and HIV RNA: rho=0.17, p= 0.07; HLA-DR MFI: rho=0.16 p=0.07. Dual 
expression of CD38 and HLA-DR on CD4 cells was significantly associated with HIV RNA (rho=0.33, 
p<0.0001).  There was a trend towards an association between CD4 PD-1 expression and HIV RNA 
levels (rho=0.17, p=0.07). 
For CD4 CD38%, CD4 HLA-DR-% and PD-1%, lower levels of immune activation were seen in the 
lower 2 viral strata, but the relationship is less clear for the upper VL strata (Figure 6.5). There is a 
clear rise in dual CD38 HLA-DR% for every VL stratum.   
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Figure 6.5. Effect of VL on level of CD4 T-cell activation in UK SPARTAC patients at baseline 
  
 Box-plots showing CD4 T-cell activation markers CD38%, HLA-DR% and dual CD38 HLA-DR%, and PD-1% expression 
(median, IQR and upper and lower adjacent values) for individuals as divided by VL strata (VL<400 n=7; VL 400-9999 
n=26; VL 10,000-99999 n=55, VL>100,000 n=60) 
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Viral tropism  
Primary HIV infection is characterized by the predominance of CCR5 tropic virus.  CXCR4  tropic virus 
is associated with faster disease progression (Koot, et al. 1993; Tersmette, et al. 1989). We 
hypothesised that increased immune activation associated with CXCR4 tropic variants may be a 
potential mechanism explaining this observed enhanced rate of immunological decline.  Viral 
tropism was assessed genotypically from samples taken at baseline and was available in 146 patients 
of whom 135 (92.5 %) had R5 and 11 (7.5 %) had X4 tropic virus. PBMCs for T-cell activation were 
available in 120 of these individuals, of whom 110 (93.7%) had R5 virus and 10 (8.3%) had X4 virus. 
HIV-1 parameters (CD4 and VL), markers of T-cell activation, PD-1 expression, and biomarkers IL-6 
and D-dimer were compared in individuals with R5 versus X4 using virus using Mann-Whitney U 
tests.  Results are shown in Table 6.4. 
Overall, for the 146 individuals in whom tropism results were available, median VL was 64,046 (IQR 
17602, 193758) copies/ml in individuals with R5 virus and 28,800 (IQR 3682, 40937) copies/ml in 
those with X4 virus (p=0.08). Median CD4 cell count was 540 (IQR 401, 664) cells/µl in those with R5 
virus and 550 (IQR 441, 563) cells/µl for those with X4 viruses (p=0.9).  In the 120 individuals with 
available PBMCs for T-cell activation included in this analysis, median CD4 cell count was 550 (IQR 
412, 668) vs. 520 (460, 563) cells/µl in those with R5 and X4 variants respectively (p=0.7), and 
median VL was 59623 (IQR 14965, 184103) vs. 28462 (IQR 4855, 44713) copies/ml in those with R5 
and X4 variants respectively (p=0.2). 
X4 variants were associated with higher levels of CD4 T-cell activation as measured by percentage of 
CD4 cells expressing HLA-DR (19.6% vs. 10.6% p=0.01), HLA-DR MFI (76.9 vs. 49.5, p=0.005), and dual 
CD38 HLA-DR% expression (9.3% vs. 4.9% p=0.01). There was a trend toward higher CD4 CD38 MFI in 
those with X4 using variants (591.5 vs. 451.5, p=0.06). The difference in CD4 T-cell activation 
between individuals with R5 vs. X4 variants is further demonstrated on box-plot graphs shown in 
Figure 6.6.  
There was no significant association between CD8 T-cell activation and viral tropism. However there 
was a trend towards higher CD8 HLA-DR expression in those with X4 variants (HLA-DR%: 41.2% vs. 
30.9%, p=0.06; HLA-DR MFI: 262.5 vs. 178.5, p=0.07). PD-1 expression was not related to viral 
tropism (Table 6.4).  
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Table 6.4. Effect of viral tropism on HIV-1 parameters, markers of immune activation and 
inflammation  
 Parameter R5 virus  X4 virus  p-value 
  N median (IQR) N median (IQR) 
HIV-1 
parameters 
CD4 cell count 135 540 (401, 664) 11 550 (441, 563) 0.9 
HIV RNA 135 64,046 (17602, 193758) 11 28,800 (3682, 40937) 0.08 
CD8 cells CD38 110 41.5 ( 29.6, 59.5) 10 42.7 (26.5, 54.9) 0.9 
CD38 MFI 110 401.5 (262, 630) 10 439 (296, 1563) 0.4 
HLA-DR 110 30.9 (18.9, 43.0) 10 41.2 (26.5, 73.4) 0.06 
HLA-DR MFI 110 178.5 (108, 303) 10 262.5 (153, 885) 0.07 
CD38 HLA-DR 110 17.3 (8.3, 30.1) 10 23.5 (13.3, 40.1) 0.2 
PD-1 110 4.7 (2.3, 7.4) 10 4.4 (2.1, 5.3) 0.4 
CD4 cells CD38 110 50.1 (37.0, 65.1) 10 57.2 (51.2, 73.1) 0.1 
CD38 MFI 110 451.5 (310, 579) 10 591.5 (474, 919) 0.06 
HLA-DR 110 10.6 (6.7, 14.1) 10 19.6 (11.6, 27.8)  0.01 
HLA-DR MFI 110 49.5 (35.9, 59.7)  10 76.9 (55.9, 100) 0.005 
CD38 HLA-DR 110 4.9 (3.3, 8.8) 10 9.3 (6.5, 15.5) 0.01 
PD-1 110 8.4 (6.0, 10.1) 10 8.4 (4.3, 11.8) 0.9 
Biomarkers IL-6 116 1.5 (0.9, 2.8) 11 1.4 (0.9, 2.4) 0.8 
D-dimer 108 0.4 (0.2, 0.7) 10 0.4 (0.3, 0.5) 0.7 
 
Median (IQR) HIV RNA, CD4 cell count and immune activation and inflammation parameters are shown in 
individuals with CCR5 versus CXCR4 tropic virus. Patients with R5 virus were compared to those with X4 virus 
using Mann-Whitney U tests.  Significant results are shown in bold type. 
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Figure 6.6. CD4 T-cell activation in individuals with R5 vs. X4 virus 
 
  
p=0.01 
P=0.005 
P=0.01 
Levels of CD4 activation are compared between individual with R5 (n=110) and X4 tropic virus (n=10) using 
Mann-Whitney tests. Median, IQR & upper and lower adjacent values for HLA-DR%, HLA-DR MFI and dual 
CD38 HLA-DR% expression are shown. 
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Viral subtype 
Levels of immune activation were compared between B (n=107) and non-B (n=15) subtypes using 
Mann-Whitney U tests. There was no relationship between non-B subtypes and levels of immune 
activation.  
Transmitted drug resistance  
Of 149 UK SPARTAC participants, at baseline, 12 (8%) had transmitted ART drug resistance classified 
at Stanford level 3 to 5 (low, intermediate or high level resistance to commonly used ART drugs), 7 
(4.7%) had resistance at Stanford level  4 to 5 (intermediate or high-level resistance), and 4 (2.7%) 
had Stanford level 5 high level ART drug resistance. In 122 individuals with available PBMCs for 
immune activation studies, there was no association between transmitted genotypic drug resistance 
and T cell activation.   
Host factors and immune activation 
CD4 cell count 
Lower levels of CD4 cell count were associated with higher levels of immune activation.  There was 
an inverse correlation between CD8 CD38 expression and CD4 cell count (CD38% and CD4 cell count: 
Spearman Rho -0.22, p=0.01; CD38 MFI and CD4 cell count: Rho- 0.24, p=0.008) and CD8 CD38 HLA-
DR dual expression (Rho -0.2, p-0.02) but not CD8 HLA-DR expression alone (HLA-DR% and CD4 cell 
count: Rho= -0.1 p=0.28; HLA-DR MFI and CD4: Rho =-0.15, p=0.1). CD8 PD% was inversely correlated 
with CD4 cell count (Spearman Rho=-0.2, p=0.02) 
There was a trend toward an inverse correlation between CD4 CD38 expression and CD4 cell count 
(CD38% and CD4 cell count: Rho=-0.17, p=0.06; CD38 MFI and CD4 cell count: Rho =-0.17, p=0.06). 
HLA-DR expression was not related to CD4 cell count (HLA-DR% and CD4 cell count: Rho=0.03, p=0.7; 
HLA-DR MFI and CD4 cell count: Rho=-03, p=0.7). There was a trend towards inverse correlation 
between CD4 PD-1% and CD4 cell count (rho=-0.16, p=0.09) 
Age 
HLA-DR expression on CD8 T-cells increased with age (HLA-DR% and age: Spearman Rho = 0.23, 
p=0.01; HLA-DR MFI: Rho=0.27, p=0.003). However there was no relationship between CD4 HLA-DR 
expression and age (CD4 HLA-DR% and age: Rho=0.14, p=0.1; CD4 HLA-DR MFI and age: Rho=0.12, 
p=0.2). 
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There was no relationship between CD8 CD38 expression and age, however, consistent with 
previous studies (McCloskey, et al. 1997) there was an inverse correlation between CD4 CD38 
expression and age (CD38% and age: Rho=-0.25, p=0.005; CD38 MFI and age: Rho =-0.21, p=0.02) .  
There was no relationship between age and dual CD38 HLA-DR expression on CD8 or CD4 T-cells 
(CD8 CD38 HLA-DR% and age: Rho=0.13, p=0.15; CD4 CD38 HLA-DR% Rho=0.02, p=0.9).  
There was a trend towards higher CD8 PD-1 expression with higher age (CD8 PD-1% and age: 
Rho=0.15, p=0.08). CD4 PD-1 expression was not significantly correlated with age (CD4 PD-1% and 
age: Rho=0.09, p=0.3)  
Gender 
Levels of T-cell activation were compared between male (n=117) and female participants (n=5) using 
Mann-Whitney U tests.  Female gender was associated with significantly lower levels of HLA-DR 
expression and dual CD38 HLA-DR expression on both CD8 and CD4 T-cells (CD8 HLA-DR% p=0.03; 
CD8 CD38 HLA-DR% p=0.04; CD4 HLA-DR p=0.03; CD4 CD38 HLA-DR p=0.02) 
Blood pressure and BMI 
There was no significant correlation between CD8 or CD4 cell immune activation and systolic or 
diastolic blood pressure or BMI. 
HLA type 
Carriers of class 1 HLA alleles B*27 and B*57 have delayed HIV-1 disease progression. We 
hypothesized that reduced levels of immune activation could be a contributing factor to reduced 
disease progression in patients with protective HLA types.  To assess the effect of protective HLA 
types on immune activation, IL-6 and D-dimer, patients were categorised as being HLA B*57 positive, 
HLA B*27 positive or having another HLA type. Markers of T-cell activation, PD-1 expression, IL-6 and 
D-dimer were compared between HLA positive and negative individuals using Mann-Whitney U 
tests.  The effect of HLA type adjusting for other factors was further examined using linear 
regression.  
HLA type was available in 145/149 UK participants. 10 (7%) and 14 (10%) individuals were 
heterozygous carries of HLA B*57 and HLA B*27 respectively. The prevalence of these alleles in the 
general UK population is similar (estimated 6.8-8.7% for HLA B*57 and 8.3-9.3% for HLA B*27 
(Middleton D 2003).There were no homozygous carriers of either HLA type. All HLA B*57 positive 
patients were HLA B*5701 and B*27 positive patients were B27*05 on 4 digit typing. Of those with 
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available HLA typing, 120 individuals had PBMCs available for T-cell activation studies and of these 
10 were HLA B*27 positive and 13 were HLA B*27 positive. 
Table 6.5 shows VL, CD4 cell count, biomarker and immune activation results in HLA B*57 positive 
and negative individuals respectively. HLA B*57 positive individuals had significantly lower VL 
(p=0.001) and higher CD4 cell counts (p=0.002). 
Positivity for HLA B*57 was associated with lower levels of both CD8 and CD4 T-cell activation as 
measured by CD38% expression and CD38 MFI on CD8 and CD4 T-cells (CD8 CD38%: 43.5% vs.14.6% 
for HLA B57 negative vs. positive, respectively, p<0.0001; CD8 CD38 MFI: 414 vs. 193, p<0.0001; CD4 
CD38%: 53.4% vs.36.7%, p=0.005; CD4 CD38 MFI 470 vs. 307 p=0.02). In addition CD8 CD38 HLA-DR 
dual expression was significantly lower in HLA B*57 positive individuals (CD8 CD38 HLA-DR %: 18.5% 
vs. 6.8% for HLA B57 negative vs. positive, respectively, p<0.0001) and there was a trend toward 
lower dual expression on CD4 T-cells (CD4 CD38 HLA=DR%: 5.6 vs. 3.7 p=0.07).   PD-1 expression on 
CD8 T-cells did not differ between HLA B*57 negative and positive individuals although there was a 
trend towards lower CD4 PD-1% expression (8.5% vs. 6.4% p=0.08). There was no association 
between HLA B*57 positivity and level of IL-6 or D-dimer.  
Differences in immune activation between individuals who were HLA B*57 positive versus negative 
is further demonstrated in Figure 6.7. On linear regression analysis, the differences between HLA 
B*57 positive and negative individuals remained robust on adjustment for VL and other variables, 
described in section 6.3.3. 
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Table 6.5. HIV-1 and immune activation / inflammation parameters in individuals with protective 
HLA type B*57  
HLA B*57 positive and negative populations were compared using the Mann-Whitney U test.  
  
 Parameter HLA B*57 –ve HLA B*57 +ve  
  N Median (IQR) N Median (IQR) p-value 
HIV-1 
parameters 
HIV RNA 135 64046 (17603, 94859) 10 7245 (411, 26851) 0.001 
CD4  135 530 (401, 658) 10 712 (635, 830) 0.002 
CD8 cells CD38% 110 43.5 (31.2, 61.1) 10 14.6 (12.1, 17.2) <0.0001 
CD38 MFI 110 414 (314, 677) 10 193 (161, 238) <0.0001 
HLA-DR% 110 32.3 (18.8, 45.1) 10 25.5 (20.2, 31.2) 0.3 
HLA-DR MFI 110 181 (110, 311) 10 155 (91.4, 175) 0.15 
CD38 HLA-DR % 110 18.5 (9.9, 32.1) 10 6.8 (4.7, 8.3) <0.0001 
PD-1 110 4.9 (2.3, 7.4) 10 3.6 (2.9, 4.4) 0.1 
CD4 cells CD38% 110 53.4 (39.4, 65.3) 10 36.7 (31.0, 40.3) 0.005 
 CD38 MFI 110 470 (319, 604) 10 307 (257, 365) 0.02 
 HLA-DR% 110 10.6 (6.7, 15.9) 10 11.7 (10.7, 12.0) 0.8 
 HLA-DR MFI 110 51.5 (35.1, 66.8) 10 51.2 (43.2, 55.0) 0.8 
  CD38 HLA-DR%  110 5.6 (3.3, 9.3) 10 3.7 (2.7, 4.8) 0.07 
 PD-1 110 8.5 (6.2, 11.8) 10 6.4 (5.1, 8.5) 0.08 
Biomarkers IL-6 116 1.54 (0.9, 2.7) 10 1.16 (0.8, 1.8) 0.4 
 D-dimer 109 0.38 (0.26, 0.61) 8 0.32 (0.18, 0.58) 0.4 
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Figure 6.7. Levels of CD4 and CD8 T-cell activation in HLA B*57 positive and negative individuals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immune activation in HLA B*57 negative (n=110) and positive individuals (n=10) were compared using Mann-
Whitney U tests. Median, IQR & upper and lower adjacent values for CD8 CD38%, CD8 CD38 MFI, CD8 dual 
CD38 HLA-DR expression and CD4 CD38% expression are shown on box-plot graphs.  
p<0.0001 p<0.0001 
p<0.0001 
p=0.005 
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Table 6.6 shows VL, CD4 cell count, biomarker and immune activation results in HLA B*27 positive 
and negative individuals respectively. HLA B*27 positive individuals had significantly lower VL than 
HLA B*27 negative individuals (p=0.01) although there was no significant difference in CD4 cell 
count.   
There was no significant association between CD8 T-cell activation (CD38 or HLA-DR expression) and 
HLA B*27 positivity, although there was a trend towards lower CD8 CD38% in HLA B*27 positive 
individuals (44.5% vs. 13%, p=0.08). CD8 PD-1 expression was significantly lower in HLA B*27 
positive individuals (4.9% vs. 2.9%, p=0.008, figure 6.8) and this difference remained significant on 
linear regression analysis adjusting for VL (see next section).  There were no significant differences in 
CD4 T-cell activation or PD-1 expression between those who were HLA*B27 positive and HLA B*27 
negative.  
D-dimer was significantly lower in HLA B*27 positive individuals (0.24 mg/L vs. 0.42 mg/L, p=0.002, 
figure 6.8).  To adjust for other variables associated with D-dimer, linear regression analysis was 
carried out using log10 transformed D-dimer as the dependant variable. On adjusting for log HIV RNA 
and age, D-dimer was 0.69 (95% CI 0.51, 0.93) mg/L lower, equating to a difference of 31%, (95% CI 
7%, 49%) between HLA B*27 positive and negative individuals (p=0.016). There was no association 
between IL-6 and HLA B*27 positivity. 
The prevalence of protective HLA alleles was examined in patients displaying HIV-1 control in PHI, 
defined in this analysis as patients with HIV RNA <400 copies/ml at baseline.  As seen in figures 6.4 
and 6.5, CD8 and CD4 immune activation was lower in these individuals.  Seven of 149 UK patients 
(4.7%) had VL<400copies/ml. Of 120 patients with available HLA typing 6/120 (5%) had HIV RNA 
<400 copies/ml.  Of these, HLA B*27 was present in one (16%) individual and HLA B*57 present in 
one individual (16%).  
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Table 6.6. HIV-1 and immune activation / inflammation parameters in individuals with protective 
HLA type B*27  
HLA B*27 positive and negative populations were compared using Mann-Whitney U tests.  
  
 Parameter HLA B*27 –ve HLA B*27 +ve p-value 
  N Median (IQR) N Median (IQR) 
HIV-1 
parameters 
HIV RNA 131 62386 (17121,196182) 14 22921 (1248, 40200) 0.01 
CD4  131 535 (400, 670) 14 571 (502, 691) 0.2 
CD8 cells CD38% 107 44.5 (28.8, 61.5) 13 37.0 (31.8, 39.2) 0.08 
CD38 MFI 107 402 (258, 680) 13 373 (393, 418) 0.5 
HLA-DR% 107 31.2 (18.8, 45.1) 13 26.5 (23.0, 37.0) 0.5 
HLA-DR MFI 107 179  (103, 307) 13 173 (133, 280) 0.9 
CD38 HLA-DR % 107 18.2 (8.7, 32.4) 13 14.2 (8.6, 17.5) 0.2 
PD-1 107 4.9 (3.1, 7.6) 13 2.9 (2.0, 4.0) 0.008 
CD4 cells CD38% 107 50.1 (36.3, 66.3) 13 54.4 (48.6, 57.7) 0.8 
 CD38 MFI 107 447 (290, 584) 13 546 (458, 590) 0.2 
 HLA-DR% 107 10.7 (6.7, 15.1) 13 11.7 (7.8, 16.4) 0.7 
 HLA-DR MFI 107 49.9 (35.1, 61.5) 13 55.9 (47.7, 70.2) 0.2 
 CD38 HLA-DR%  107 4.9 (3.2, 9.5) 13 6.5 (3.9, 7.9) 0.9 
 CD4 PD-1 107 8.2 (6.2, 11.) 13 8.8 (3.7, 11.0) 0.9 
Biomarkers IL-6 112 1.55 (0.94, 2.68) 14 1.22 (0.80, 1.42) 0.1 
 D-dimer 103 0.42 (0.28, 0.69) 14 0.24 (0.17, 0.34) 0.002 
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Figure 6.8. PD-1 and D-dimer levels in HLA B*27 positive and negative individuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box-plots displaying PD-1 and D-dimer (median, IQR & upper and lower adjacent values) in HLA B*27 negative 
and positive individuals. Mann-Whitney U tests were used to compare populations. For PD-1: HLA B*27 –ve 
n=107; HLA B*27 +ve n=13; for D-dimer HLA B*27 –ve n=103, HLA B*27 +ve n=14.  
p=0.008 
P=0.002 
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Linear regression model of factors associated with immune activation in PHI 
To further explore the relationship between immune activation, plasma VL and other significant 
baseline characteristics (age, sex, CD4 cell count, HLA type, viral tropism), a linear regression analysis 
was undertaken. Time since estimated seroconversion was also included in the model in order to 
assess whether immune activation was related to duration of HIV-1 infection. Multivariate 
regression models were constructed using backwards selection and variables were included if the p-
value was <0.1 on univariate analysis. VL and T-cell activation markers (all except CD38% which was 
already normally distributed) were log10 transformed to achieve normality for analysis purposes.  
Factors associated with CD8 T-cell activation  
Overall linear regression results for factors associated with CD8 T-cell activation are shown in Table 
6.7. On univariate analysis, higher CD8 CD38% expression was significantly associated with 
increasing VL, and inversely associated with HLA B*57 positivity, CD4 cell count and duration of 
infection. There was a trend toward lower CD38% in HLA B*27 positive individuals. On multivariate 
analysis, VL, duration of infection and HLA B*57 positivity remained significant.  Adjusting for 
baseline variables, CD38% remained 21% lower in HLA B*57% positive individuals (95% CI 9.9%, 
32%). For every log increase in VL there was an 8.6% rise in CD38% expression (95% CI 5.4%, 11.8%) 
and for every estimated day since seroconversion, CD38% was 0.1% lower (95% CI 0.01%, 0.2%).  
Higher CD8 HLA-DR% expression was associated with increasing age, male sex and higher VL on 
univariate analysis. There was a trend towards higher HLA-DR levels associated with X4 tropism. On 
multivariate analysis, adjusting for age, gender and HIV RNA, X4 virus was significantly related to CD8 
HLA-DR expression. X4 tropism was associated with a 51.3% relative increase in HLA-DR expression 
compared to R5 tropism (95% CI 4.7%, 99.5%).  VL was associated with a 20.2% relative increase in 
HLA-DR expression for every log increase in HIV RNA (95% CI 7.1%, 25.8%) and there was 12.2% 
relative increase in HLA-DR% for every 10 year increase in age (95% CI 1.0%, 25.8%).  
Higher dual expression of CD38 HLA-DR on CD8 T-cells was significantly associated with higher HIV 
RNA and male sex, and inversely associated with CD4 cells count and HLA B*57 positivity on 
univariate analysis. On multivariate analysis, HIV RNA and HLA B*57 positivity remained significant. 
After accounting for HIV RNA, HLA B*57 positivity was associated with a 47.0% relative reduction in 
dual CD38 HLA-DR expression (95% CI 10.9%, 60.2%). A log increase in HIV RNA was associated a 
relative increase in HLA-DR expression of 47.9% (95% CI 31.8%, 69.8%). 
PD-1% expression on CD8 cells was associated with increased age and higher HIV RNA levels and was 
lower in HLA B*27 positive individuals on both univariate and multivariate analysis.  HLA-B*27 
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positivity was associated with a relative reduction in PD-1 expression of 30.9% (95% CI 0.2%, 49.9%).  
A log increase in HIV RNA was associated with a 25.8% relative increase in PD-1 expression (95% CI 
12.2%, 38.0%) and an 10 year increase in age was associated with a 12.2% relative increase in PD-1 
expression on CD8 T-cells (1%, 25.8%)   
Factors associated with CD4 T-cell activation 
Overall results for factors associated with CD4 T-cell activation are shown in Table 6.8. CD38% 
expression on CD4 cells was inversely associated with age, CD4 cell count and with HLA B*57 
positivity on univariate analysis. On multivariate analysis, after adjusting for age and CD4 cell count, 
CD4 CD38%  activation remained 12% lower (p=0.04, 95% CI 0.8%, 23%) in HLA B*57 positive 
individuals. CD4 cell count was no longer related to CD38 expression on adjusting for other factors.  
Age remained inversely related to CD38 activation; for every 10 year increase in age there was a 
4.2% reduction in CD8 CD38% (0.08%, 7.5%). 
Higher HLA-DR% expression on CD4 cells was associated with HLA RNA, X4 tropism and male sex, 
with a borderline association with increasing age.  On multivariate analysis both X4 tropism and HIV 
RNA remained significant. X4 tropism was associated with a relative increase in CD4 HLA-DR 
expression of 77.8% (95% CI 20.2%, 150%).  For a log increase in HIV RNA, there was a relative 
increase in HLA-DR expression of 14.8% (95% CI 14.8, 25.8%). 
Dual expression of CD38 and HLA-DR on CD4 T-cells was significantly associated with X4 tropism, 
male sex and HIV RNA levels on univariate analysis. X4 tropism and HIV RNA remained significant in 
the multivariate model.  X4 tropism was associated with a relative increase of 113.7% (95% CI 34.8%, 
246.7%). A log increase in HIV RNA was associated with a 34.5% relative increase in dual expression 
(17.5%, 47.9%)  
CD4 PD-1% expression was not associated with any baseline covariates except for HIV RNA. A log 
increase in HIV RNA was associated with a relative increase in PD-1 expression of 12.2% (95% CI 1%, 
25.8%). 
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Table 6.7. Factors associated with CD8 T-cell activation and PD-1 expression in PHI 
  Univariate Multivariate 
 Parameter Coefficient 95% CI  p-value  Coefficient 95% CI p-value 
C
D
8
 C
D
3
8
 %
 
Age(+10 years)  -0.5 -4.3 , 3.4  0.8     
Sex (female) -12.5 -30.5, 5.5 0.2    
CD4 (+100 cells)  -2.5 -4.2, -0.8 0.004    
HIV RNA  (+1log)  10.6 7.3,  13.9  <0.0001   8.6 5.4, 11.8  <0.0001  
HLA B*57 +ve -31.6 -43.8 , -19.8  <0.0001  -21.0 -32.1, -9.9  <0.0001  
HLA B*27 +ve -10.6 -22.1, 0.8  0.07     
X4 tropism  0.04 -13, 13 0.9    
Duration (+1day) -0.1 -0.2, -0.01 0.03 -0.1 -0.2, -0.01 0.02 
Lo
g 1
0 
C
D
8
 H
LA
-D
R
 %
 
Age(+10 years)  0.07 0.02, 0.2 0.005 0.05 0.003, 0.1 0.04 
Sex (female) -0.26 -0.49, -0.03 0.03    
CD4 (+100 cells)  -0.01 -0.03, 0.01 0.6    
HIV RNA  (+1log)  0.08 0.04, 0.1 0.001 0.08 0.03, 0.1 0.002 
HLA B*57 +ve -0.07 -0.2, 0.1 0.4    
HLA B*27 +ve -0.06 -0.2, 0.1 0.4    
X4 tropism  0.2 -0.004, 0.3 0.06 0.18 0.02, 0.3 0.03 
Duration (+1day) 0.000 -0.002, 
0.001 
0.5    
Lo
g 
10
C
D
8
 C
D
3
8
  H
LA
-D
R
%
 Age(+10 years)  0.06 -0.009, 0.1 0.09    
Sex (female) -0.33 -0.63, -0.03 0.03    
CD4 (+100 cells)  -0.03 -0.06, -0.003 0.03    
HIV RNA  (+1log)  0.2 0.1, 0.3 <0.0001 0.17 0.12, 0.23 <0.0001 
HLA B*57 +ve -0.4 -0.6, -0.2 <0.0001 -0.2 -0.4, -0.05 0.015 
HLA B*27 +ve -0.1 -0.3, 0.07 0.2    
X4 tropism 0.2 -0.07, 0.4 0.2    
Duration (+1day) -0.002 -0.003, 
0.000 
0.1    
Lo
g 1
0 
 C
D
8
 P
D
-1
 %
 
 
Age(+10 years)  0.07 0.02, 0.1 0.01 0.05 0.000, 0.1 0.05 
Sex (female) -0.1 -0.34, 0.15 0.43    
CD4 (+100 cells)  -0.02 -0.04, 0.007 0.2    
HIV RNA  (+1log)  0.1 0.07, 0.2 <0.0001 0.1 0.05, 0.14 <0.0001 
HLA B*57 +ve -0.1 -0.2, 0.07 0.2    
HLA B*27 +ve -0.2 -0.4, 0.06 0.008 -0.16 -0.3, -0.001 0.01 
Tropism X4 -0.08 -0.3, 0.1 0.4    
Duration (+1day) -0.001 -0.003, 
0.001 
0.2    
Linear regression analysis of factors associated with CD8 T-cell activation and PD-1 expression in PHI (n=120).  HIV RNA, HLA-
DR%, dual CD38 HLA-DR% and PD-1% were log transformed to normalize the distribution. Multivariate regression models 
were constructed using backwards selection and variables were included if the p-value was <0.1 on univariate analysis. The 
regression coefficient (95% CI) and p-value are given for each variable. 
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Table 6.8. Factors associated with CD4 T-cell activation and PD-1 expression 
 
  
  Univariate Multivariate 
 Parameter Coefficient 95% CI  p-value  Coefficient 95% CI p-value 
C
D
4
 C
D
3
8
 %
 
 
Age  (+10 years)  -4.1 -7.5, -0.7  0.02 -4.2 -7.5, -0.08  0.02  
Sex (female) -2.8 -19.1, 13.3 0.72    
CD4(+100 cells)  -1.6 -3.2, -0.08 0.04     
HIV RNA  (+1log)  2.6 -0.7, 5.9  0.12     
HLA B*57 +ve -16.1 -27.6, -4.7  0.006 -12.3 -24.0, -0.8  0.04 
HLA B*27 +ve 1.1 -9.4, 11.5  0.8     
X4 tropism  9.7 -1.8, 21.4 0.1    
Duration (+1day) -0.03 -0.1, 0.07 0.5    
Lo
g 1
0 
C
D
4
 H
LA
-D
R
%
 
 
Age  (+10 years)  0.05 -0.005, 0.1 0.08    
Sex (female) -0.27 -0.51, -0.02 0.03    
CD4(+100 cells)  0.002 -0.02, 0.03 0.9    
HIV RNA  +1log)  0.06 0.01, 0.1 0.015 0.06 0.01, 0.1 0.02 
HLA B*57 +ve 0.02 -0.2, 02 0.8    
HLA B*27 +ve -0.02 -0.2, 0.1 0.8    
X4 tropism 0.2 -0.06, 0.4 0.009 0.26 0.08, 0.4 0.004 
Duration (+1day) 0.000 -0.001, 0.002 0.7    
Lo
g 1
0 
C
D
4
 C
D
3
8
  H
LA
-D
R
%
 
 
Age  (+10 years)  0.01 -0.05, 0.08 0.7    
Sex (female) -0.35 -0.65, -0.05 0.02    
CD4(+100 cells)  -0.02 -0.05, 0.01 0.3    
HIV RNA  (+1log)  0.1 0.06, 0.2 <0.0001 0.13 0.07, 0.17 <0.0001 
HLA B*57 +ve -0.2 -0.4, 0.04 0.1    
HLA B*27 +ve -0.01 -0.2, 0.1 0.9    
X4 tropism 0.3 -0.08, 0.5 0.007 0.33 0.13, 0.54 0.001 
Duration (+1day) 0.000 -0.002, 0.002 0.7    
Lo
g 1
0 
C
D
4 
P
D
-1
%
 
 
Age  (+10 years)  0.02 -0.03, 0.07 0.4    
Sex (female) 0.05 -0.19, 0.3 0.7    
CD4(+100 cells)  -0.02 -0.04, 0.004 0.1    
HIV RNA  (+1log)  0.05 0.000, 0.1 0.05 0.05 0.000, 0.1 0.05 
HLA B*57 +ve -0.08 -0.2, 0.08 0.3    
HLA B*27 +ve -0.1 -0.3, 0.03 0.1    
Tropism X4 -0.002 -0.2, 0.2 0.9    
Duration (+1day) 0.000 -0.001, 0.002 0.6    
Linear regression analysis of factors associated with CD4 T-cell activation and PD-1 expression in PHI (n=120).  HIV 
RNA, HLA-DR%, dual CD38 HLA-DR% and PD-1% were log transformed to normalize the distribution. Multivariate 
regression models were constructed using backwards selection and variables were included if the p-value was <0.1 
on univariate analysis. The regression coefficient (95% CI) and p-value are given for each variable 
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6.4. Summary of results in this chapter 
Levels of T-cell activation were raised in PHI and at week 60 compared to healthy controls and 
highest closest to seroconversion. Markers of T-cell activation were correlated with each other, with 
HIV RNA and with IL-6 and D-dimer. Host factors, such as age and HLA type, and viral factors such 
viral tropism, affect levels of T-cell activation in PHI. PD-1 expression in PHI correlates with T-cell 
activation and HIV RNA, and HLA B*27 positive individuals have lower CD8 PD-1 expression.  
Discussion 
The level of immune activation is an important predictor of HIV-1 disease progression. In this 
chapter, we describe levels of T-cell activation in a UK cohort of 122 individuals with PHI, and assess 
both viral and host factors associated with immune activation at this time.   
Consistent with previous studies we demonstrated raised levels of T-cell activation in HIV-1 infection 
compared to healthy controls. Higher levels of T-cell activation were seen in PHI compared with the 
same individuals at week 60.  In addition, in individuals with PHI, a significant inverse association was 
seen between estimated time since seroconversion and level of immune activation as measured by 
CD38 expression. The baseline study visit in this group of individuals represents a wide range of 
estimated time since seroconversion (8 to 156 days) and in some, the acute events associated with 
seroconversion may have resolved by the time of the baseline visit. Our data indicate that the high 
VL associated with PHI is also associated with high levels of immune activation which reduces 
naturally over time, but remains higher than seen in healthy controls, even in the chronic phase of 
disease.  It should be noted, however, that our healthy controls were not age or gender matched, 
nor were they formally tested for HIV infection, thus their comparability may be limited.  It should be 
also be noted that the week 60 results in this cohort represent a heterogeneous group of individuals, 
two thirds of whom have received either 12 or 48 weeks of ART as per the SPARTAC study protocol. 
Once the SPARTAC study is unblinded it will be possible to perform a comparison of levels of 
immune activation across the 3 arms of the study to assess whether short-course ART, by 
dampening the immunological and virological events associated with PHI, impacts on long-term 
levels of immune activation, even after treatment is discontinued.  
In this study, T-cell activation was evaluated by assessing expression of CD38 and HLA-DR on both 
CD4 and CD8 T-cells.  We assessed both the percentage of cells expressing these activation markers, 
and the median fluorescent intensity, which represents the median density of activation marker per 
cell. The MFI method has some advantages as it is not dependant on the placement of negative 
gates during flow cytometry analysis and therefore could be seen as a more objective measure of T-
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cell activation than percentage.    Liu et al (1996) compared relative fluorescent intensity for CD38 to 
percentage expression,  and found that elevated mean fluorescence intensity of CD38 expression on 
CD8 cells had prognostic value for development of AIDS that was almost identical to the prognostic 
value of the percentage of CD8 cells expressing CD38 (Liu, et al. 1996b), however other studies 
provide conflicting reports as to the best predictive activation marker for HIV-1 disease progression 
(Hazenberg, et al. 2003b). In our study, all measures of immune activation on both CD4 and CD8 T-
cells were highly correlated with each other, and when assessing factors associated with immune 
activation in PHI, results were similar when measured by percentage or MFI. Once SPARTAC is 
unblinded it will be possible to compare the different measures of immune activation used in this 
study with HIV-1 outcomes to determine the best predictive markers for disease progression. 
In this study we measured PD-1 expression, a marker associated with T-cell exhaustion, alongside T-
cell activation. We demonstrated that in PHI there was a close relationship between CD8 T-cell 
expression of PD-1, CD38 and HLA-DR. This supports data reported by Sauce et al., which showed 
that the proportion of total CD8+ PD-1+ T-cell population positively correlate with the proportion of 
total CD8+ CD38+ T-cell population in chronic infection. This has not been previously demonstrated 
in PHI.  In addition we demonstrate a correlation between CD4 PD-1 expression and CD4 cell 
activation (HLA-DR and dual expression) indicating a relationship between CD4 cell activation and 
PD-1 expression in this population.   
We also demonstrate a significant correlation between both CD8 and CD4 PD-1% expression and HIV 
RNA levels. However, as described here and by others (Sauce, et al. 2007) it is not possible to 
determine if PD-1 expression is a cause of increased plasma VL, as a result of T-cell exhaustion and 
impaired viral control, or a consequence of high VL leading to T-cell activation and subsequent PD-1 
upregulation. On controlling for CD38 expression, the magnitude of the correlation between PD-1 
and HIV RNA, whilst remaining statistically significant, was reduced, indicating that the relationship 
between PD-1 and HIV RNA may, in part, be due to T-cell activation. Adjusting for HLA-DR expression 
had little effect on the strength of the relationship between PD-1 and HIV RNA indicating a direct 
relationship between PD-1 and HIV-1 viraemia independent of activation status of the total CD8 
population.  However, in a related study, using specimens obtained from SPARTAC participants at 
baseline, Hickling et al. (2010) showed that, on HIV-1 specific cells, PD-1 expression correlated with 
CD38 expression but not plasma HIV RNA, supporting the hypothesis that PD-1 expression is due to 
T-cell activation in this setting (personal communication Stephen Hickling, Oxford University).  
Although high PD-1 expression has been associated with worse disease outcome in studies of 
chronic infection (Holm, et al. 2008; Zhang, et al. 2007) there are few data on the clinical 
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consequence of PD-1 expression when measured in PHI.  Once the SPARTAC study is unblinded, it 
will be possible to establish the prognostic value of measuring PD-1 expression in the total CD8 and 
CD4 T-cell population by evaluating the relationship between baseline PD-1 expression in PHI and 
clinical disease outcomes in the untreated arm of SPARTAC.      
Differences in clinical outcome in HIV-1 infected individuals may represent differences in genetic 
variants amongst HIV-1 infecting strain, host genetics differences, or differences in the virus specific 
immune response (Altfeld, et al. 2003). This is the first study to assess the impact of host factors 
such as HLA type and viral factors such as tropism on markers of T activation in PHI.  It has been 
previously established that the level of immune activation in recent infection correlates with HIV-1 
viraemia (Deeks, et al. 2004) and this is confirmed in our study. CD8 T-cell activation was highly and 
significantly correlated with HIV-1 viraemia for all activation markers. Unlike Deeks, however, we did 
not see a significant correlation between CD4 CD38 expression and HIV RNA, although there was a 
trend, and this may be due a difference in laboratory techniques or cohort differences.  However HIV 
RNA was correlated with HLA-DR expression and dual CD38 HLA-DR expression on CD4 cells 
confirming that CD4 T-cell activation is associated with HIV RNA levels in PHI.  
The majority of transmitted HIV-1 variants are CCR5 using viruses (Keele, et al. 2008).  Recent 
publications have reported faster disease progression for individuals newly infected with CXCR4 
tropic HIV-1 variants. In a cohort of individuals with PHI, CXCR4-using viruses were associated with 
an accelerated rate of disease progression, estimated by a faster decline of CD4 T-cell count to less 
than 350 cells/µl and by reduced time to initiating ART (Raymond, et al. 2010). We demonstrated 
that increased levels of immune activation were associated with more pathogenic CXCR4-tropic 
variants and this may be a potential mechanism explaining this observed enhanced rate of 
immunological decline in previous studies. Our study supports findings by Hazenburg et al. which 
showed that in individuals followed up since PHI over a 5 year period, increased proportions of CD4 
T-cells positive for Ki67, a marker of T-cell division, were seen in individuals in whom emergence of 
X4 variants occurred, compared to those maintaining R5 virus (Hazenberg, et al. 2003a). Hazenburg 
previously showed that as the number of proliferating Ki-67 positive cells decreases on ART, its 
expression is likely to be driven by generalised immune activation associated with HIV-1 viraemia 
rather than being a T-cell homeostatic response to compensate for T-cell depletion (Hazenberg, et 
al. 2000). In our study, the significantly higher levels of T-cell activation in patients infected with 
CXCR4-tropic viruses were seen in the absence of any significant differences in VL or CD4 cell count, 
indicating that immune activation may be an early step reflecting underlying pathogenic processes at 
this initial stage of HIV-1 infection. 
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 Previously reported prevalence of X4 viruses in PHI varies according to subtype and methodology of 
determining tropism, with a low frequency of CXCR4-using viruses described in PHI patients with 
non-B subtype infection (Frange, et al. 2010), compared to frequencies of up to 15.9% of X4 or 
mixed-tropic viruses at the time of PHI in individuals with subtype B infection (Frange, et al. 2009). In 
SPARTAC, the prevalence of X4 variants was 8.3%, measured using the geno2pheno algorithm with 
the false positive rate (FPR) set at 5.75%.  This is comparable to findings by Raymond, et al. who 
described a prevalence of 6.4% in PHI when using an ultrasensitive phenotypic assay and a 
prevalence of 5.6% when using the geno2pheno algorithm with the FPR set at 5.75% (Raymond, et 
al. 2010).  
This is the first study correlating HLA type with markers of immune activation, inflammatory and 
coagulation biomarkers in PHI.  We found that HLA type B*57 was associated with lower levels of 
CD4 and CD8 T-cell activation and HLA B*27 was associated with lower levels of PD-1 expression and 
fibrinolysis. These protective HLA types have been associated with slower rates of HIV-1 progression 
in previous studies (O'Brien, et al. 2001). These findings were independent of levels of plasma HIV 
RNA.  It is thought that the interaction between the genetic HLA background in an individual and the 
viral epitopes recognised by that HLA type direct both the magnitude of HIV-1 specific T-cell 
responses and the ability for viral escape.  Our findings support the hypothesis that reduced levels of 
immune activation associated with these protective HLA alleles contribute towards reduced levels of 
HIV-1 disease progression. In addition, the reduced PD-1 expression seen in HLA B*27 positive 
individuals could reflect a mechanism for enhanced viral control due to a less exhausted T-cell 
population.  Our findings are consistent with studies in elite controllers, who are known to have 
higher prevalence of protective HLA alleles.  Hunt et al. showed that elite controllers have lower 
levels of immune activation, compared with individuals with detectable HIV RNA levels, however the 
prevalence of protective HLA types in this cohort was not directly examined (Hunt, et al. 2008).  A 
further study in elite controllers demonstrated a peculiar activation phenotype where viral control 
was associated with low CD38 expression and high HLA-DR expression on HIV-1 specific cells (Saez-
Cirion, et al. 2007).  Although we did not specifically look at HIV-1 specific cells, our study 
demonstrated significantly lower CD38 activation in those with protective HLA types but no 
difference in HLA-DR activation, in keeping with these findings.  
It is not understood whether high levels of viral replication in PHI initially lead to higher levels of 
immune activation, or whether the initial level of immune activation dictates subsequent VL. We 
demonstrate that host genetic differences contribute to level of immune activation supporting the 
latter hypothesis.  This is consistent with data from Hazenburg et al (2003) which shows that the 
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level of CD70 expression, a further marker of immune activation, dictates HIV-1 progression even 
prior to HIV-1 acquisition, and other studies showing that immune activation can predict disease 
progression in the absence of detectable virus (Hunt, et al. 2008; Hunt, et al. 2003).   
We see a similar prevalence of protective HLA alleles to that seen in the general UK population.  This 
is in contrast to previous data reporting lower prevalence of these alleles in PHI.  Altfeld et al 
reported 3.4% prevalence of HLA B*57 in individuals with symptomatic PHI in contrast to 9.6% 
prevalence in chronically infected individuals, and concluded that, individuals with protective HLA 
alleles are less likely to present with symptoms and therefore may be underrepresented in acute 
infection cohorts (Altfeld, et al. 2003). Participants entered into the SPARTAC study reflect a more 
representative cohort of individuals due to the broader entry criteria which are not restricted to 
symptomatic disease.    
CD38 is an early T-cell differentiation marker and expression is known to be increased in children and 
decline with age (McCloskey, et al. 1997). Consistent with previous studies, we saw an inverse 
relationship between the proportion of CD4 CD38 expression, and age. However, we did not see a 
relationship between CD8 CD38 expression and age, possibly reflecting differences in our cohort 
which is restricted to adults aged 18 to 65, in contrast to other studies which include children.  HLA-
DR expression, a known marker of immune senescence, was positively correlated with age and HIV 
RNA, and this may reflect one mechanism by which the accelerated aging that has been reported in 
HIV-1 infected individuals occurs. In addition the increased immune activation seen in older 
participants, alongside higher levels of IL-6 and D-dimer (chapter 4) may explain why older 
individuals experience faster disease progression. 
In conclusion, we demonstrate high levels of immune activation associated with PHI, which reduce 
over time but remain higher than in healthy controls. Immune activation was correlated with PD-1 
expression, IL-6 and D-dimer, and determined by both host factors, such as age and HLA type, and 
viral factors such as levels of HIV RNA and viral tropism.  Whether initial immune activation drives 
viraemia, or whether the reverse is true, remains unclear, yet this a likely to be a self perpetuating 
cycle.  
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Chapter 7: Assessment of markers of microbial translocation, endothelial activation and tissue 
factor in PHI 
Introduction 
Irrespective of the route of HIV-1 acquisition there is early trafficking of HIV-1 to the GALT during 
PHI, resulting in high level HIV-1 replication and massive depletion of CCR5 positive memory T-
lymphocytes (McMichael, et al. 2010). It has been hypothesized that HIV-1 related immunological 
and structural deficits in the GI tract allow an increase in gut permeability, permitting translocation 
of gut-colonising bacteria and their metabolites across the gut epithelium and into the systemic 
circulation. This process, known as microbial translocation, has been postulated to be a major factor 
contributing towards the persistent immune activation characteristic of chronic HIV-1 infection 
(Douek 2007).  
Microbial translocation has been quantified by measuring circulating plasma levels of LPS, a cell wall 
component of gram negative bacteria. LPS binds soluble LPS binding protein (LBP) in plasma which 
transfers it onto a peripheral membrane protein, CD14, expressed on the cell surface of monocytes 
and macrophages. The LPS-CD14 complex triggers recognition by Toll-like Receptor 4 (TLR 4) on the 
monocyte cell surface, activating the cell to produce proinflammatory cytokines and chemokines, 
thus inducing further immune activation. LPS recognition through the innate immune system 
therefore results in  macrophage activation and subsequent initiation of adaptive immune responses 
(Janeway and Medzhitov 2002). Brenchley et al. (2006) demonstrated raised levels of LPS in 
individuals with chronic HIV-1 infection, compared to HIV-negative controls, and showed that LPS 
directly correlated with activated CD38+HLA-DR+ CD8 T-cells, but not with CD4 cell count or VL. This 
was supported by a further study showing an association between plasma levels of bacterial rDNA 
and T-cell activation (Jiang, et al. 2009).  
Soluble CD14 (sCD14) is secreted by CD14 positive monocytes in response to LPS stimulation and 
directly correlates with LPS levels in HIV-1 infected individuals (Brenchley, et al. 2006; Papasavvas, et 
al. 2009). Baseline plasma levels of sCD14 were independently predictive of mortality in the SMART 
trial (Sandler, et al. 2010). LPS-Binding Protein (LBP) is produced by GI and hepatic epithelial cells 
and correlates with both sCD14 (Brenchley, et al. 2006) and LPS (Ancuta, et al. 2008). Naturally 
occurring antibodies to LPS core oligosaccharide are produced in response to LPS to neutralise LPS 
activity(Strutz, et al. 1999). These endotoxin core antibodies (EndoCAb) are increased in conditions 
of chronic microbial translocation such as inflammatory bowel disease (Barclay 1995), but have been 
shown to inversely correlate with LPS in chronic HIV-1 infection (Ancuta, et al. 2008; Brenchley, et al. 
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2006; Papasavvas, et al. 2009), suggesting that they are insufficient to neutralise LPS in this setting 
(Brenchley, et al. 2006). 
Exposure to LPS is a key inducer of procoagulant tissue factor expression both in vivo and in vitro 
(Breitenstein, et al. 2010; Derhaschnig, et al. 2004; Funderburg, et al. 2010b). Kuller et al. 
hypothesised that activation of tissue factor pathways could be a key event explaining the adverse 
rise in all cause mortality seen in those stopping ART in the SMART study (Kuller, et al. 2008).  Tissue 
factor is expressed on monocytes and the sub-endothelium of the blood vessel wall, and becomes 
activated when vascular endothelium is damaged to initiate the extrinsic coagulation pathway.  
Funderburg et al. showed that in chronic HIV-1 infection, monocyte tissue factor expression 
correlated with soluble CD14 levels, T-cell activation, and D-dimer levels, as well as with HIV-1 
viraemia and inversely with CD4 cell count, and concluded that drivers of immune activation such as 
HIV-1 viraemia and microbial translocation activate clotting cascades through this pathway.  In 
chronic HIV-1 infection raised soluble tissue factor levels have been linked to cardiac events (Ford, et 
al. 2010). There are no data examining tissue factor in PHI.  
HIV-1 infected individuals have increased endothelial dysfunction as measured by brachial artery 
flow mediated vasodilation (Blum, et al. 2005; Solages, et al. 2006), and raised levels of endothelial 
adhesion molecules such as ICAM-1 and VCAM-1 (Wolf, et al. 2002).  ICAM-1 and VCAM-1 levels 
decrease with ART (Wolf, et al. 2002), and increase on ART treatment interruption (Papasavvas, et al. 
2008). Animal models have shown that enteric microflora directly contribute to constitutive ICAM-1 
expression on vascular endothelial cells (Komatsu, et al. 2000), and studies on human coronary 
artery endothelial cells show that LPS directly results in TLR 4 mediated inflammatory activation of 
the endothelium and induction of adhesion molecules such as ICAM-1 (Zeuke, et al. 2002). There are 
no current data on examining endothelial dysfunction in PHI.  
Several studies have now confirmed raised levels of microbial translocation in HIV-1 infected 
compared to HIV-negative cohorts (Brenchley, et al. 2006; Cassol, et al. 2010; Nowroozalizadeh, et 
al. 2010; Troseid, et al. 2010; Wallet, et al. 2010), and this process provides a potential mechanism 
for T-cell activation, endothelial activation, and initiation of pro-coagulatory pathways in HIV-1 
infection. No longitudinal studies have assessed LPS levels in relation to HIV-1 disease progression in 
untreated individuals in Western cohorts, and thus the clinical significance of microbial translocation 
remains uncertain. A longitudinal African study found no relationship between  LPS and sCD14 levels 
and  HIV-1 disease progression (Redd, et al. 2009). In contrast to data from Brenchley et al. (2006), 
several studies have failed to demonstrate a direct association between T-cell activation and LPS 
levels (Cassol, et al. 2010; Papasavvas, et al. 2009; Wallet, et al. 2010). In addition there are few data 
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on the relationship between microbial translocation, immune activation, endothelial activation and 
HIV-1 disease parameters in individuals with PHI. 
The aims of this chapter were to: 
i. estimate levels of microbial translocation in PHI and how these change over time.  
ii. assess the relationship between surrogate markers of microbial translocation and other bio-
markers of inflammation/coagulation (IL-6, D-dimer) and cellular markers of immune 
activation (CD38+ and HLA-DR+ expression on CD4 and CD8 T-cells) in PHI and at week 60. 
iii. assess levels of soluble tissue factor (sTF) and soluble ICAM-1 in PHI and compare these to 
markers of immune activation, microbial translocation, and coagulation. 
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Results 
7.1 Baseline characteristics  
The overall assays employed for this analysis are described in detail in the materials and methods 
(chapter 2.4).  As SPARTAC samples were not collected specifically for LPS analysis, the following  
markers of LPS activity were measured: sCD14, LBP and EndoCAb. Samples from 90 UK and 
Australian SPARTAC participants with paired available samples at week 0 and week 60, and from 30 
healthy controls (chapter 2.3), were analysed. Subjects were chosen on the basis of available plasma 
at the specific SPARTAC time points, and on the availability of results on inflammatory and 
coagulatory biomarkers and markers of immune activation from SPARTAC analyses (chapter 4 and 
6). Baseline characteristics of the 90 SPARTAC participants included in this analysis are shown in 
Table 7.1. Participants were predominantly MSM with subtype B virus.  The median age was 34 
years. Estimated time since seroconversion was 73.5 [IQR 52, 93.5] days.  
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Table 7.1. Baseline characteristics of SPARTAC participants included in microbial translocation 
studies 
Baseline variable  Number or Median  (%) or [IQR]  
Sex: Male 87 (97) 
 Female 3 (3) 
Risk factor MSM 84 (93) 
 Heterosexual sex 5 (6) 
 Not reported 1 (1) 
Age (years) 34.6 [30, 41.4] 
Estimated time from seroconversion (days) 73.5 [52, 93.5] 
Clade B 82 (91) 
CD4 (cells/µl)  550 [412, 682] 
HIV RNA (copies/ml)  overall 50783 [9010, 190000] 
                                        <1000 8 (9) 
                                         1000-9999 15 (17) 
                                         10000-99999 31 (34) 
                                         >100000        36 (40) 
Site of recruitment     UK 85 (94) 
                                        Australia 5 (6) 
Baseline characteristics of 90 SPARTAC participants included in microbial translocation analysis.  Subjects were 
chosen on the basis of available plasma. 
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7.2 Markers of LPS activity (sCD14, EndoCAb and LBP) in SPARTAC participants and healthy 
controls 
Absolute results for median values and interquartile (IQR) range are given below in Table 7.2.  All 
markers of LPS activity fell within similar ranges to those reported by Brenchley et al. (2006), except 
EndoCAb levels for healthy controls which tended to be lower in our analysis (median 174 MMU/ml  
vs. >500 MMU/ml).   
Results at week 0 and 60 were compared to healthy controls using Mann-Whitney U tests, and 
differences in biomarkers at week 60 compared to week 0 were assessed using the Wilcoxon signed 
rank test. Figure 7.1 shows box-plot graphs demonstrating changes between week 0 and week 60 in 
SPARTAC participants and comparison with healthy controls.   
sCD14 and LBP were significantly higher in HIV-1 infected individuals at both week 0 and week 60 
compared to healthy controls, suggesting that levels of microbial translocation are higher in HIV-1 
infected individuals in both PHI and early chronic infection in patients in this cohort. There was no 
significant change between the 2 study time points in either biomarker.  There was no difference in 
EndoCAb levels compared to healthy controls at week 0 or week 60.  However, a significant decline 
in EndoCAb was seen between week 0 and week 60 in SPARTAC participants. 
 
Table 7.2. LPS activity at week 0, week 60 and healthy controls 
Biomarker Week 0 (n=90) Week 60 (n=90) Healthy control  (n=30) 
 Median [IQR] Median [IQR] Median [IQR] 
sCD14  x 106 pg/ml 2.17 [1.85, 2.52] 2.23 [1.78, 2.52] 1.66 [1.39, 1.94] 
LBP x 104 ng/ml 3.05 [2.2, 3.6] 2.65 [1.90,3.6] 1.85 [1.1, 3.1] 
EndoCAb MMU/ml 202.7 [135.6, 280.7] 174.3 [112.5, 241.3] 174.1 [129.5, 237,4] 
Markers of LPS activity (median [IQR]) are shown in 90 SPARTAC participants and in 30 healthy controls.   
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Figure 7.1. Markers of LPS activity in SPARTAC participants at week 0 and week 60 and in healthy 
controls  
  
p<0.0001 
 
p=0.9 p<0.0001 
 
p=0.4 p=0.02 
p=0.002 
p=0.4 
p=0.03 p=0.7 
Box-plots showing median, IQR and upper and lower adjacent values for sCD14, LBP and EndoCAB in 
SPARTAC participants at week 0 and week 60, and in healthy controls.  Week 0 was compared to week 60 
using Wilcoxon signed ranks test for paired samples. Mann-Whitney U tests were used to compare healthy 
controls to SPARTAC participants 
 
164 
 
7.3 Factors associated with microbial translocation in PHI 
Relationship between markers of LPS activity and each other 
All biomarkers measured in this chapter were normally distributed except sTF and EndoCAb which 
had skewed distributions. On log10 transformation sTF and EndoCAb became normally distributed. 
To assess the relationship between different surrogate markers of microbial translocation, Pearson 
correlations were undertaken. In keeping with findings by Brenchley et al (2006), there was a 
significant correlation between sCD14 and LBP (Pearson correlation coefficient 0.24, p=0.02). There 
was no significant relationship between levels of EndoCAb and either LBP or sCD14 (log10 EndoCAb 
and sCD14: Pearson correlation coefficient 0.08, p=0.5; log10 EndoCAb and LBP: 0.01, p=0.9). Non 
parametric Spearman correlations gave similar results. 
Baseline patient characteristics and markers of LPS activity 
The relationship between baseline characteristics and markers of microbial translocation was 
examined using linear regression. There was no association between surrogate markers of microbial 
translocation and age, BMI, blood pressure or estimated time since seroconversion.  
Relationship between HIV-1 parameters and markers of LPS activity in PHI 
On linear regression analysis, there was a significant correlation between HIV RNA levels at week 0 
and both sCD14 and LBP (Table 7.3). A one log rise in HIV RNA was associated with a rise in sCD14 of 
0.16 x106 pg/ml (p=0.005) and a rise in LBP of 3007 ng/ml (p=0.006). This is in contrast to findings by 
Brenchley et al. (2006) in chronic infection, which did not show an association with HIV RNA levels 
and sCD14 or LBP.  No significant relationship was seen between log10 EndoCAb and log10HIV RNA. 
Participants were divided according to HIV RNA strata (HIV RNA <10,000 n=23; 10,000-99999 n=31, 
>100,000 n=36).  The relationship between HIV RNA strata and biomarkers of microbial translocation 
is demonstrated in Figure 7.2. LBP and sCD14 increased with increasing VL strata, although the 
relationship was less clear for sCD14 at high VL strata.   
sCD14 was inversely associated with CD4 cell count.  A rise in CD4 cell count of 100 cells/µl was 
associated with 0.05 x 106 pg/ml lower levels of sCD14 (95% CI 0.001 x 106, 0.1 x106, p=0.046). There 
was no relationship between EndoCAb or LBP and CD4 cell count.  
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Table 7.3. Linear regression analysis of factors related to LPS activity in PHI 
 Parameter Coefficient 95% CI P-value 
sCD14 HIV RNA (+1 log) 0.16  0.05, 0.26 0.005 
x106pg/ml CD8 CD38% (+1%) -0.004 -0.006, 0.005 0.9 
 CD8 HLA-DR (+1 log) 0.19 -0.22, 0.61 0.4 
 CD8 CD38 HLA-DR (+1 log) 0.21 -0.10, 0.22  0.2 
 CD4 CD38 (+ 1%) -0.001 -0.007, 0.005 0.7 
 CD4 HLA-DR (+1log) 0.29 -0.10, 0.68 0.1 
 CD4 CD38 HLA-DR (+1 log) 0.24 -0.07, 0.56 0.1 
 IL-6  (+1 log) 0.20 -0.08, 0.49 0.2 
 D-dimer (+1 log) 0.56 0.15, 0.98 0.007 
LBP HIV RNA (+1 log) 3007 876.8, 5138 0.006 
ng/ml CD8 CD38% (+1%) 36.2 -75.6, 148.2 0.5 
 CD8 HLA-DR (+1 log) 2444.4 -5363, 10254.6 0.5 
 CD8 CD38 HLA-DR (+1 log) 2879.7 -3006.8, 8766.3 0.3 
 CD4 CD38 (+ 1%) -30.6 -151.0, 89.6 0.6 
 CD4 HLA-DR (+1log) 2738.4 -4708.7, 10185.5 0.5 
 CD4 CD38 HLA-DR (+1 log) 3085.4 -2945, 9116.6 0.3 
 IL-6  (+1 log) 9159.8 3812.6, 14505.9 0.001 
 D-dimer (+1 log) 8482.3 328.6, 16636.1 0.04 
Log10 
EndoCAb 
MMU/ml 
HIV RNA (+1 log) -0.004 -0.06, 0.05 0.9 
CD8 CD38% (+1%) 0.000 -0.003, 0.003 0.8 
CD8 HLA-DR (+1 log) -0.06 -0.3, 0.2 0.6 
 CD8 CD38 HLA-DR (+1 log) -0.009 -0.2, 0.1 0.9 
 CD4 CD38 (+ 1log) 0.002 -0.001, 0.005 0.3 
 CD4 HLA-DR (+1log) 0.003 -0.2, 0.2 0.9 
 CD4 CD38 HLA-DR (+1 log) 0.04 -0.1, 0.2 0.6 
 IL-6  (+1log) 0.02 -0.1, 0.2 0.8 
 D-dimer (+1 log) 0.005 -0.2, 0.2 0.9 
 
 
Linear regression analysis of factors associated with surrogate markers of microbial translocation (sCD14, LBP 
and EndoCAb) in 90 SPARTAC participants with PHI (week 0). EndoCAb, IL-6, D-dimer, and HLA-DR% and CD38 
HLA-DR% expression on CD4 and CD8 T-cells were log10 transformed to achieve normality for analysis purposes. 
The regression coefficient (95% CI) and p-value are given for each variable. 
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Figure 7.2.  Relationship between VL strata and markers of LPS activity 
 
  
Relationship between surrogate markers of LPS activity and different VL strata are shown. In previous studies LBP 
and sCD14 have been shown to correlate with LPS levels and EndoCAB inverse correlates with LPS. Individuals are 
divided according to VL (HIV RNA<10,000 n=23, 10,000-99,999 n=31 and>100,000 n=36).  Box-plot graphs 
demonstrate median values, IQR and upper and lower adjacent values.  
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Relationship between markers of LPS activity and immune activation in PHI (SPARTAC week 0).  
Microbial translocation has been hypothesized to be a key cause of immune activation in chronic 
HIV-1 infection (Brenchley, et al. 2006). We assessed the relationship between markers of LPS 
activity and markers of T-cell immune activation, IL-6 and D-dimer in PHI, using samples from 
SPARTAC patients at baseline (week 0). Of the 90 individuals included in this analysis, 80 had results 
available from T-cell activation studies, and 89 and 87 individuals had IL-6 and D-dimer results 
available, respectively. 
 Results from linear regression analysis of the relationship between markers of immune activation 
and microbial translocation are shown in Table 7.3. Results for CD38% and HLA-DR% expression are 
given although results examining CD38 MFI and HLA-DR MFI were similar.  
In this cohort of individuals with PHI, there was no significant relationship between markers of LPS 
activity and T-cell activation. However, higher sCD14 was significantly associated with a rise in D-
dimer and higher LBP was significantly associated with increases in both IL-6 and D-dimer. There was 
no association between EndoCAb levels and T-cell activation, IL-6 or D-dimer. 
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7.4 Factors associated with microbial translocation at week 60 
The relationship between markers of LPS activity measured at SPARTAC week 60, and markers of 
immune activation at this time point, was examined using linear regression. At week 60, T-cell 
activation results were available in 77 individuals and IL-6 and D-dimer available in 89 individuals. 
Due to the blinded nature of the SPARTAC trial, week 60 results were analysed together regardless 
of randomisation arm, and it should be noted that two-thirds of participants had received either 12 
weeks or 48 weeks treatment by this time point, whilst one third had not been treated at all. All 
individuals had discontinued the ART given as a trial intervention by week 60.   
Results from linear regression are given in Table 7.4. Results for CD38 and HLA-DR percentage 
expression are given although MFI gave similar values. In contrast to our observations in PHI, there 
was a significant association between these surrogate markers of microbial translocation and T-cell 
activation at week 60. sCD14 was associated with rises in CD4 T-cell activation as measured by HLA-
DR% expression and dual CD38 HLA-DR% expression, as well as increases in IL-6 and D-dimer. sCD14 
was not associated with HIV RNA levels at this time point.  LBP was associated with CD8 activation 
(CD8 CD38% and CD8 CD38 HLA-DR% dual expression) with a trend towards an association with 
raised CD4 HLA-DR% expression (p=0.08). LBP was also significantly associated with rises in IL-6 and 
D-dimer, and with higher HIV RNA. EndoCAb was significantly associated with CD4 T-cell activation 
as measured by CD38% expression and dual CD38 HLA-DR% expression.  There was no significant 
relationship between EndoCAb levels and HIV RNA. 
There was a trend towards an inverse association between sCD14 and total CD4 cell count at week 
60 (0.04 x 106 reduction in sCD14 for every 100 rise in CD4 cell count 95% CI -0.004 x 106, 0.1 x 106, 
p=0.07). CD4 cell count was not related to LBP or EndoCAb levels. 
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Table 7.4. Linear regression analysis of factors related to LPS activity at week 60 
 Week 60 Parameter Coefficient 95% CI P-value 
sCD14 HIV RNA (+1 log) -0.02 -0.12, 0.08 0.7 
x106pg/ml CD8 CD38% (+1%) 0.03 -0.005, 0.01 0.5 
Week 60 CD8 HLA-DR% (+1 log) 0.15 -0.31, 0.61 0.5 
 CD8 CD38 HLA-DR% (+1 log) 0.09 -0.22, 0.40  0.6 
 CD4 CD38% (+ 1%) -0.002 -0.009, 0.004 0.5 
 CD4 HLA-DR % (+1 log) 0.70 0.28, 1.12 0.001 
 CD4 CD38 HLA-DR % (+1 log) 0.29 0.00, 0.59 0.05 
 IL-6  (+1 log) 0.47 0.18, 0.76 0.002 
 D-dimer (+1 log) 0.52 0.10, 0.96 0.02 
LBP HIV RNA (+1 log) 2759.7 729.5, 4789.9 0.01 
ng/ml CD8 CD38% (+1%) 188.6 39.9, 337.3 0.01 
Week 60 CD8 HLA-DR% (+1 log) 2494.1 -7516.1, 12504.5 0.6 
 CD8 CD38 HLA-DR% (+1 log) 7001.0 470.4, 13531.5  0.04 
 CD4 CD38% (+ 1%) 12.3 -137.7, 162.2 0.8 
 CD4 HLA-DR% (+1log) 8519.8 -1034, 18073.5 0.08 
 CD4 CD38 HLA-DR% (+1 log) 5287 -1241.5, 11815.6 1.1 
 IL-6  (+1 log) 8489.7 2248.8, 14730.7 0.01 
 D-dimer (+1 log) 13874.7 5184.3, 22565.2 0.002 
Log 10 
EndoCAb 
MMU/ml 
HIV RNA (+1 log) 0.002 -0.01, 0.02 0.7 
CD8 CD38% (+1%) 0.0001 -0.001, 0.001 0.7 
CD8 HLA-DR% (+1 log) 0.03 -0.03,  0.08 0.4 
Week 60 CD8 CD38 HLA-DR% (+1 log) 0.005 -0.03, 0.05 0.8 
 CD4 CD38% (1%) 0.001 0.0004, 0.002 0.02 
 CD4 HLA-DR% (+1log) 0.04 -0.01, 0.1 0.1 
 CD4 CD38 HLA-DR% (+1 log) 0.04 0.007, 0.08 0.02 
 IL-6  (+1log) -0.001 -0.04, 0.04 0.9 
 D-dimer (+1 log) 0.004 -0.05, 0.06 0.9 
 
 
Linear regression analysis of factors associated with surrogate markers of microbial translocation (sCD14, LBP 
and EndoCAb) in 90 SPARTAC participants with at week 60. EndoCAb, IL-6, D-dimer, and HLA-DR% and CD38 
HLA-DR% expression on CD4 and CD8 T-cells were log10 transformed to achieve normality for analysis purposes. 
The regression coefficient (95% CI) and p-value are given for each variable. 
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7.5 Soluble tissue factor and ICAM-1 in PHI 
Analysis of sTF and ICAM-1 were completed on 90 patients at SPARTAC week 0 and week 60, and 30 
healthy controls. Due to samples haemolysis, tissue factor results were excluded for 3 samples at 
week 0, and for one patient at week 60, as particles released during haemolysis may be tissue factor-
positive thus affecting results.  
Absolute results for median values and IQR are given below in Table 7.5. sTF values were within the 
detection range of the assay, and within the normal range given by the kit manufacturer (25-57.8 
pg/ml). ICAM-1 levels also fell within the detection range of the assay. In healthy controls ICAM-1 
levels fell within the normal range as given by the kit manufacturer (100-307 ng/ml), but in HIV-1 
infected subjects, ICAM-1 median levels were slightly above this range.   
Box-plot graphs demonstrating sTF and ICAM-1 levels are shown in Figure 7.3. There was no 
significant change in sTF levels between SPARTAC week 0 and 60 (p=0.1).  Levels of sTF were 
however were significantly higher at week 60 compared to healthy controls.  ICAM-1 levels were 
higher in both early infection and week 60 compared with healthy controls and there was a 
significant decline from week 0 to week 60.  
 
 
Table 7.5. Median (IQR) ICAM-1 and sTF results at week 0, week 60 and in healthy controls 
Biomarker Week 0 (n=90) Week 60 (n=90) Healthy control  (n=30) 
 Median [IQR] Median [IQR] Median [IQR] 
sTF pg/ml* 53.1 [44.7, 61.4] 52.6 [47.4, 64.4] 48.0 [42.3, 55.8] 
ICAM-1 ng/ml 349.7 [272.1, 438.5] 318.6 [254.3, 404.7] 212.4 [152.8, 272.4] 
sTF and ICAM-1 shown in 87 and 90 SPARTAC participants respectively and in 30 healthy controls.  *Due to 
sample haemolysis, sTF results from 3 samples were excluded at week 0 and 1 excluded at week 60. 
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Figure 7.3.  sTF and ICAM-1 levels in SPARTAC participants at week 0 and week 60 and in healthy 
controls  
 
  p=0.2 
p=0.1 p=0.02 
p<0.0001 
P=0.03 p<0.0001 
Box-plots showing median, IQR and upper and lower adjacent values for sTF and ICAM-1 in SPARTAC 
participants at week 0 and week 60, and in healthy controls.  Week 0 was compared to week 60 using 
Wilcoxon signed ranks test for paired samples. Mann-Whitney U tests were used to compare healthy 
controls to SPARTAC participants 
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7.6 Factors associated with sTF and ICAM-1 levels in PHI 
sTF 
The relationship between sTF and other baseline parameters including HIV RNA, CD4 cell count, 
duration of infection, was examined using linear regression (Table 7.6).  sTF results were log10 
transformed to normalise the distribution for analysis purposes. There was no relationship between 
sTF and age, BMI, blood pressure.  sTF levels increased with increasing estimated days since 
seroconversion (p=0.02). 
Log10 sTF was inversely correlated with log10 HIV RNA. A one log increase in HIV RNA was associated 
with a 6% decrease in sTF (95% CI 1%, 11% p=0.02). The relationship between sTF levels and 
different VL strata is shown in Figure 7.4 and demonstrates a decrease in sTF with increasing VL 
strata.  sTF was not related to CD4 cell count.  
sTF levels were also inversely associated with IL-6 and there was a trend towards an inverse 
association with D-dimer. In addition, sTF was inversely correlated with T-cell activation as measured 
by CD8 CD38% expression and CD4 CD38 HLA-DR dual expression, and there was a trend towards 
inverse an association with CD8 CD38 HLA-DR% and CD4 HLA-DR expression. Thus it appears that in 
PHI, sTF is inversely associated with both levels of HIV-1 viraemia, and levels of T-cell activation and 
inflammation. 
ICAM-1  
The relationship between ICAM-1 and other baseline parameters is shown in Table 7.6. There was no 
relationship between sTF and age, BMI, blood pressure.  There was a significant association between 
increasing levels of ICAM-1 and log10 HIV RNA; a one log increase in HIV RNA resulted in an increase 
in ICAM-1 of 35.4 ng/ml (95% CI 10.2, 60.7, p=0.01). The relationship between ICAM-1 and VL strata 
is shown in Figure 7.4 and there was an increase in ICAM-1 with every stratum.  There was no 
relationship between ICAM-1 and CD4 cell count. 
ICAM-1 was associated with markers of microbial translocation markers sCD14 (p=0.02) and LBP 
(p=0.03), and there was a trend for correlation with IL-6 (p=0.05).  There was no association between 
ICAM-1 and markers of T-cell activation.   
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Table 7.6. Factors associated with sTF and ICAM-1 at in PHI  
 Parameter Coefficient 95 % CI p-value 
soluble tissue 
factor (log10) 
HIV RNA copies/ml (+1 log)  -0.03 -0.05, -0.004 0.02 
days since seroconversion (+1 day) 0.001 0.000, 0.002 0.02 
IL-6  pg/ml(+ 1 log10) -0.07 -0.13, -0.002 0.04 
D-dimer mg/L( +1 log10) -0.08 -0.17, 0.015 0.09 
CD8 CD38% (+1%) -0.001 -0.001, 0.000 0.05 
CD8 HLA-DR% (+1 log) -0.06 -0.14, 0.03 0.17 
CD8 CD38+HLA-DR % (+1 log) -0.06 -0.1, 0.008 0.08 
CD4 CD38% (+1%) -0.001 -0.002, 0.001 0.3 
CD4 HLA-DR% (+1 log ) -0.08 -0.16, 0.005 0.07 
CD4 CD38+ HLADR% (+ 1 log ) -0.08 -0. 15, -0.02 0.015 
LPS Binding Protein (+1 ng/ml) -1.8 -4.2,  0.47 0.12 
sCD14 (+1x106 pg/ml) 0.0001 -0.004, 0.05 0.85 
 EndoCAb (1 log MMU) 0.006 -0.09, 0.11 0.9 
ICAM-1 HIV RNA copies/ml (+1 log)  35.4 10.2, 60.7 0.01 
 days since seroconversion (+1 day) 0.16 -0.6, 0.9 0.95 
 IL-6  pg/ml(+ 1 log10) 66.0 -0.7, 132.6 0.052 
 D-dimer mg/L( +1 log10) 79.9 -16.6, 176.4 0.1 
 CD8 CD38% (+1%) 0.8 -0.5, 2.2 0.2 
 CD8 HLA-DR (+1 log) 18.9 -77.6, 115.4 0.7 
 CD8 CD38+HLA-DR% (+1 log) 29.3 -43.4, 102.1 0.4 
 CD4 CD38 (+1%) 0.3 -1.1, 1.8 0.6 
 CD4 HLA-DR %(+1 log ) 38.1 -53, 129.9 0.4 
 CD4 CD38+ HLADR %(+ 1 log) 52.2 -21.7, 126 0.16 
 LPS Binding Protein (+1 ng/ml) 0.003 0.0003, 0.005 0.03 
 sCD14 (x 106 pg/ml ) 0.58 0.1, 1.0 0.02 
 EndoCAb (+ 1log MMU) -53.1 -155.4, 49.2 0.3 
  Linear regression analysis of factors related to sTF (n=87) and ICAM-1 (n=90) in PHI. HIV RNA, sTF Factor, 
EndoCAb, IL-6, D-dimer, and HLA-DR% and CD38 HLA-DR% expression on CD4 and CD8 T-cells were log10 
transformed to achieve normality for analysis purposes. The regression coefficient (95% CI) and p-value are 
given for each variable. 
174 
 
Figure 7.4.  Relationship between VL strata and ICAM-1 and sTF levels 
 
  
Relationship between ICAM-1 and sTF with different VL strata are shown. Individuals are divided according to VL 
(ICAM-1: HIV RNA <10,000 n=23, 10,000-99,999 n=31 and>100,000 n=36; sTF: HIV RNA <10,000 n=21, 10,000-99,999 
n=31 and>100,000 n=35).  Box-plot graphs demonstrate median values, IQR and upper and lower adjacent values.  
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7.7. Summary of findings in Chapter 7 
LBP and sCD14, both markers of bacterial LPS activity, were raised in HIV-1 infected individuals 
compared to healthy controls at the time of HIV-1 acquisition and remained raised at week 60. In 
PHI these two biomarkers directly correlated with HIV RNA. sCD14 also correlated positively with D-
dimer and inversely with CD4 cell count, and LBP with both IL-6 and D-dimer. There was no 
correlation in PHI between markers of LPS activity and T-cell activation.  At week 60, there was a 
significant association between all markers of LPS activity and T-cell activation: sCD14 and EndoCAb 
correlated with CD4 T-cell activation, and LBP correlated with CD8 T-cell activation. LBP and sCD14 
also correlated with IL-6 and D-dimer. 
In PHI, sTF inversely correlated with HIV RNA, IL-6 and T-cell activation. sTF was significantly raised 
compared to healthy controls at week 60. ICAM-1 was significantly raised compared to healthy 
controls at both time points and correlated with HIV RNA, sCD14 and LBP. 
Discussion 
Consistent with previous reports, we demonstrate raised levels of LPS activity in HIV-1 infected 
individuals. In a cross-sectional study examining individuals at different stages of HIV-1 infection, 
Brenchley et al. (2006) found that LPS levels increased as disease advanced, and were raised in 
chronic HIV-1 infection compared to HIV-negative controls and higher still in patients with AIDS. In 
our study, LBP and sCD14, surrogate markers of LPS activity, were raised in both PHI and at week 60 
compared to healthy controls, suggesting that microbial translocation occurs in HIV-1 infected 
individuals at both PHI and early chronic infection. Brenchley et al. also examined markers of 
microbial translocation in acutely infected individuals within 4 weeks of seroconversion, and found 
that levels of sCD14 were raised, and EndoCAb levels low, but LPS and LBP were no different from 
healthy controls, and concluded that microbial translocation occurs at this early stage of disease but 
LPS is neutralised by EndoCAb. SPARTAC participants at baseline were less acutely infected than 
those described by Brenchley et al (within 6 months of seroconversion vs. 4 weeks), which may 
explain why we also saw changes in LBP, reflecting higher levels of microbial translocation at this 
later time point.  
Consistent with findings from Brenchley et al. (2006), we saw a decline in EndoCAb levels from week 
0 to week 60. In other conditions of chronic microbial translocation, such as inflammatory bowel 
disease, EndoCAb levels are increased, and Brenchley hypothesized that EndoCAb bind LPS to 
remove it from the circulation but are insufficiently replaced due to the dysfunctional B cell 
responses associated with HIV-1 infection (Titanji, et al. 2006). We did not see a difference in 
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EndoCAb levels compared with healthy controls, however, in our study, healthy controls had lower 
levels of EndoCAb than those reported by Brenchley et al, which may reflect cohort differences. In 
particular it should be noted that our healthy controls were not formally HIV-1 tested which may 
confound these results 
sCD14 is secreted by monocytes and macrophages that have been stimulated via LPS and has been 
associated with increased mortality in HIV-1 infected cohorts (Lien, et al. 1998; Sandler, et al. 2010). 
We saw a direct correlation between sCD14 and HIV RNA levels in PHI, and inverse correlation 
between sCD14 and CD4 cell count. This is consistent with findings by Lien et al. in advanced disease 
but has not been previously demonstrated in PHI. We also saw correlations between sCD14 and D-
dimer levels, indicating that monocyte activation in response to LPS may lead to activation of 
coagulation pathways, as hypothesised by Funderburg et al (2010). In addition LBP levels were 
correlated with D-dimer and IL-6 levels, as well as HIV RNA, indicating a relationship between LPS 
activity, inflammatory and coagulatory processes and HIV-1 replication. It is no clear from these data 
whether HIV-1 replication is a driver or consequence of these processes. 
There was no association in PHI between surrogate markers of microbial translocation and T-cell 
activation.  This is in contrast to week 60 where a direct correlation was seen between T-cell 
activation and markers of LPS activity in the same individuals, in agreement with findings described 
by Brenchley et al (2006) who showed that LPS levels correlated with CD38 HLA-DR expression on 
CD8 T-cells, and Jiang et al (2009), who found that bacterial rDNA levels also correlated with CD8 T-
cell activation. The discrepancy between PHI and chronic infection may reflect different mechanisms 
driving T-cell activation in chronic compared with early infection, where, for example, the direct 
effects of high plasma viraemia may be the key driver of T-cell activation.   
A limitation of our study is that due to logistic constraints we did not measure LPS directly, although 
several studies in HIV-1 infected cohorts have indicated that sCD14, LBP and EndoCAb are good 
indicators of LPS activity (Ancuta, et al. 2008; Brenchley, et al. 2006; Papasavvas, et al. 2009), and 
these are well-established markers of LPS activity in HIV-negative studies (Kitchens and Thompson 
2005; Strutz, et al. 1999; Voss, et al. 2006). Although predictors of disease progression such as VL 
and CD4 cell count correlated with some of these markers, our data give little indication of the 
prognostic significance of these parameters. Once SPARTAC is unblinded an analysis of the predictive 
value of sCD14, LBP and EndoCAb, when measured both in PHI and at week 60 will be undertaken. 
The impact of intermittent ART in PHI on these markers will also be assessed. It is also possible that 
intervention with short-course ART in PHI, by controlling HIV-1 replication in the gut, may in turn 
limit markers of microbial translocation. 
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Recent studies have suggested that tissue factor (TF) activity is increased in chronic HIV-1 infection, 
and that monocyte TF expression is induced by LPS, and correlates with T-cell activation and D-dimer 
(Funderburg, et al. 2010b). Soluble TF is an easily measurable parameter that has been linked to 
cardiovascular events in HIV-1 infected individuals (Ford, et al. 2010). We did not see any 
relationship between sTF levels and markers of LPS activity. However, in contrast to our expectations 
we found an inverse relationship between sTF and HIV RNA, and an inverse association between sTF, 
IL-6, and markers of T-cell activation.  A study in the pre-HAART era showed there was a selective 
reduction in LPS induced monocyte TF mRNA production in individuals with symptomatic HIV-1 
infection, and that there was a continuum of diminished TF function in patients with asymptomatic 
disease, AIDS-related complex, and AIDS  (Lathey, et al. 1990).  The investigators went on to show a 
positive correlation between LPS stimulated TF expression and CD4 cell count, and a negative 
correlation between TF and plasma β2 microglobulin and neopterin, consistent with our findings of a 
negative correlation between inflammatory and immune activation markers and sTF (Lathey, et al. 
1992). Funderburg et al. (2010) also found that samples exposed to LPS in vitro showed increased 
monocyte TF expression, but samples exposed to IL-6 tended to decrease TF expression. The 
mechanism behind these findings, and the clinical consequences, are not clear. It is possible that 
inflammatory processes secondary to HIV-1 viraemia inhibit sTF production, for example as a 
negative feedback pathway.  It should be noted that sTF is a surrogate marker only and the precise 
role and regulation of circulating sTF in blood remains unclear (Bogdanov, et al. 2003; Censarek, et 
al. 2007; Parhami-Seren, et al. 2006).  Measuring monocyte TF expression and TF activity may help 
clarify the relationship between these markers; however samples required for these laboratory 
techniques were not available.  
Levels of sTF increased with increasing time since estimated seroconversion. This could reflect 
resolving immune activation and high levels of HIV-1 viraemia associated with PHI.  Conversely sTF 
levels may increase with duration of infection, supported by higher levels of sTF at week 60 
compared to healthy controls. 
Elevated levels of circulating adhesion molecules such as ICAM-1 and VCAM-1 predict future cardiac 
events in HIV-negative individuals (Hwang, et al. 1997; Ridker, et al. 2000a) and in chronic HIV-1 
infection (Ford, et al. 2010). In this study, ICAM-1 levels were raised in both PHI and chronic HIV-1 
infection compared to healthy controls.  This has previously been demonstrated in chronic infection 
but not in PHI (Francisci, et al. 2009; Wolf, et al. 2002). There was a reduction in ICAM-1 levels from 
PHI to week 60 but whilst the study remains blinded it is not possible to determine whether this is 
due to the natural history of HIV-1 disease, or due to the receipt of short-course ART in some of the 
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week 60 population. We demonstrate a direct correlation between HIV RNA levels and ICAM-1, in 
keeping with previous reports showing a direct correlation between VCAM-1-1 and HIV RNA and a 
reduction in both ICAM-1 and VCAM-1 in response to ART (Wolf, et al. 2002). Melendez et al (2008) 
found that raised levels of circulating adhesion molecules were associated with inflammation in 
chronic HIV-1 infection. We demonstrate a weak association between ICAM-1 levels and IL-6 in PHI. 
In addition we showed a direct correlation between this marker of endothelial activation and sCD14 
and LBP. These data suggest that endothelial dysfunction, as reflected by raised ICAM-1 levels, is 
related to macrophage activation and LPS activity and also to the magnitude of HIV-1 viraemia.   
In conclusion, we demonstrate an association between surrogate markers of LPS activity, immune 
activation, inflammatory and coagulatory pathways, and endothelial activation. The interactions 
between HIV-1 and pathways of microbial translocation are complex and not fully understood, 
however it is likely that this process contributes to HIV-1-associated immune activation and 
inflammation and their subsequent complications. 
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Chapter 8: Discussion  
This thesis has addressed four main goals in relation to PHI and the effect of short-course ART at this 
stage of infection. These were the assessment of:  
i. the degree of inflammation and immune activation in PHI and the relationship between 
surrogate markers of immune activation, inflammation and coagulation, and microbial 
translocation. 
ii. host and viral factors associated with these parameters. 
iii. the impact of commencing short-course ART in PHI on biomarkers of inflammation and 
coagulation.  
iv. the effects of discontinuing ART on viral rebound and biomarkers of inflammation and 
coagulation, and comparison with the SMART trial in chronic infection. 
Assessment of markers of inflammation and immune activation in PHI 
Markers of inflammation, coagulation, and endothelial activation, were elevated in HIV-1 infected 
individuals, both in PHI and 60 weeks later.  In contrast to reports from the SMART study in chronic 
HIV-1 infection, which did not show a correlation between HIV RNA and levels of IL-6 or D-dimer 
(Baker, et al. 2010; Kuller, et al. 2008), in our study IL-6, D-dimer and ICAM directly correlated with 
plasma HIV RNA in PHI, confirming that HIV-1 replication is a key driver of inflammatory and 
coagulation pathways early in the course of infection.  As these biomarkers are well established 
predictors of CVD in HIV-negative individuals (Ridker, et al. 1994; Ridker, et al. 1998; Ridker, et al. 
2000b) and predictive of AIDS and non-AIDS adverse outcome in individuals with chronic HIV-1 
infection (Ford, et al. 2010; Kuller, et al. 2008; Rodger, et al. 2009; Sipsas, et al. 2003), elevations of 
these biomarkers occurring early in HIV-1 infection may have significant implications for future 
disease course and outcome.  
Deeks et al. (2004) showed that in individuals within a year of seroconversion, levels of T-cell 
activation, measured by CD38 expression on CD4 and CD8 T-cells, correlated with HIV RNA and were 
predictive of outcome.  We confirmed that levels of T-cell activation were elevated when measured 
within six months of seroconversion, and were associated with HIV RNA levels and with levels of 
inflammatory and coagulation biomarkers.  In addition, we have shown that PD-1 expression on both 
CD4 and CD8 T-cells was associated with both T-cell activation and with VL. This has not been 
previously demonstrated in PHI. Expression of PD-1 may occur to regulate T-cell activation, but in 
chronic HIV-1 infection it is associated with functional T-cell exhaustion, reduced viral control, 
increased tendency to apoptosis and faster CD4 T-cell decline (Day, et al. 2006; Holm, et al. 2008; 
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Petrovas, et al. 2006). Thus elevated PD-1 in PHI may have profound implications for future disease 
course. 
We sought to verify previous findings suggesting that gut microbial translocation contributes to 
ongoing immune activation in HIV-1 infection. This was investigated by measuring surrogate markers 
of LPS activity. We confirmed findings from a previous study showing that surrogate markers of LPS 
activity are raised in HIV-1 infected individuals compared to healthy controls (Brenchley, et al. 2006), 
and demonstrated an association between LPS activity, and HIV RNA, IL-6 and D-dimer. We found 
that markers of LPS activity correlated with T-cell activation in chronic HIV-1 infection (SPARTAC 
week 60), but not in PHI (SPARTAC week 0), suggesting that microbial translocation may be a more 
important driver of immune activation in chronic infection than in PHI, where other factors such as 
high level viral replication are likely to predominate. These findings highlight the complex interplay 
between HIV-1 replication, immune activation, inflammation and LPS activity. However, while we 
and others have demonstrated a close relationship between these parameters, there remain few 
longitudinal data assessing microbial translocation in HIV-1 infection and hence its prognostic 
relevance remains uncertain. This will be investigated once the SPARTAC trial is unblinded.  
Evaluation of host and viral factors associated with inflammation and immune activation 
In addition to the level of HIV RNA, other viral factors and host characteristics determined the level 
of immune activation. We showed that X4 tropism is associated with T-cell activation in individuals 
with PHI, in keeping with previous data showing increased CD4 T-cell proliferation, measured by 
increased Ki67 expression, in individuals with X4 virus both one and 5 years after seroconversion 
(Hazenberg, et al. 2003a). As the X4 receptor is mainly expressed on naive T-cells, increased 
activation, proliferation and apoptosis of these cells may lead to faster depletion of the naive CD4 T-
cell pool and explain the accelerated disease progression known to be associated with X4 viruses 
(Hazenberg, et al. 2003a).  
This study has shown an independent association between HLA type and magnitude of T-cell 
activation and PD-1 expression which has not been previously demonstrated. There was an 
association between HLA B*57 positivity and reduced CD38 expression, and between HLA B*27 and 
reduced PD-1 expression as well as lower levels of fibrinolysis. These factors may contribute towards 
the delayed HIV-1 disease progression known to be associated with these HLA alleles, and, in 
addition, reduced PD-1 expression could reflect a mechanism of enhanced viral control in HLA B*27 
positive individuals. These findings highlight the importance of host genetic factors in determining 
immunological response to HIV-1 infection.   
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We observed a significant correlation between increasing age and markers of inflammation, 
fibrinolysis, T-cell activation and T-cell exhaustion which could reflect a mechanism by which HIV-1 
infection is associated with poorer prognosis in older individuals. Our data are in keeping with 
studies in HIV-negative individuals which show that aging is associated with raised levels of 
circulating pro-inflammatory cytokines, in particular IL-6 (Ershler and Keller 2000) and higher levels 
of T-cell activation, manifest by increasing HLA-DR expression(Czesnikiewicz-Guzik, et al. 2008). In 
addition, studies in a mouse model show increased PD-1 expression with increasing age 
(Channappanavar, et al. 2009). The many similarities between clinical and immunological 
manifestations of HIV-1 infection and those observed with age have led to the suggestion that 
persistent immune activation and inflammation lead to accelerated aging in HIV-1 infected 
individuals (Desai and Landay 2010). With advancing age, as with HIV-1, there is a generalised 
decline in immune competence to deal with infection and malignancy, and an increase in 
inflammation mediated disease processes such as CVD, neurocognitive dysfunction, and reduced 
bone mineral density. As HIV-1 infected individuals age, the clinical significance of these 
observations is likely to become more apparent, as patients are affected by increasing age in 
addition to the effects of HIV infection.  
Assessment of the impact of commencing short-course ART in PHI on markers of inflammation and 
coagulation  
There are no previous data on the effect of starting ART in PHI on inflammation and coagulation.  In 
chronic infection, starting ART results in reductions in D-dimer (Baker, et al. 2010; Calmy, et al. 2009; 
Wolf, et al. 2002). Baker et al (2010) showed that IL-6 decreased compared to baseline levels in 
those achieving an undetectable HIV RNA level in chronic infection, but overall found no differences 
in IL-6 between treated and untreated individuals after six months of ART. In PHI, we saw reductions 
in IL-6 and D-dimer 12 weeks after commencing ART.  As these biomarkers were correlated with HIV 
RNA levels in PHI, it is likely the decline in these biomarkers was a direct result of treatment. In 
addition, we saw greater reductions in IL-6 in individuals with higher CD4 cell counts indicating that 
starting ART at an earlier disease stage may lead to greater benefits in dampening inflammatory 
responses.   
Assessment of the effects of discontinuing ART on these markers and comparison to the SMART 
trial 
Whilst the SMART trial identified the risks of stopping ART in chronic HIV-1 infection irrespective of 
immunological recovery, the effect of interrupting ART following treatment in PHI has not previously 
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been investigated. In the SMART trial, stopping ART given during chronic infection was associated 
with a rise in both IL-6 and D-dimer four weeks after treatment interruption, which correlated with 
the magnitude of viral rebound. Viral rebound on stopping ART initiated in SPARTAC was significantly 
lower compared to SMART, which may reflect smaller reservoir size in PHI versus chronic infection in 
agreement with other reports (Strain, et al. 2005). However, we found that stopping ART given in 
PHI was associated with a significant rise in IL-6 and D-dimer, which rebounded to pre-treatment 
levels at 4 weeks. Although the magnitude of this rebound may be smaller than that observed in 
SMART at 4 weeks, the long-term trends in Il-6 and d-dimer after stopping ART have not yet been 
examined, and further rises in these biomarkers could be anticipated in parallel with increasing viral 
load.   
The adverse events seen in SMART may reflect years of chronic inflammation, ART exposure and 
metabolic complications (Grunfeld, et al. 2008) and, given the short duration of HIV-1 infection in 
SPARTAC, treatment interruption following ART in PHI may not be associated with same adverse 
clinical events, regardless of magnitude of viral and inflammatory biomarker rebound. However, 
even in the absence of an observed adverse outcome in the short-term, long-term biomarker 
changes following ART discontinuation in PHI may be associated with significant long-term 
morbidity.  Stopping ART commenced in PHI also has significant public health implications (Rieder, et 
al. 2010). The majority of individuals in SPARTAC and SMART, regardless of stage of infection, 
experienced viral rebound above those sufficient to pose a risk of onward HIV-1 transmission. Even if 
short-course ART is proven a safe and beneficial intervention compared to untreated individuals 
with PHI, long-term ART resulting in sustained suppression of plasma viraemia, immune activation 
and inflammatory responses may be a preferable intervention. 
Clinical Implications  
While the findings of the SPARTAC trial will inform the value of short-pulse ART in PHI, the trial does 
not address the long-term role of life-long immediate ART, nor will it enable clinicians to target 
therapy to individuals who will gain most benefit from immediate therapy. Although short-term ART 
is associated with HIV RNA and biomarker rebound on treatment discontinuation, commencing long-
term ART in PHI may present overwhelming problems of acceptability, feasibility, toxicity, and cost. 
The important question of when to start long-term ART will be addressed in the START trial which 
compares early (CD4 cell count >500 cells/µl) versus deferred ART (CD4 cell count 350 cells/µl). The 
START trial will include cardiovascular and biomarker sub-studies, and will investigate the risk 
benefit analysis between ART-associated toxicities and complications relating to ART versus the 
impact of uncontrolled viral replication. However, although the START trial will include participants 
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with PHI, it is not specifically powered to examine the benefits of long-term treatment at the time of 
primary infection. 
 Although it is known that those with severe clinical manifestations during acute infection 
experience faster progression to AIDS (Lavreys, et al. 2006; Vanhems, et al. 1998), for most 
individuals it is difficult to predict the rate of disease progression at the time of PHI presentation. 
Development of a clinically relevant predictive algorithm, potentially combining indicators such as 
CD4 cell count, VL, viral tropism, HLA type, age, cardiovascular risk factors such as smoking, lipids 
and blood pressure, and biomarker results, could provide a useful tool for managing PHI. 
Measurement of inflammatory and coagulation biomarkers could be a useful strategy to assess 
individual risk and response to interventions, however, before such as strategy can be implemented, 
it is important to identify the threshold biomarker value at which intervention would be started and 
also confirm that the intervention reduces both the biomarker and also the clinical outcome in HIV-1 
infected populations (Nixon and Landay 2010). Case control studies have shown that many of the 
biomarkers examined in this thesis, including IL-6, D-dimer, sTF and sCD14, are predictive of clinical 
outcome in chronic HIV-1 infection (Ford, et al. 2010; Kuller, et al. 2008; Sandler, et al. 2010); 
however the relationship between plasma biomarkers when measured in PHI and prognosis has not 
yet been established. Once the SPARTAC trial is unblinded, long-term clinical outcome data from a 
minimum of 3.5 years follow up will be available, allowing an assessment of the predictive value and 
clinical utility of these biomarkers in evaluating long-term outcomes, when measured within six 
months of seroconversion and in early chronic infection. Soluble plasma biomarkers are easier to 
measure than cellular markers of T-cell activation, and could be more easily translated into clinical 
practice. Interventions in high risk individuals could include starting ART, adjustment of modifiable 
risk factors such as smoking cessation and weight loss, as well as novel approaches to reduce 
inflammation and immune activation.  
Although ART may help to reduce risk associated with inflammatory complications of HIV-1, treated 
individuals still have considerably higher levels of inflammatory and coagulation biomarkers 
compared to HIV-negative individuals, even among those with HIV RNA levels <400 copies/ml 
(Neuhaus, et al. 2010). The causes of ongoing inflammation and immune activation in ART treated 
individuals are likely to be multi-factorial but may include inflammatory processes triggered by 
specific ART agents (Lundgren 2008; Madden, et al. 2008), residual low level HIV-1 replication 
(Bonora, et al. 2009; Havlir, et al. 2003; Palmer, et al. 2008), or responses to other antigens, such as 
CMV (Hsue, et al. 2006; Naeger, et al. 2010). Recent strategies intensifying standard regimens with 
additional agents,  such as raltegravir did not reduce low level HIV-1 replication (Gandhi, et al. 2010; 
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McMahon, et al. 2010) and had minimal effects on immune activation (Yukl, et al. 2010). Mixed 
results have been reported for the use of ART with potential anti-inflammatory properties, such as 
maraviroc, to dampen immune activation (Evering, et al. 2010; Funderburg, et al. 2010a; Wilkin, et 
al. 2010).  Other interventions to limit the effects of immune activation and inflammation in HIV-1 
infected individuals include non-ART agent such as statins, known to block pro-inflammatory 
signalling by inhibiting the endotoxin TLR-4 pathway (Stoll, et al. 2004), and other anti-inflammatory 
agents or aspirin (Tornero, et al. 2010).  
The main aim of SPARTAC is to determine the effects of short-course ART on long-term HIV-1 
surrogate markers of clinical disease such as CD4 T-cell decline.  The use of short-course ART in PHI, 
by influencing the immunological and virological events surrounding this phase of infection, may 
have a long-term impact after discontinuation of therapy, not just on clinical HIV-1 outcomes but 
also levels of inflammation and immune activation. However, to be effective, intervention in PHI 
may need to occur at a very early stage of acute infection, before an extensive viral reservoir has 
been established and massive immunological damage has taken place (Centlivre, et al. 2007; 
McMichael, et al. 2010). It has been hypothesised that intervention should be introduced before the 
development of peak viraemia, around 21-28 days after transmission (McMichael, et al. 2010). 
SPARTAC participants received intervention up to six months following seroconversion and may have 
missed this early window of opportunity. Identifying individuals with PHI poses a major challenge, 
and clinical and patient awareness as well as development of new incidence tests are crucial if 
individuals with very early infection are to be targeted.  A benefit of SPARTAC is that, although it 
represents individuals at a later stage of PHI, if SPARTAC does show a positive result it should be 
possible to translate this strategy into clinical practice using currently available diagnostic tools. 
Although novel cross sectional incidence assay are currently in development there remain no reliable 
and easily accessible methods of identifying very early infection (Cohen, et al. 2010) 
The main limitation of this thesis is that the SPARTAC study remains blinded at the time of writing. 
Future analyses will include assessing the predictive value of the biomarkers measured in this thesis, 
assessing the natural history of biomarker changes in untreated individuals, and assessing the effects 
of short-course ART across the three arms of SPARTAC. This study also has some key advantages. 
The bias associated with starting and stopping ART in many observational studies, including the pilot 
study described in this thesis, is limited by the randomised nature of SPARTAC, and the large 
numbers of participants included in the study means that the data are powered to clinically relevant 
endpoints.   
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Conclusion 
In conclusion, HIV-1 infection is a pro-inflammatory state characterised by chronic immune 
activation, microbial translocation, endothelial activation and activation of coagulation pathways. 
These processes play a key role in disease pathogenesis in HIV-1 infected individuals. The 
concurrence of viral and host factors contribute to the magnitude of immune activation, which itself 
is a driver of further viral replication. The biomarkers of inflammation, coagulation and immune 
activation measured in this thesis may provide additional prognostic information to identify 
individuals at high risk of HIV-1 disease progression or co-morbidities. By examining the natural 
history of these biomarkers, and understanding the effects of stopping and starting ART, it may be 
ultimately possible to target interventions designed at limiting these processes. As the HIV-1 
infected population continues to age, and the impact of non-opportunistic disease becomes more 
apparent, an appreciation of these underlying pathogenic mechanisms is critical to enhance 
prevention, diagnosis and management of co-morbidities, and to optimise the use of current ART 
agents. 
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Appendix 1: Summary of SPARTAC study design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Confirmed Primary HIV-1 infection 
Randomisation 
12 weeks 
ART 
48 weeks 
ART No ART 
Clinical follow up (minimum 3.5 years)  
Primary study outcome: 
 Time from randomisation to CD4 of <350 cells/μl measured on 
two consecutive occasions not more than 4 weeks apart 
 Time to the initiation of late treatment  
Secondary outcomes: 
 Development of new drug resistance not present at baseline 
 Development of an AIDS defining illness or death 
 HIV-1 specific CD4+ and CD8+ T-cell responses at week 60 
 Time from randomisation to virological failure of first regimen  
 Changes in blood pressure 
 
A summary of the SPARTAC trial design is shown.  Patients with PHI were randomised to one of 3 study arms and 
followed up for a minimum of 3.5 years. Primary and secondary study endpoints are shown. 
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Appendix 2: Antibody titrations used to determine the optimal antibody concentrations for flow 
cytometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The optimal antibody concentrations for flow cytometry were established using the antibody titrations shown above. 
Assays were run in triplicate and mean and standards deviation are plotted for each antibody concentration. Chosen 
concentrations are indicated by the arrow.  
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